VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 22 (1-11 octubre / 2022)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil. Usted puede realizar sugerencias sobre los contenidos y de esta forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Resumen de la información publicada por la OMS sobre candidatos vacunales en desarrollo contra la COVID-19 a nivel mundial.
- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en Patentscope sobre vacunas.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

Resumen de la información publicada por la OMS sobre los candidatos vacunales contra la COVID-19 en desarrollo a nivel mundial

Última actualización por la OMS: 11 de octubre de 2022.

Fuente de información utilizada: World Health Organization; R&DBlueprint Powering research to prevent epidemics

172 Vacunas en evaluación clínica y 199 en evaluación preclínica

Candidatos vacunales en evaluación clínica por plataforma

Platform		Candidate vaccines (no. and %)	
PS	Protein subunit	55	32%
VVnr	Viral Vector (non-replicating)	23	13%
DNA	DNA	16	9%
IV	Inactivated Virus	22	13%
RNA	RNA	40	23%
VVr	Viral Vector (replicating)	4	2%
VLP	Virus Like Particle	6	4%
VVr + APC	VVr + Antigen Presenting Cell	2	1%
LAV	Live Attenuated Virus	2	1%
VVnr + APC	VVnr + Antigen Presenting Cell	1	1%
BacAg-SpV	Bacterial antigen-spore expression vector	1	1%
		172	

Candidatos vacunales mucosales en evaluación clínica

Desarrollador de la vacuna/fabricante/país	Plataforma de la vacuna	Vía de administración	Fase
University of Oxford/Reino Unido	Vector viral no replicativo	Intranasal	1
CanSino Biological Inc./Beijing Institute of Biotechnology/China	Vector viral no replicativo	Inhalación	4
CanSino Biological Inc./China	Vector viral no replicativo	Intranasal	3
Vaxart/Estados Unidos	Vector viral no replicativo	Oral	2
Univ. Hong Kong, Xiamen Univ./Beiging Wantai Biol. Pharm./China	Vector viral replicativo	Intranasal	3
Symvivo/Canadá	ADN	Oral	1
ImmunityBio, Inc./Estados Unidos	Vector viral no replicativo	Oral y SL	1/2
Codagenix/Serum Institute of India	Virus vivo atenuado	Intranasal	3
Center for Genetic Engineering and Biotechnology (CIGB)/Cuba	Subunidad proteica	Intranasal	1/2
Razi Vaccine and Serum Research Institute/India	Subunidad proteica	Intranasal	3
Bharat Biotech International Limited/India	Vector viral no replicativo	Intranasal	3
Meissa Vaccines, Inc./Estados Unidos	Virus vivo atenuado	Intranasal	1
Laboratorio Avi-Mex/México	Virus inactivado	Intranasal	2/3
USSF + VaxForm/Estados Unidos	Subunidad proteica	Oral	1
CyanVac LLC/Estados Unidos	Vector viral no replicativo	Intranasal	1
DreamTec Research Limited/Hong Kong	BacAg-SpV	Oral	NA
Sean Liu, Icahn School of Medicine at Mount Sinai	Vector viral replicativo	Intranasal	2/3
Hannover Medical School/Alemania	Vector viral no replicativo	Inhalación	1
ACM Biolabs/Singapur	Subunidad proteica	Intranasal	1
CanSino Biologics Inc.	Vector viral no replicativo	Intranasal	3

Candidatos vacunales más avanzados/fabricante/país	Plataforma de la vacuna	Fase
Sinovac/China	Virus Inactivado	4
Sinopharm/Beijing Institute of Biological Products/China	Virus Inactivado	4
University of Oxford/AstraZeneca/Reino Unido	Vector viral no replicativo	4
CanSino Biological Inc./Beijing Institute Biotechnology/China (IM e IH)	Vector viral no replicativo	4
Gamaleya Research Institute/Rusia	Vector viral no replicativo	3
Janssen Pharmaceutical Companies/Estados Unidos	Vector viral no replicativo	4
Novavax/Estados Unidos	Subunidad proteica	3
Moderna/NIAID/Estados Unidos	ARN	4
Pfizer/BioNTech Fosun Pharma/Estados Unidos	ARN	4
Anhui Zhifei Longcom Biopharmac./Inst. Microbiol, Chin Acad Sci/China	Subunidad proteica	3
CureVac AG/Alemania	ARN	3
Institute of Medical Biology/Chinese Academy of Medical Sciences	Virus inactivado	3
Research Institute for Biological Safety Problems, Kazakhstan	Virus inactivado	3
Inovio Pharmac. + Intern. Vacc Inst. + Advaccine Biopharm Co., Ltd	ADN	3
Zydus Cadila Healthcare Ltd./India	ADN	3
Bharat Biotech International Limited/India	Virus Inactivado	3
Sanofi Pasteur + GSK/Francia/Gran Bretaña	Subunidad proteica	3
Shenzhen Kangtai Biological Products Co., Ltd./China	Virus Inactivado	3
Clover Biopharmaceuticals Inc./GSK/Dynavax/China/Reino Unido/EE.UU	Subunidad proteica	3
Vaxine Pty Ltd. + CinnaGen Co./Australia, Irán	Subunidad proteica	3
Medigen Vaccine Biol./Dynavax/NIAID/Taiwán/EE.UU	Subunidad proteica	4
Instituto Finlay de Vacunas/Cuba	Subunidad proteica	3
Federal Budget Res Inst State Res Cent Virol Biotechnol "Vector"/Rusia	Subunidad proteica	3
West China Hospital + Sichuan University/China	Subunidad proteica	3
Vaxxinity/EE.UU	Subunidad proteica	3
Univ. Hong Kong, Xiamen Univ. & Beijing Wantai Biological Pharm./China	Vector viral replicativo	3
Acad Milit Sci (AMS) Walvax Biotechnol, Suzhou Abogen Biosci/China	ARN	3
Medicago Inc./Canadá	Partícula similar a virus	3
Codagenix/Serum Institute of India	Virus vivo atenuado	3
Center for Genetic Engineering and Biotechnology (CIGB)/Cuba	Subunidad proteica	3
Valneva, National Institute for Health Research, Reino Unido	Virus inactivado	3
Biological E. Limited/India	Subunidad proteica	3
Nanogen Pharmaceutical Biotechnology/Vietnam	Subunidad proteica	3
Shionogi/Japón	Subunidad proteica	3
Erciyes University/Turquía	Virus inactivado	3
SK Bioscience Co., Ltd./CEPI/Corea del Sur/Noruega	Subunidad proteica	3
Razi Vaccine and Serum Research Institute/Irán, India	Subunidad proteica	3
Bharat Biotech International Limited/India	Vector viral no replicativo (IN)	3
Providence Therapeutics/Canadá	ARN	3
Jiangsu Rec-Biotechnology/China	Subunidad proteica	3
Radboud University/Holanda	Partícula similar a virus	3
Arcturus Therapeutics, Inc./Estados Unidos	ARN	3
Livzon Pharmaceutical/China	Subunidad proteica	3
KM Biologics Co., Ltd.	Virus inactivado	3
Bagheiat-allah University of Medical Sciences/AmitisGen/Irán	Subunidad proteica	3
Laboratorios Hipra, S.A.	Subunidad proteica	3
Sinocelltech Ltd./China	Subunidad proteica	3
Chumakov Federal Scientific Center for Research/Rusia	Virus Inactivado	3
Airlangga University/Indonesia	Virus Inactivado	3
PT Bio Farma/Indonesia	Subunidad proteica	3
AIM Vaccine and Liverna Therapeutics/China	ARN	3
China National Biotec Group Company Limited	Virus inactivado	3

Noticias en la Web

Cuba´s COVID-19 vaccine effectiveness to be exhibited in Vietnam

Oct 1. Favorable situation Cuba is presently showing to fight off COVID-19 is closely related to the effectiveness of its homegrown vaccines, the Health Minister Jose Angel Portal said.

Only the close relation with scientists since the first Covid-19 outbreaks and the accelerated development of five vaccine candidates -three of which became vaccines- as well as the country´s health system efforts and the discipline shown by the Cuban people, made it possible to put coronavirus under control, Portal stated.

In a Friday´s meeting with members of solidarity groups, Cuban residents in Vietnam as well as the Cuban embassy staffers, Portal stressed that Cuba is currently reporting an average toll of 15 coronavirus-infected patients, with no serious cases or deaths. This is evidence of our vaccines´ effectiveness, he remarked.

So far, he praised, 42 million vaccine doses have been applied nationwide, allowing over 98% of the Cuban population (a bit more than 11 million inhabitants) to be fully vaccinated and over 85% to receive booster doses.

Cuba has been the world´s first nation in vaccinating children over two years of age, Portal added, while recalling that the highest peak of the pandemic in Cuba popped in July-September 2021 period, but by the end of that year national situation was already more favorable.

Referring to the Prime Minister Manuel Marrero Cruz visit to Vietnam, Portal valued the meetings with Health Ministry leaders as positive, which ended up with the signing of an Action Plan for 2023-2025 period.

Portal stated that seven Cuban doctors are presently working in Vietnam, six of them in hospitals, and he also considered it possible this cooperation could be expanded in the near future.

Fuente: Prensa Latina. Disponible en https://bit.ly/3g3W7uC

Minsap confirma cuarto caso de viruela símica diagnosticado en Cuba

1 oct. El Ministerio de Salud Pública informó este sábado primero de octubre sobre la confirmación del cuarto caso de viruela símica diagnosticado en el territorio nacional.

MINISTERIO DE SALUD PÚBLICA
República de Cuba

Se trata de un ciudadano cubano residente en la provincia de Cienfuegos, de 26 años de edad, trabajador de la salud, que tuvo contacto directo con el tercer caso de la enfermedad notificado en el país.

El día 30 comenzó con lesiones en la piel, sugestivas de la enfermedad, por lo que se tomó muestra de las mismas y fue confirmado por el Laboratorio Nacional de Referencia del Instituto Pedro Kouri (IPK) el día de hoy.

El paciente se encontraba en aislamiento estricto por ser contacto directo, por lo que no se declaran nuevos contactos. Está evolucionando de manera favorable y sin complicaciones.

El resto de los contactos aislados por el tercer caso se mantienen asintomáticos en el octavo día de la vigilancia.

Fuente: Cubadebate. Disponible en https://bit.ly/3VtzZKj

Khosta-2: descubierto en Rusia un nuevo y preocupante coronavirus

2 oct. Después de que en 2020 el virus SARS-CoV-2 se convirtiera en protagonista de una pandemia mundial, el estudio de animales que pudieran actuar como reservorios del virus ha sido constante. Eso ha llevado a estudiar una gran diversidad de murciélagos insectívoros del género *Rhinolophus*, los llamados murciélagos de herradura.

En ello estaba un grupo de virólogos rusos cuando encontraron y describieron genéticamente dos nuevos virus emparentados con el SARS-CoV-2. Se trata de dos sarbecovirus hallados en las heces y en la boca de murciélagos de herradura mayor (*Rhinolophus ferrumequinum*) y menor (*Rhinolophus hipposideros*) del sur de Rusia. Los llamaron Khosta-1 y Khosta-2. Y, desde entonces, no les han quitado ojo.

Últimamente han detectado en ellos algunos rasgos que son motivo de preocupación. En concreto, un equipo de investigadores estadounidenses ha confirmado que el virus Khosta-2, al igual que SARS-CoV-2, tiene preferencia por el receptor ACE2 y puede utilizar la proteína S para infectar células humanas. Son malas noticias.

Murciélagos y coronavirus, una relación ancestral

Los murciélagos son los huéspedes reservorios de tres de los diez grupos de virus de preocupación pandémica: henipavirus (virus Nipah y virus Hendra), filovirus (virus Ébola y virus Marburg) y coronavirus. Los murciélagos de herradura están ampliamente distribuidos en Asia, Europa y África del Norte y son considerados un reservorio natural principal y una fuente de coronavirus zoonóticos.

En las últimas dos décadas, han surgido tres coronavirus con orígenes ancestrales en murciélagos que han causado brotes generalizados en humanos.

Entre ellos están incluidos el síndrome respiratorio agudo severo por coronavirus 2 (SARS-CoV-2), responsable de la pandemia de covid-19, y síndrome respiratorio agudo severo (SARS), que causó un brote epidémico en 2002. Ambos virus pertenecen al subgénero *Sarbecovirus* del género *Betacoronavirus* de la familia *Coronaviridae*.

En realidad, los coronavirus son un amplio grupo de virus que pueden infectar a una gran variedad de animales, incluidos por supuesto los humanos. Desde el primer informe del virus de la bronquitis infecciosa (IBV) en 1937, han sido aislados y/o identificados numerosos coronavirus en varias especies animales, así como en humanos.

Los murciélagos son el segundo orden de mamíferos más diverso, con más de 1 400 especies, y albergan una diversidad excepcional de coronavirus con linajes virales antiguos distribuidos en los seis continentes donde habitan los murciélagos. Han sido detectadas más de 4 800 secuencias de coronavirus en murciélagos, lo que representa más del 30 % de todos los virus de murciélago secuenciados, aunque la verdadera diversidad de coronavirus de murciélago es probablemente mucho mayor.

Por qué debe preocuparnos Khosta-2

Las enfermedades emergentes causadas por coronavirus de probable origen en murciélagos son un foco de preocupación porque han perturbado la salud y las economías mundiales en los últimos tiempos. La evidencia sugiere que algunos coronavirus podrían infectar a las personas directamente y que su propagación es más frecuente de lo que se creía anteriormente.

Los dos nuevos coronavirus encontrados en Rusia, que pertenecen al subgénero *Sarbecovirus* como el SARS-CoV-2, merecen especial atención. Por un lado, diversos análisis han determinado que, aunque Khosta-1 representa un riesgo bajo para los humanos, el virus Khosta-2 tiene ciertos rasgos preocupantes. Entre ellos, ser resistente a los anticuerpos monoclonales, al suero de personas vacunadas contra el SARS-CoV-2 y al suero de personas que habían sido infectadas por la variante Ómicron.

Además, como ya hemos señalado, al igual que SARS-CoV-2, tiene preferencia por el receptor ACE2 y puede utilizar la proteína S para infectar células humanas.

Al parecer, Khosta-2 carece de algunos de los genes implicados en la patogénesis en humanos. Pero existe el riesgo de recombinación con otros virus cercanos, como el SARS-CoV-2, y de que se convierta en un virus muy peligroso para los humanos. Las enfermedades emergentes causadas por coronavirus de probable origen en murciélagos son un enorme foco de preocupación.

Este hallazgo confirma que los sarbecovirus que circulan en la vida silvestre fuera de Asia también representan una amenaza para la salud mundial y para las campañas de vacunación en curso contra el SARS-CoV-2. Por ello, es necesario desarrollar vacunas universales que protejan contra los coronavirus en general, y no solo contra las variantes conocidas del SARS-CoV-2.

Cada derrame zoonótico de un nuevo coronavirus representa una oportunidad para la adaptación evolutiva y una mayor propagación. Por tanto, los programas de prevención son esenciales. Obtener una vacuna pancoronavirus supone un reto que, de conseguirse, sería uno de los mayores logros relacionados con la salud mundial.

Fuente: The Conversation. Disponible en https://bit.ly/3ep0e49

Cambodia's COVID-19 vaccination coverage close to 95%

Oct 3. Cambodia has so far administered at least one dose of COVID-19 vaccine to some 15.19 million people, or 94.9% of its 16-million population, Prime Minister Samdech Techo Hun Sen said on October 3.

Addressing a graduation ceremony of students at the Vanda Institute in Phnom Penh, the Cambodian PM said the government's tough measures, together with high vaccination rates, have enabled the Southeast Asian nation to control the pandemic successfully, protecting millions of lives.

Cambodia has seen no new deaths from COVID-19 since April, as 90.9% of its population had been fully vaccinated with two required vaccine doses, the health ministry said the same day.

Also, about 63.6% of the people had received a third dose, 27% a fourth jab, and 5.4% a fifth shot, the ministry added.

China's Sinovac and Sinopharm vaccines have been widely used in Cambodia's immunisation programme.

Fuente: Vietnam Plus. Disponible en https://bit.ly/3Ms6Zi2

Cambodia's COVID-19 vaccination coverage close to 95%

Oct 3. Cambodia has so far administered at least one dose of COVID-19 vaccine to some 15.19 million people, or 94.9% of its 16-million population, Prime Minister Samdech Techo Hun Sen said on October 3.

Addressing a graduation ceremony of students at the Vanda Institute in Phnom Penh, the Cambodian PM said the government's tough measures, together with high vaccination rates, have enabled the Southeast Asian nation to control the pandemic successfully, protecting millions of lives.

Cambodia has seen no new deaths from COVID-19 since April, as 90.9% of its population had been fully vaccinated with two required vaccine doses, the health ministry said the same day.

Also, about 63.6% of the people had received a third dose, 27% a fourth jab, and 5.4% a fifth shot, the ministry added.

China's Sinovac and Sinopharm vaccines have been widely used in Cambodia's immunisation programme.

Fuente: PR Newswire. Disponible en https://prn.to/3U1zJkZ

Costa Rica begins Covid-19 vaccination for children under five

Oct 4. I want to call on all parents to come our health centers for their children to be vaccinated against Covid-19, Deputy Health Minister Alexei Carrillo said in a press conference.

Both Carrillo and the CCSS President Marta Esquivel agreed upon the significance of full immunization to protect population from infecting or dying of Covid-19.

"The Covid-19 vaccination for children aged six months to five will officially start on Tuesday at all Costa Rica´s Social Security Fund (CCSS) centers."

For this vaccination, the CCSS acquired, through the National Emergency Commission, the first Pfizer/ BioNTech 450,000-vaccine batch, of which over 302,000 arrived in Costa Rica last week and the rest will be delivered by the end of this year.

Being approved by the National Vaccination and Epidemiology Commission, the immunization for this age group is mandatory, which means that parents, guardians and other people in charge of minors must take them to vaccination centers to receive the three respective doses.

Fuente: Prensa Latina. Disponible en https://bit.ly/3CW3gWM

España: Confirman primer caso de gripe aviar H5N1 en humanos

5 oct. La víspera autoridades españolas confirmaron el primer caso de gripe aviar H5N1 en humanos en el país, y el segundo registrado en Europa tras ser descubierto en Reino Unido el primer paciente.

La noticia publicada además por medios locales ha tenido lugar cuando se confirmó el 2 de octubre la detección de 2 467 brotes en aves de corral, que han provocado el sacrificio de alrededor de 48 millones de aves en los 37 países europeos afectados.

El enfermo, quien trabaja en una granja avícola en la provincia de Guadalajara, en Castilla-La Mancha, resultó positivo el pasado 27 de septiembre tras el análisis muestral realizado cuatro días antes.

La persona afectada permaneció asintomática y se encontraba aislada hasta el día 28, cuando le repitieron la prueba diagnóstico y resultó negativo a la infección. Por otra parte, el resto de sus compañeros de trabajo han dado negativo.

Especialistas españoles confirmaron que los contactos laborales del paciente han estado consumiendo de forma preventiva un antiviral contra este tipo de gripe, el oseltamivir.

El 12 de septiembre, el Ministerio de Agricultura, Pesca y Alimentación notificó que en una granja de gallinas se detectó un brote de gripe aviar, debido a lo cual se sacrificaron 601 000 gallinas ponedoras.

Durante 2022 se han detectado en España 36 focos de gripe aviar H5N1en aves de corral. Por otro lado, desde que comenzó el presente siglo la Organización Mundial de la Salud (OMS) ha presentado más de 800 casos en humanos, con una tasa de letalidad del 52 por ciento.

Fuente: Cubadebate. Disponible en https://bit.ly/3g6ilML

Las vacunas CanSino contra el COVID se fabricarán en la Argentina

6 oct. La compañía argentina Laboratorios Richmond y la empresa farmacéutica CanSino Biologics Inc. (CanSinoBIO), de origen chino, firmaron un acuerdo para la producción y comercialización de distintas vacunas en el país. En un futuro, estas dosis podrán exportarse a todo Latinoamérica.

La primera vacuna a transferir tecnológicamente será la de COVID-19, cuyo nombre comercial es Convidecia®.

Las dosis van a elaborarse en la planta biotecnológica que la compañía argentina tiene en Pilar, Provincia de Buenos Aires. El convenio creará 120 puestos de trabajo directos y potenciará el desarrollo de conocimiento científico argentino.

A su vez, permitirá sustituir las importaciones de estas dosis, que desde agosto de 2021 se aplican en la Argentina. El acuerdo, además, busca ubicar al país como referente de vacunas para América Latina. El laboratorio es el fabricante local de los dos componentes de la vacuna rusa Sputnik V contra el COVID-19, la primera que se aplicó en el país.

"Como laboratorio siempre estamos en busca de nuevos desarrollos y exploramos acuerdos con compañías de todo el mundo. Ahora, las plataformas tecnológicas que incorporaremos derivarán en la producción de vacunas para tratar diversas patologías. En una primera instancia, comenzaremos con la producción de la vacuna contra COVID-19 de CanSinoBIO", señaló Juan Manuel Artola, CEO de Laboratorios Richmond.

La vacuna Convidecia® fue desarrollada por la empresa CanSino Biologics en colaboración con el Instituto de Biotecnología de Pekín. Se trata de una vacuna de vector viral de dosis única que puede almacenarse entre los 2 y los 8 grados centígrados.

Las vacunas con vectores virales utilizan un virus distinto al SARS-CoV-2, por ejemplo un adenovirus, genéticamente modificado que no puede provocar la enfermedad, pero sí puede producir proteínas de ese coronavirus para generar una respuesta inmunitaria segura.

El acuerdo de transferencia contempla incluir en varias etapas tecnologías tales como adenovirus, proteínas recombinantes, ARN mensajero, entre otras. "La producción abrirá un nuevo capítulo de crecimiento también para nuestros científicos. Somos un laboratorio que hace escuela", expresó Elvira Zini, directora de Asuntos Científicos de Laboratorios Richmond.

CanSino Biologics Inc. es una compañía biofarmacéutica que desarrolló proyectos de 17 vacunas para 12 enfermedades infecciosas, entre ellas la meningitis, la neumonía, la tuberculosis, el COVID-19, la enfermedad por el virus del Ébola, la tos ferina, la difteria, el tétanos y la culebrilla, entre otras.

En cuanto al flamante convenio con la compañía argentina, el doctor Xuefeng Yu, presidente y director ejecutivo de CanSinoBIO, expresó: "Nos complace alcanzar esta colaboración con el Laboratorio Richmond, una de las compañías farmacéuticas de primer nivel en América Latina. Comenzando con la producción local de la vacuna para COVID-19, esperamos explorar más opciones en el futuro. Nuestro objetivo conjunto es seguir adelante con una amplia cartera de productos en desarrollo y lograr un compromiso a largo plazo".

La vacuna Convidecia

La fórmula contra el coronavirus de CanSino Biologics desarrollada en China, se administra en una sola dosis, y fue autorizada para uso de emergencia en Argentina, Chile, Ecuador, Hungría, Indonesia, Malasia, México, Moldavia y Pakistán.

La vacuna Convidecia® fue aprobada por la Organización Mundial de la Salud (OMS) en mayo de este año. Los estudios publicados en diciembre pasado en la revista The Lancet demostraron que la vacuna mostró

alta eficacia como refuerzo: la monodosis otorgó 91,7% de protección para prevenir el COVID-19 grave a partir de los 28 días posteriores a la vacunación. El ensayo clínico se hizo en Argentina, Chile, México y Pakistán.

Estudios más recientes, de marzo de este año, demostraron además que Convidecia® mostró ventajas como potenciador heterólogo (combinación de plataformas de las vacunas disponibles) frente a Ómicron, según informó esa compañía farmacéutica.

De acuerdo con información dada a conocer por el laboratorio, la vacuna de CanSinoBIO en sus dos versiones, inyectable e inhalable, "puede inducir una respuesta inmune más fuerte que las inyecciones de proteína recombinante inactivadas". Las vacunas basadas en proteínas utilizan fragmentos inocuos de proteínas o estructuras proteicas que imitan el virus causante de COVID-19, con el fin de generar una respuesta inmunitaria.

"La respuesta de anticuerpos neutralizantes generada por el refuerzo de la vacuna Inhalable de CanSino contra Ómicron es 14,1 veces mayor que, por ejemplo, la del refuerzo de Sinovac y dos veces mayor que la misma inyección de CanSino intramuscular", agregó el estudio.

Tanto Sinovac como Sinopharm, que se aplica en Argentina, están desarrolladas con virus inactivados o atenuados, que utilizan el virus SARS-CoV-2 previamente inactivado o atenuado, de modo que no provoca la enfermedad, pero sí genera una respuesta inmunitaria.

Fuente: infobae. Disponible en https://bit.ly/3CzeDT7

Indonesia está en conversaciones con países africanos para exportar su vacuna artesanal contra el COVID

6 oct. Indonesia está en conversaciones con varios países africanos, incluido Nigeria, para exportar y donar su vacuna casera contra el COVID-19, dijo el viernes su desarrollador, luego de convertirse en el primer país del sudeste asiático en aprobar una vacuna contra el COVID-19 desarrollada a nivel nacional.

La aprobación de Indonesia de la inyección, para la cual aún no se han anunciado datos detallados de prueba y que se basa principalmente en variantes de coroanvirus que son anteriores a Omicron, subraya el progreso en la investigación de vacunas y la reducción de la dependencia de tecnologías extranjeras.

"Con Indovac… esta es una oportunidad para que Indonesia done", dijo a Reuters Honesti Basyir, director ejecutivo de la estatal Bio Farma, en referencia a la vacuna COVID de proteína recombinante que ha sido aprobada por el regulador de medicamentos del gobierno, BPOM, el mes pasado.

Bio Farma dijo que también había presentado documentos a la Organización Mundial de la Salud para obtener una Autorización de uso de emergencia (EUL) para IndoVac, lo que le permitiría estar sujeto a donaciones a través de organizaciones como el Programa Global de Intercambio de Vacunas COVAX.

Mientras tanto, Indonesia puede exportar la vacuna.

"No cierra nuestra capacidad de exportación, siempre que los reguladores locales puedan aceptar la aprobación de BPOM", dijo Honesti, y agregó, sin embargo, que la prioridad era vacunar primero a los indonesios.

Sin embargo, las perspectivas de exportación de la vacuna se consideran limitadas, ya que las dosis de

COVID están en exceso en todo el mundo e Indovac no se está desarrollando para apuntar a la variante dominante de Omicron.

Al comienzo de la pandemia, los países africanos lucharon por obtener las vacunas contra el COVID, mientras los países ricos acumulaban las dosis. Pero muchos ahora están bien abastecidos de vacunas y tienen dificultades para administrarlas, ya sea por vacilación o por preocupaciones logísticas.

IndoVac, desarrollado en conjunto con el Centro para el Desarrollo de Vacunas del Hospital Infantil de Texas en el Colegio de Medicina de Baylor, está disponible como inyección primaria para adultos en Indonesia.

Honesti dijo que la investigación ha comenzado a fabricar una versión específica de Omicron, y agregó que el desarrollo de la vacuna COVID le ha dado a Indonesia la confianza para reducir su dependencia de la tecnología extranjera.

Bio Farma planea producir 20 millones de dosis de IndoVac este año, pero el suministro final depende de los planes de vacunación del gobierno.

Indonesia ha vacunado completamente a más del 63% de sus 270 millones de habitantes con vacunas fabricadas por Pfizer/BioNTech, Moderna y la empresa china Sinovac Biotech.

Honesti dijo que Bio Farma dejó de producir la vacuna de Sinovac el año pasado y no está en proceso de obtener más de la compañía china, ya que se enfoca en IndoVac.

Fuente: News.Es Euro. Disponible en https://bit.ly/3g8gqHe

Puntera de la vacunación en el mundo

8 oct. La Soberana 02, cuyo nombre técnico es FINLAY- FR-2 anti SARS-CoV-2, es una vacuna contra la COVID-19 desarrollado por el Instituto Finlay de Vacunas del Ministerio de Ciencia, Tecnología y Medio Ambiente Cuba. Es una vacuna conjugada, donde se combina el antígeno del virus y el toxoide tetánico y se basa en el enfoque de las vacunas de subunidad proteica, según un estudio de Ecured

La vacuna contra la COVID-19, destinada a convalecientes de la enfermedad creada por expertos del Instituto Finlay de Vacunas, es la Soberana Plus, que constituye por excelencia el producto seleccionado para 'boostear' una respuesta inmune preexistente, es decir, reforzar los títulos de anticuerpos en pacientes expuestos al virus o vacunados con otros candidatos, dicen los especialistas.

La vacuna Abdala, creada por el Centro de Ingeniería Genética y Biotecnología (CIGB), fue la primera de su tipo creada en América Latina. En su prueba mostró el 92,28 % de eficacia en su esquema único de tres dosis. Esta vacuna es un 100 % eficaz contra la enfermedad en estado severa y muerte por Covid-19. Así ha sido reconocido por las autoridades de salud de Venezuela, Irán, México y países del Caribe.

Estos resultados, cuyo mayor indicador es el haberse logrado el control de esta letal enfermedad, han estado presididos por la unidad de acción y el trabajado cohesionado de profesionales cuyos saberes han sido puestos a disposición de crear un valladar a favor de la salud de su pueblo y otros pueblos del mundo, que reconocen su importantísima labor, por encima de campañas mediática de los odiadores públicos y privados contra Cuba, financiados por organismos de Estados Unidos.

Fuente: Sierra Maestra. Disponible en https://bit.ly/3TbHT9o

Nuevas vacunas COVID-19 adaptadas a las variantes: ¿en qué punto estamos?

10 oct. Hace apenas unos días, España comenzó a administrar la cuarta dosis de la vacuna COVID-19 a personas mayores de 80 años y aquellas viviendo en residencias. Estas cuartas dosis tienen una novedad: además de la secuencia Spike original, incluyen la secuencia Spike de la variante ómicron (ya sea la BA.1 o la BA.5). Como recalca el Grupo Colaborativo Multidisciplinar para el Seguimiento Científico de la COVID-19 (GCMSC), impulsado por el Instituto de Salud Global de Barcelona (ISGlobal) y el Colegio Oficial de Médicos de Barcelona (CoMB), las personas mayores y las personas con problemas de salud subyacentes son las que más se beneficiarán de la protección adicional que ofrece un refuerzo con estas nuevas vacunas.

En un nuevo documento, el GCMSC analiza la situación actual del virus y la evidencia disponible sobre las nuevas vacunas adaptadas a las variantes del SARS-CoV-2. Los principales mensajes del grupo son:

La subvariante BA.5 sigue dominando en muchas regiones, incluida Cataluña, pero han ido surgiendo múltiples descendientes de BA.2 y BA.4/5 que comparten mutaciones que permiten al virus evadir mejor los anticuerpos generados por la vacunación o las infecciones previas.

Por esta razón, y porque la eficacia de la vacuna decae con el tiempo, se recomienda una cuarta dosis en las personas más vulnerables (personas mayores de 60 o con comorbilidades, así como mujeres embarazadas), de preferencia con las nuevas vacunas bivalentes.

Aunque se espera que las vacunas de refuerzo que contienen BA.5 sean las más eficaces contra las subvariantes actualmente en circulación, los datos indican que cualquier tipo de refuerzo (original o adaptada a variantes) proporcionan una protección adicional.

Por el momento, no se recomienda una cuarta dosis a la población menor de 60 años y sin indicación médica, sobre todo considerando que gran parte de la misma se infectó recientemente con ómicron. Esto puede cambiar si llega una (sub)variante con mayor capacidad de evasión inmune.

El GCMSC también recomienda mantener el uso de mascarillas en ciertos lugares como hospitales y residencias, e insiste en la necesidad de mantener la vigilancia del virus a nivel mundial, para poder detectar nuevas variantes y mitigar su potencial impacto sobre el diagnóstico, las estrategias de vacunación o los tratamientos.

Sobre el Grupo Colaborativo Multidisciplinar para el Seguimiento Científico de la COVID-19 (GCMSC)

El GCMSC es un grupo promovido por el Instituto de Salud Global de Barcelona (ISGlobal), centro impulsado por la Fundación ”la Caixa”, y el Colegio Oficial de Médicos de Barcelona (CoMB), con el apoyo de la Asociación Catalana de Centros de Investigación.

Fuente: Instituto de Salud Global de Barcelona ISGlobal. Disponible en https://bit.ly/3sdsGcB

Otras proteínas del SARS-CoV-2 son importantes para la gravedad de la enfermedad, según un estudio



10 oct. Investigadores de la Facultad de Medicina de la Universidad de Maryland (Estados Unidos) han identificado el modo en que múltiples genes del SARS-CoV-2 afectan a la gravedad de la enfermedad, lo que podría conducir a nuevas formas de desarrollar futuras vacunas o elaborar nuevos tratamientos.

Los genes controlan el sistema inmunitario del huésped, contribuyendo a la ferocidad con la que el organismo responde a una infección por covid-19. Aunque la gente suele pensar en la proteína de la espiga (S) que forma la corona estructural como el factor impulsor de cada nueva variante de covid-19, los resultados de la investigación también muestran que las mutaciones en estos otros genes "accesorios" también desempeñan un papel en la forma en que progresa la enfermedad.

Por ello, los investigadores creen que estas proteínas accesorias merecen un estudio más profundo, ya que sus mutaciones pueden ser cada vez más significativas a medida que surgen nuevas variantes.

El virus del SARS-CoV-2 tiene tres tipos de genes: los que intervienen en la fabricación de más copias del virus, los que hacen la estructura del virus y los genes accesorios que tienen otras funciones. Para este nuevo estudio, los investigadores querían averiguar la función de los genes accesorios.

Para ello, recrearon virus que carecían de cada una de las cuatro proteínas accesorias y luego infectaron a ratones con estos nuevos virus o con el virus original. A continuación, observaron cómo afectaba cada virus a los ratones.

El estudio, publicado en la revista científica 'PNAS', descubrió que los virus a los que les faltaba el gen ORF3a/b provocaban infecciones más leves que el virus original del SARS-CoV-2. Los ratones con esta cepa del virus perdían menos peso y tenían menos virus en los pulmones que los ratones infectados con el virus original.

Estos resultados indicaron que el gen ORF3a/b probablemente desempeña un papel en la fabricación de más copias del virus a través de la replicación viral o en el bloqueo de la respuesta inmunitaria a la infección.

Otros experimentos sugirieron que el ORF3a/b tiene un trabajo extra en el virus, ya que parece activar el sistema inmunitario innato del cuerpo, la primera línea de defensa lanzada por el sistema inmunitario, señalando que hay que derrotar a un invasor extraño.

En cambio, los investigadores descubrieron que los ratones infectados con el virus al que le faltaba el gen ORF8 estaban más enfermos que los ratones con la cepa original del SARS-CoV-2. Estos ratones presentaban una mayor inflamación en los pulmones en comparación con el SARS-CoV-2 original. Los investigadores dijeron que el ORF8 parece controlar la respuesta inmunitaria en los pulmones.

"Al inhibir la respuesta inmunitaria, el ORF8 ayuda al virus a replicarse más en los pulmones, lo que empeora la infección. Cuando se eliminó, permitió que el sistema inmunitario luchara con más fuerza", ha comentado el doctor Matthew Frieman.

A continuación, los investigadores analizaron la importancia de la proteína de espiga para la gravedad de la enfermedad en cada una de las diferentes variantes del SARS-CoV-2. Tomaron el virus original y cambiaron el gen por el de la espiga de la variante alfa, beta, gamma o delta.

A continuación, infectaron células y ratones y observaron cómo cada uno de estos virus se replicaba y entraba en las células sanas. El virus utiliza la proteína S para hacer 'autostop' en los receptores ACE2 del huésped, que se encuentran en el exterior de las células que recubren los pulmones, como forma de entrar e infectar las células.

El equipo de investigación evidenció que la proteína S determina la gravedad de algunas de las variantes, pero no de otras. La variante gamma era más débil que las demás en su capacidad de replicarse e infectar.

Los investigadores creen que las mutaciones en los genes fuera de la espiga, en particular en el gen ORF8, parecen desempeñar un papel en hacer que esta versión sea más débil que las demás. Aunque la variante gamma circuló en Brasil, no se extendió más por el mundo, ya que fue superada por variantes más fuertes.

Fuente: Heraldo. Disponible en https://bit.ly/3g8Hg27

Artículos científicos publicados en Medline

Filters activated: Publication date from 2022/10/01 to 2022/10/11. "Vaccine" (Title/Abstract) 829 records.

COVID-19 **vaccine** - can it affect fertility?
Schaler L, Wingfield M. Ir J Med Sci. 2022 Oct;191(5):2185-2187. doi: 10.1007/s11845-021-02807-9. Epub 2021 Oct 15. PMID: 34651258

SARS-CoV-2 **vaccine**-related cutaneous manifestations: a systematic review.
Avallone G, Quaglino P, Cavallo F, Roccuzzo G, Ribero S, Zalaudek I, Conforti C. Int J Dermatol. 2022 Oct;61(10):1187-1204. doi: 10.1111/ijd.16063. Epub 2022 Feb 9. PMID: 35141881

COVID-19: Clinical status of **vaccine** development till date.
Kumar S, Basu M, Ghosh P, Ansari A, Ghosh MK. Br J Clin Pharmacol. 2022 Oct 2:10.1111/bcp.15552. doi: 10.1111/bcp.15552. Online ahead of print. PMID: 36184710

A Bivalent Omicron-Containing Booster **Vaccine** against Covid-19.
Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, McGhee N, Tomassini JE, Chen X, Chang Y, Sutherland A, Montefiori DC, Girard B, Edwards DK, Feng J, Zhou H, Baden LR, Miller JM, Das R. N Engl J Med. 2022 Oct 6;387(14):1279-1291. doi: 10.1056/NEJMoa2208343. Epub 2022 Sep 16. PMID: 36112399

Influenza **vaccine** for 2022-2023.
[No authors listed] Med Lett Drugs Ther. 2022 Oct 3;64(1660):153-157. PMID: 36206165

The consequences of COVID-19 and its **vaccine** on pregnant and lactating mothers.
Obaid AF, Shlash AMJ, Abdulrasol ZA, Lafta MA. Egypt J Immunol. 2022 Oct;29(4):58-74. PMID: 36197154

Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of **Vaccine**-Related Adverse Events: Results From PREVENT-COVID.
Weaver KN, Zhang X, Dai X, Watkins R, Adler J, Dubinsky MC, Kastl A, Bousvaros A, Strople JA, Cross RK, Higgins PDR, Ungaro RC, Bewtra M, Bellaguarda E, Farraye FA, Boccieri ME, Firestine A, Kappelman MD, Long MD. Inflamm Bowel Dis. 2022 Oct 3;28(10):1497-1505. doi: 10.1093/ibd/izab302. PMID: 34871388

This Month in JAAD International: October 2022: **Vaccine** hesitancy and medical specialists.
Kantor J. J Am Acad Dermatol. 2022 Oct;87(4):751. doi: 10.1016/j.jaad.2022.08.018. Epub 2022 Aug 17. PMID: 35987396

Myocarditis After Vaccination.
Canakci ME, Mert KU, Aydin N. Prehosp Disaster Med. 2022 Oct;37(5):716-717. doi: 10.1017/S1049023X22001236. Epub 2022 Aug 30. PMID: 36040478

Vaccine-Induced Myocarditis: Correspondence.
Sookaromdee P, Wiwanitkit V. Prehosp Disaster Med. 2022 Oct;37(5):718. doi: 10.1017/S1049023X2200125X. Epub 2022 Sep 2. PMID: 36052478

COVID-19 **Vaccine**-Associated Pericarditis.
Famularo G, Macciomei MC. Ann Pharmacother. 2022 Oct;56(10):1188-1189. doi: 10.1177/10600280211073970. Epub 2022 Feb 8. PMID: 35130746

Dengue **vaccine** development: challenges and prospects.
Wilder-Smith A. Curr Opin Infect Dis. 2022 Oct 1;35(5):390-396. doi: 10.1097/QCO.0000000000000871. PMID: 36098260

Recommendations for Prevention and Control of Influenza in Children, 2022-2023.
COMMITTEE ON INFECTIOUS DISEASES. Pediatrics. 2022 Oct 1;150(4):e2022059275. doi: 10.1542/peds.2022-059275. PMID: 36065750

The early-life gut microbiome and **vaccine** efficacy.
Jordan A, Carding SR, Hall LJ. Lancet Microbe. 2022 Oct;3(10):e787-e794. doi: 10.1016/S2666-5247(22)00185-9. Epub 2022 Sep 8. PMID: 36088916

Nanovaccines to combat virus-related diseases.
Wu F, Qin M, Wang H, Sun X. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022 Oct 2:e1857. doi: 10.1002/wnan.1857. Online ahead of print. PMID: 36184873

A **vaccine** for human babesiosis: prospects and feasibility.
Al-Nazal H, Low LM, Kumar S, Good MF, Stanisic DI. Trends Parasitol. 2022 Oct;38(10):904-918. doi: 10.1016/j.pt.2022.07.005. Epub 2022 Aug 3. PMID: 35933301

Cable news and COVID-19 **vaccine** uptake.
Pinna M, Picard L, Goessmann C. Sci Rep. 2022 Oct 7;12(1):16804. doi: 10.1038/s41598-022-20350-0. PMID: 36207425

COVID-19 **vaccine** design and vaccination strategy for emerging variants.
Chavda VP, Apostolopoulos V. Expert Rev Vaccines. 2022 Oct;21(10):1359-1361. doi: 10.1080/14760584.2022.2112571. Epub 2022 Aug 16. PMID: 35949150

A Hitchhiker's Guide to Worldwide COVID-19 Vaccinations: A Detailed Review of Monovalent and Bivalent **Vaccine** Schedules, COVID-19 **Vaccine** Side Effects, and Effectiveness Against Omicron and Delta Variants.
Goyal L, Zapata M, Ajmera K, Chaurasia P, Pandit R, Pandit T. Cureus. 2022 Oct 2;14(10):e29837. doi: 10.7759/cureus.29837. eCollection 2022 Oct. PMID: 36204257

'Mix and Match' vaccination: Is dengue next?
Odio CD, Katzelnick LC. Vaccine. 2022 Oct 1:S0264-410X(22)01101-X. doi: 10.1016/j.vaccine.2022.09.007. Online ahead of print. PMID: 36195473

COVID-19 **vaccine** hesitancy among young adults in Canada.
Santavicca T, Ngov C, Frounfelker R, Miconi D, Levinsson A, Rousseau C. Can J Public Health. 2022 Oct 7:1-12. doi: 10.17269/s41997-022-00693-x. Online ahead of print. PMID: 36207641

HPV **Vaccine** Experiences and Preferences Among Young Adult Cancer Survivors and Caregivers of Childhood Cancer Survivors.
Waters AR, Mann K, Vaca Lopez PL, Kepka D, Wu YP, Kirchhoff AC. J Cancer Educ. 2022 Oct;37(5):1519-1524. doi: 10.1007/s13187-021-01992-6. Epub 2021 Mar 19. PMID: 33740231

Safety of Dengue **Vaccine**?
Biswal S, Patel SS, Rauscher M. Clin Infect Dis. 2022 Oct 5:ciac808. doi: 10.1093/cid/ciac808. Online ahead of print. PMID: 36196620

COVID-19 **Vaccine** Hesitancy in Patients with Inflammatory Bowel Disease.
Clarke K, Pelton M, Stuart A, Tinsley A, Dalessio S, Bernasko N, Williams ED, Coates M. Dig Dis Sci. 2022 Oct;67(10):4671-4677. doi: 10.1007/s10620-021-07377-5. Epub 2022 Jan 29. PMID: 35092534

COVID-19 **Vaccine** Administration and Hesitation Among Psychiatric Emergency Services Patients.
Mitchell L, Wilkosz M, Fuehrlein B. Community Ment Health J. 2022 Oct;58(7):1381-1384. doi: 10.1007/s10597-022-00949-3. Epub 2022 Feb 12. PMID: 35150353

COVID-19 **Vaccine** Hesitancy, Acceptance, and Promotion Among Healthcare Workers: A Mixed-Methods Analysis.
Hoffman BL, Boness CL, Chu KH, Wolynn R, Sallowicz L, Mintas D, Douaihy AB, Felter EM, Sidani JE. J Community Health. 2022 Oct;47(5):750-758. doi: 10.1007/s10900-022-01095-3. Epub 2022 Jun 8. PMID: 35676390

A review of the sustainability of **vaccine** funding across Europe and implications for post-COVID policymaking.
Lawlor R, Wilsdon T, Rémy-Blanc V, Nogal AÁ, Pana A. Health Policy. 2022 Oct;126(10):956-969. doi: 10.1016/j.healthpol.2022.08.004. Epub 2022 Aug 10. PMID: 36008177

Immune responses to Vibrio vulnificus formalin-killed **vaccine** and ghost **vaccine** in Scophthalmus maximus.
Zhou S, Li Y, Yi J, Zheng X, Huang Q, Su L, Guo B, Yang Z, Xiu Y. J Fish Dis. 2022 Oct;45(10):1511-1527. doi: 10.1111/jfd.13678. Epub 2022 Jun 30. PMID: 35771999

Livedo reticularis after COVID-19 vaccination.
Horino T, Inotani S, Nakajima K, Terada Y. J Rheumatol. 2022 Oct 1:jrheum.220584. doi: 10.3899/jrheum.220584. Online ahead of print. PMID: 36182117

Vaccines against SARS-CoV-2 variants and future pandemics.
Park T, Hwang H, Moon S, Kang SG, Song S, Kim YH, Kim H, Ko EJ, Yoon SD, Kang SM, Hwang HS. Expert Rev Vaccines. 2022 Oct;21(10):1363-1376. doi: 10.1080/14760584.2022.2110075. Epub 2022 Aug 12. PMID: 35924678

Lichen planus pigmentosus post COVID-19-vaccination.
Chaima K, Fatma H, Nadine K, Chahir K, Emna B, Khadija S, Mariem A, Sonia B, Abderrahman M, Tahya B, Hamida T. Dermatol Ther. 2022 Oct 1:e15891. doi: 10.1111/dth.15891. Online ahead of print. PMID: 36183151

Original Research: COVID-19 **Vaccine** Hesitancy Among Southern California Nurses.
Roberts LR, Dubov A, Distelberg B, Peteet B, Abdul-Mutakabbir JC, Montgomery S, Patel P, Chrissian AA. Am J Nurs. 2022 Oct 6;Published Ahead of Print. doi: 10.1097/01.NAJ.0000892492.43587.5f. Online ahead of print. PMID: 36201394

Perceptions and Attitudes toward COVID-19 Vaccination among Pregnant and Postpartum Individuals.
Siegel MR, Lumbreras-Marquez MI, James K, McBay BR, Gray KJ, Schantz-Dunn J, Diouf K, Goldfarb IT. Am J Perinatol. 2022 Oct;29(14):1489-1495. doi: 10.1055/a-1877-5880. Epub 2022 Jun 16. PMID: 35709744

US Evaluation of Axillary Lymphadenopathy Following COVID-19 Vaccination: A Prospective Longitudinal Study.
Ha SM, Chu AJ, Lee J, Kim SY, Lee SH, Yoen H, Cho N, Moon WK, Chang JM. Radiology. 2022 Oct;305(1):46-53. doi: 10.1148/radiol.220543. Epub 2022 Apr 26. PMID: 35471107

Race, ethnicity and COVID-19 vaccination: a qualitative study of UK healthcare staff.
Woodhead C, Onwumere J, Rhead R, Bora-White M, Chui Z, Clifford N, Connor L, Gunasinghe C, Harwood H, Meriez P, Mir G, Jones Nielsen J, Rafferty AM, Stanley N, Peprah D, Hatch SL. Ethn Health. 2022 Oct;27(7):1555-1574. doi: 10.1080/13557858.2021.1936464. Epub 2021 Jun 6. PMID: 34092149

Influenza **vaccine** administration in a paediatric intensive care unit.
Elia S, Moore Y, Duke T, Crawford NW, Tosif S. J Paediatr Child Health. 2022 Oct;58(10):1766-1770. doi: 10.1111/jpc.16083. Epub 2022 Jun 24. PMID: 35748619

Decreased influenza vaccination coverage among Chinese healthcare workers during the COVID-19 pandemic.
Ma L, Han X, Ma Y, Yang Y, Xu Y, Liu D, Yang W, Feng L. Infect Dis Poverty. 2022 Oct 8;11(1):105. doi: 10.1186/s40249-022-01029-0. PMID: 36209258

Recent advances in the **vaccine** development for the prophylaxis of SARS Covid-19.
Kumar V, Kumar S, Sharma PC. Int Immunopharmacol. 2022 Oct;111:109175. doi: 10.1016/j.intimp.2022.109175. Epub 2022 Aug 17. PMID: 35994853

Understanding parental **vaccine** refusal: Implicit and explicit associations about vaccines as potential building blocks of **vaccine** beliefs and behavior.
Howell JL, Gasser ML, Kaysen D, Lindgren KP. Soc Sci Med. 2022 Oct;310:115275. doi: 10.1016/j.socscimed.2022.115275. Epub 2022 Aug 13. PMID: 36037608

Partisan Polarization of Childhood Vaccination Policies, 1995–2020.
Estep K, Muse A, Sweeney S, Goldstein ND. Am J Public Health. 2022 Oct;112(10):1471-1479. doi: 10.2105/AJPH.2022.306964. Epub 2022 Aug 25. PMID: 36007205

Effectiveness of influenza and pneumococcal vaccines on chronic obstructive pulmonary disease exacerbations.
Li Y, Zhang P, An Z, Yue C, Wang Y, Liu Y, Yuan X, Ma Y, Li K, Yin Z, Wang L, Wang H. Respirology. 2022 Oct;27(10):844-853. doi: 10.1111/resp.14309. Epub 2022 Jun 15. PMID: 35705329

Vaccines, adjuvants and key factors for mucosal immune response.
Correa VA, Portilho AI, De Gaspari E. Immunology. 2022 Oct;167(2):124-138. doi: 10.1111/imm.13526. Epub 2022 Jul 12. PMID: 35751397

COVID-19 **vaccine** acceptance: influential roles of political party and religiosity.
Milligan MA, Hoyt DL, Gold AK, Hiserodt M, Otto MW. Psychol Health Med. 2022 Oct;27(9):1907-1917. doi: 10.1080/13548506.2021.1969026. Epub 2021 Aug 18. PMID: 34407721

Travelers' preferences for tick-borne encephalitis vaccination.
Poulos C, Boeri M, Coulter J, Huang L, Schley K, Pugh SJ. Expert Rev Vaccines. 2022 Oct;21(10):1495-1504. doi: 10.1080/14760584.2022.2108798. Epub 2022 Sep 25. PMID: 36154795

Innate Immune Response and Inflammasome Activation During SARS-CoV-2 Infection.
Islamuddin M, Mustfa SA, Ullah SNMN, Omer U, Kato K, Parveen S. Inflammation. 2022 Oct;45(5):1849-1863. doi: 10.1007/s10753-022-01651-y. Epub 2022 Aug 11. PMID: 35953688

Associations between COVID-19 **vaccine** hesitancy and the experience of violence among women and girls living with and at risk of HIV in Nigeria.
Folayan MO, Arije O, Enemo A, Sunday A, Muhammad A, Nyako HY, Abdullah RM, Okiwu H, Lamontagne E. Afr J AIDS Res. 2022 Oct 3:1-11. doi: 10.2989/16085906.2022.2118615. Online ahead of print. PMID: 36189759

Hybrid and **vaccine**-induced immunity against SAR-CoV-2 in MS patients on different disease-modifying therapies.
Kister I, Curtin R, Pei J, Perdomo K, Bacon TE, Voloshyna I, Kim J, Tardio E, Velmurugu Y, Nyovanie S, Valeria Calderon A, Dibba F, Stanzin I, Samanovic MI, Raut P, Raposo C, Priest J, Cabatingan M, Winger RC, Mulligan MJ, Patskovsky Y, Silverman GJ, Krogsgaard M. Ann Clin Transl Neurol. 2022 Oct;9(10):1643-1659. doi: 10.1002/acn3.51664. Epub 2022 Sep 27. PMID: 36165097

Public policy and conspiracies: The case of mandates.
Lewandowsky S, Holford D, Schmid P. Curr Opin Psychol. 2022 Oct;47:101427. doi: 10.1016/j.copsyc.2022.101427. Epub 2022 Jul 20. PMID: 36029701

Image-guided intratumoral immunotherapy: Developing a clinically practical technology.
Som A, Rosenboom JG, Chandler A, Sheth RA, Wehrenberg-Klee E. Adv Drug Deliv Rev. 2022 Oct;189:114505. doi: 10.1016/j.addr.2022.114505. Epub 2022 Aug 23. PMID: 36007674

An overview on nanoparticle-based strategies to fight viral infections with a focus on COVID-19.
Yasamineh S, Kalajahi HG, Yasamineh P, Yazdani Y, Gholizadeh O, Tabatabaie R, Afkhami H, Davodabadi F, Farkhad AK, Pahlevan D, Firouzi-Amandi A, Nejati-Koshki K, Dadashpour M. J Nanobiotechnology. 2022 Oct 8;20(1):440. doi: 10.1186/s12951-022-01625-0. PMID: 36209089

Improving HPV Vaccination Rates in a Racially and Ethnically Diverse Pediatric Population.
Cox JE, Bogart LM, Elliott MN, Starmer AJ, Meleedy-Rey P, Goggin K, Banerjee T, Samuels RC, Hahn PD, Epee-Bounya A, Allende-Richter S, Fu CM, Schuster MA. Pediatrics. 2022 Oct 1;150(4):e2021054186. doi: 10.1542/peds.2021-054186. PMID: 36127315

COVID-19 **vaccine** acceptance and perceived stigma in patients with depression: a network perspective.
Cai H, Bai W, Du X, Zhang L, Zhang L, Li YC, Liu HZ, Tang YL, Jackson T, Cheung T, An FR, Xiang YT. Transl Psychiatry. 2022 Oct 4;12(1):429. doi: 10.1038/s41398-022-02170-y. PMID: 36195590

Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study.
McMenamin ME, Nealon J, Lin Y, Wong JY, Cheung JK, Lau EHY, Wu P, Leung GM, Cowling BJ. Lancet Infect Dis. 2022 Oct;22(10):1435-1443. doi: 10.1016/S1473-3099(22)00345-0. Epub 2022 Jul 15. PMID: 35850128

COVID-19 **vaccine** acceptance and coverage among pregnant persons in the United States.
Regan AK, Kaur R, Nosek M, Swathi PA, Gu NY. Prev Med Rep. 2022 Oct;29:101977. doi: 10.1016/j.pmedr.2022.101977. Epub 2022 Sep 7. PMID: 36090471

Nano toolbox in immune modulation and nanovaccines.
Azharuddin M, Zhu GH, Sengupta A, Hinkula J, Slater NKH, Patra HK. Trends Biotechnol. 2022 Oct;40(10):1195-1212. doi: 10.1016/j.tibtech.2022.03.011. Epub 2022 Apr 19. PMID: 35450779

Health Care Professionals' Herpes Zoster Awareness and **Vaccine** Recommendations for Patients with COPD.
Yawn BP, Loskutova NY, Merrill DD, Martinez S, Callen E, Cotton J, Carroll JK, Williams D. Chronic Obstr Pulm Dis. 2022 Oct 4. doi: 10.15326/jcopdf.2022.0322. Online ahead of print. PMID: 36199223

Development and application of a Japanese **vaccine** database for comparative assessments in the post-authorization phase: The **Vaccine** Effectiveness, Networking, and Universal Safety (VENUS) study.
Ishiguro C, Mimura W, Murata F, Fukuda H. Vaccine. 2022 Oct 6;40(42):6179-6186. doi: 10.1016/j.vaccine.2022.08.069. Epub 2022 Sep 9. PMID: 36096969

Overcoming **Vaccine** Hesitancy for Future COVID-19 and HIV Vaccines: Lessons from Measles and HPV Vaccines.
Aguolu OG, Malik AA, Ahmed N, Omer SB. Curr HIV/AIDS Rep. 2022 Oct;19(5):328-343. doi: 10.1007/s11904-022-00622-0. Epub 2022 Sep 17. PMID: 36114951

Long-Term **Vaccine** Delivery and Immunological Responses Using Biodegradable Polymer-Based Carriers.
Malek-Khatabi A, Tabandeh Z, Nouri A, Mozayan E, Sartorius R, Rahimi S, Jamaledin R. ACS Appl Bio Mater. 2022 Oct 10. doi: 10.1021/acsabm.2c00638. Online ahead of print. PMID: 36214209

COVID-19 **vaccine** perceptions and hesitancy amongst parents of school-aged children during the pediatric **vaccine** rollout.
Byrne A, Thompson LA, Filipp SL, Ryan K. Vaccine. 2022 Oct 5:S0264-410X(22)01221-X. doi: 10.1016/j.vaccine.2022.09.090. Online ahead of print. PMID: 36220714

Vaccine hesitancy, misinformation in the era of Covid-19: Lessons from the past.
Orsini D, Bianucci R, Galassi FM, Lippi D, Martini M. Ethics Med Public Health. 2022 Oct;24:100812. doi: 10.1016/j.jemep.2022.100812. Epub 2022 Jun 13. PMID: 35721377

Semi-Synthetic Glycoconjugate **Vaccine** Lead Against Acinetobacter baumannii 17978.
Sianturi J, Priegue P, Hu J, Yin J, Seeberger PH. Angew Chem Int Ed Engl. 2022 Oct 10;61(41):e202209556. doi: 10.1002/anie.202209556. Epub 2022 Sep 1. PMID: 35950629

Shoulder Injury Related to **Vaccine** Administration.
Flores C, Choate WS, Tupler R. Ochsner J. 2022 Fall;22(3):261-264. doi: 10.31486/toj.21.0114. PMID: 36189092

COVID-19 **vaccine** and menstrual conditions in female: data analysis of the **Vaccine** Adverse Event Reporting System (VAERS).
Zhang B, Yu X, Liu J, Liu J, Liu P. BMC Womens Health. 2022 Oct 5;22(1):403. doi: 10.1186/s12905-022-01934-4. PMID: 36195902

Immunoglobulin treatment for B-cell immunodeficiencies.
Freeman CM, Squire JD, Joshi AY. J Immunol Methods. 2022 Oct;509:113336. doi: 10.1016/j.jim.2022.113336. Epub 2022 Aug 11. PMID: 35964701

Clinical advances and ongoing trials on mRNA vaccines for cancer treatment.
Lorentzen CL, Haanen JB, Met Ö, Svane IM. Lancet Oncol. 2022 Oct;23(10):e450-e458. doi: 10.1016/S1470-2045(22)00372-2. PMID: 36174631

Limiting Screening Mammography Recalls for **Vaccine**-Induced Adenopathy, a Single Institution Experience.
Maimone S, Robinson KA, Advani PP, Li Z, Gococo-Benore DA, Qosja N, Ashai AM, Mummareddy A, Chumsri S. Acad Radiol. 2022 Oct;29(10):1480-1485. doi: 10.1016/j.acra.2021.12.028. Epub 2022 Jan 26. PMID: 35090829

Phylogenomic characterization of historic lumpy skin disease virus isolates from South Africa.
van Schalkwyk A, Kara P, Heath L. Arch Virol. 2022 Oct;167(10):2063-2070. doi: 10.1007/s00705-022-05515-6. Epub 2022 Jul 6. PMID: 35792935

Can targeted messages reduce COVID-19 vaccination hesitancy? A randomized trial.
Reddinger JL, Levine D, Charness G. Prev Med Rep. 2022 Oct;29:101903. doi: 10.1016/j.pmedr.2022.101903. Epub 2022 Jul 11. PMID: 35844628

Molecular aspects of Omicron, **vaccine** development, and recombinant strain XE: A review.
K A, Sharma A, Kumar D, Singh SK, Gupta G, Chellappan DK, Dua K, Nagraik R. J Med Virol. 2022 Oct;94(10):4628-4643. doi: 10.1002/jmv.27936. Epub 2022 Jun 27. PMID: 35705439

Towards novel nano-based **vaccine** platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations.
Helmy SA, El-Morsi RM, Helmy SAM, El-Masry SM. J Drug Deliv Sci Technol. 2022 Oct;76:103762. doi: 10.1016/j.jddst.2022.103762. Epub 2022 Sep 8. PMID: 36097606

Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens.
Wang Z, Muecksch F, Muenn F, Cho A, Zong S, Raspe R, Ramos V, Johnson B, Ben Tanfous T, DaSilva J, Bednarski E, Guzman-Cardozo C, Turroja M, Millard KG, Tober-Lau P, Hillus D, Yao KH, Shimeliovich I,

Dizon J, Kaczynska A, Jankovic M, Gazumyan A, Oliveira TY, Caskey M, Bieniasz PD, Hatziioannou T, Kurth F, Sander LE, Nussenzweig MC, Gaebler C. J Exp Med. 2022 Oct 3;219(10):e20220826. doi: 10.1084/jem.20220826. Epub 2022 Aug 25. PMID: 36006380

SARS-CoV-2 **Vaccine** Breakthrough by Omicron and Delta Variants, New York, USA.
Keyel AC, Russell A, Plitnick J, Rowlands JV, Lamson DM, Rosenberg E, St George K. Emerg Infect Dis. 2022 Oct;28(10):1990-1998. doi: 10.3201/eid2810.221058. Epub 2022 Sep 1. PMID: 36048774

Clinical Nudge Impact on Herpes Zoster **Vaccine** Series Completion in Pharmacies.
Gatwood J, Brookhart A, Kinney O, Hagemann T, Chiu CY, Ramachandran S, Hohmeier KC. Am J Prev Med. 2022 Oct;63(4):582-591. doi: 10.1016/j.amepre.2022.04.018. Epub 2022 Jun 12. PMID: 35705425

Cost-effectiveness of herpes zoster vaccines in the U.S.: A systematic review.
Meredith NR, Armstrong EP. Prev Med Rep. 2022 Jul 22;29:101923. doi: 10.1016/j.pmedr.2022.101923. eCollection 2022 Oct. PMID: 35898193

Phenotypic characteristics and protective efficacy of an attenuated Mycoplasma hyopneumoniae **vaccine** by aerosol administration.
Hao F, Bai Y, Xie X, Yuan T, Wei Y, Xiong Q, Gan Y, Zhang L, Zhang Z, Shao G, Feng Z. Vaccine. 2022 Oct 6;40(42):6074-6083. doi: 10.1016/j.vaccine.2022.08.072. Epub 2022 Sep 13. PMID: 36109278

Protein **vaccine** NVX-CoV2373 elicits functional T cell immunity.
Zhou P. J Clin Invest. 2022 Oct 3;132(19):e163614. doi: 10.1172/JCI163614. PMID: 36189797

Who has not been vaccinated, fully vaccinated, or boosted for COVID-19?
Nguyen KH, Chen Y, Huang J, Allen JD, Beninger P, Corlin L. Am J Infect Control. 2022 Oct;50(10):1185-1189. doi: 10.1016/j.ajic.2022.05.024. Epub 2022 Jun 7. PMID: 35688229

Towards quality improvement of **vaccine** concept mappings in the OMOP vocabulary with a semi-automated method.
Abeysinghe R, Black A, Kaduk D, Li Y, Reich C, Davydov A, Yao L, Cui L. J Biomed Inform. 2022 Oct;134:104162. doi: 10.1016/j.jbi.2022.104162. Epub 2022 Aug 25. PMID: 36029954

A candidate multi-epitope **vaccine** against Lumpy Skin Disease.
Uddin MB, Tanni FY, Hoque SF, Sajib EH, Faysal MA, Rahman MA, Galib A, Emon AA, Hossain MM, Hasan M, Ahmed SSU. Transbound Emerg Dis. 2022 Oct 2. doi: 10.1111/tbed.14718. Online ahead of print. PMID: 36183192

Equity of the Meningitis B vaccination programme in England, 2016-2018.
Tiley KS, White JM, Andrews N, Tessier E, Edelstein M. Vaccine. 2022 Oct 6;40(42):6125-6132. doi: 10.1016/j.vaccine.2022.09.023. Epub 2022 Sep 16. PMID: 36117004

Vaccinating Veterans Experiencing Homelessness for COVID-19: Healthcare and Housing Service Providers' Perspectives.
Balut MD, Gin JL, Alenkin NR, Dobalian A. J Community Health. 2022 Oct;47(5):727-736. doi: 10.1007/s10900-022-01097-1. Epub 2022 Jun 7. PMID: 35670986

Vaccine-induced dermatomyositis following COVID-19 vaccination.
Chaima K, Mariem A, Sana B, Khadija S, Mariem R, Massara B, Emna B, Sonia B, Abderrahman M, Hamida T. Dermatol Ther. 2022 Oct;35(10):e15749. doi: 10.1111/dth.15749. Epub 2022 Aug 18. PMID: 35906839

Protective immunity by DNA **vaccine** against Micropterus salmoides rhabdovirus.
Yang B, Guo ZR, Zhao Z, Wang T, Yang F, Ling F, Zhu B, Wang GX. J Fish Dis. 2022 Oct;45(10):1429-1437. doi: 10.1111/jfd.13672. Epub 2022 Aug 5. PMID: 35930453

Importation and Circulation of **Vaccine**-Derived Poliovirus Serotype 2, Senegal, 2020-2021.
Faye M, Kébé O, Diop B, Ndiaye N, Dosseh A, Sam A, Diallo A, Dia H, Diallo JP, Dia N, Kiori DE, Diop OM, Sall AA, Faye O. Emerg Infect Dis. 2022 Oct;28(10):2027-2034. doi: 10.3201/eid2810.220847. PMID: 36148906

Major severe acute respiratory coronavirus-2 (SARS-CoV-2) **vaccine**-associated adverse effects; benefits outweigh the risks.
Esmaeilzadeh A, Maleki AJ, Moradi A, Siahmansouri A, Yavari MJ, Karami P, Elahi R. Expert Rev Vaccines. 2022 Oct;21(10):1377-1394. doi: 10.1080/14760584.2022.2116008. Epub 2022 Aug 24. PMID: 35986451

Development and exacerbation of autoimmune hemolytic anemia following COVID-19 vaccination: A systematic review.
Jafarzadeh A, Jafarzadeh S, Pardehshenas M, Nemati M, Mortazavi SMJ. Int J Lab Hematol. 2022 Oct 8. doi: 10.1111/ijlh.13978. Online ahead of print. PMID: 36208056 R

COVID-19 **vaccine** triggered autoimmune hepatitis: case report.
Mathew M, John SB, Sebastian J, Ravi MD. Eur J Hosp Pharm. 2022 Oct 7:ejhpharm-2022-003485. doi: 10.1136/ejhpharm-2022-003485. Online ahead of print. PMID: 36207131

Single-injection COVID-19 subunit **vaccine** elicits potent immune responses.
Zhou X, Wang H, Luo Y, Cui L, Guan Y, Zhang Y. Acta Biomater. 2022 Oct 1;151:491-500. doi: 10.1016/j.actbio.2022.08.006. Epub 2022 Aug 7. PMID: 35948176

Barriers to human papillomavirus (HPV) vaccination among young adults, aged 18-35.
Muthukrishnan M, Loux T, Shacham E, Tiro JA, Arnold LD. Prev Med Rep. 2022 Aug 8;29:101942. doi: 10.1016/j.pmedr.2022.101942. eCollection 2022 Oct. PMID: 36161130

A multilingual dataset of COVID-19 vaccination attitudes on Twitter.
Chen N, Chen X, Pang J. Data Brief. 2022 Oct;44:108503. doi: 10.1016/j.dib.2022.108503. Epub 2022 Aug 2. PMID: 35935093

Erythema nodosum following SARS-CoV-2 **vaccine**.
Xie Y, Yin B, Shi X. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):e752-e753. doi: 10.1111/jdv.18304. Epub 2022 Jun 21. PMID: 35680526

The French Covid-19 vaccination policy did not solve vaccination inequities: a nationwide study on 64.5 million people.

Débarre F, Lecoeur E, Guimier L, Jauffret-Roustide M, Jannot AS. Eur J Public Health. 2022 Oct 3;32(5):825-830. doi: 10.1093/eurpub/ckac125. PMID: 36102834

Sociodemographic predictors of and main reasons for COVID-19 **vaccine** hesitancy in eastern Oslo: a cross-sectional study.
Steinmetz L. BMC Public Health. 2022 Oct 7;22(1):1878. doi: 10.1186/s12889-022-14261-y. PMID: 36207702

Axillary lymph node imaging in mRNA, vector-based, and mix-and-match COVID-19 **vaccine** recipients: ultrasound features.
Igual-Rouilleault AC, Soriano I, Elizalde A, Quan PL, Fernandez-Montero A, Sobrido C, Pina L. Eur Radiol. 2022 Oct;32(10):6598-6607. doi: 10.1007/s00330-022-08846-9. Epub 2022 May 13. PMID: 35554651

Worldwide **vaccine** inequality threatens to unleash the next COVID-19 variant.
Oehler RL, Vega VR. Int J Infect Dis. 2022 Oct;123:133-135. doi: 10.1016/j.ijid.2022.08.010. Epub 2022 Aug 18. PMID: 35988865

Hemophagocytic lymphohistiocytosis after SARS-CoV-2 vaccination.
Hieber ML, Sprute R, Eichenauer DA, Hallek M, Jachimowicz RD. Infection. 2022 Oct;50(5):1399-1404. doi: 10.1007/s15010-022-01786-y. Epub 2022 Feb 26. PMID: 35218512

Current clinical status of new COVID-19 vaccines and immunotherapy.
Nagpal D, Nagpal S, Kaushik D, Kathuria H. Environ Sci Pollut Res Int. 2022 Oct;29(47):70772-70807. doi: 10.1007/s11356-022-22661-1. Epub 2022 Sep 5. PMID: 36063274

Human papilloma virus **vaccine** and VITT antibody induction.
Kanack AJ, Laegreid IJ, Johansen S, Reikvam H, Ahlen MT, Padmanabhan A. Am J Hematol. 2022 Oct;97(10):E363-E364. doi: 10.1002/ajh.26659. Epub 2022 Aug 3. PMID: 35834243

Immunogenicity and Safety of the Spikevax® (Moderna) mRNA SARS-CoV-2 **Vaccine** in Patients with Primary Humoral Immunodeficiency.
Kralickova P, Jankovicova K, Sejkorova I, Soucek O, Koprivova K, Drahosova M, Andrys C, Krejsek J. Int Arch Allergy Immunol. 2022 Oct 6:1-14. doi: 10.1159/000526375. Online ahead of print. PMID: 36202084

Extracellular vesicles: Emerging tools as therapeutic agent carriers.
Liu S, Wu X, Chandra S, Lyon C, Ning B, Jiang L, Fan J, Hu TY. Acta Pharm Sin B. 2022 Oct;12(10):3822-3842. doi: 10.1016/j.apsb.2022.05.002. Epub 2022 May 11. PMID: 36213541

Another important step toward a prophylactic **vaccine** against hepatitis C.
Neumann-Haefelin C, Thimme R. Hepatology. 2022 Oct;76(4):917-919. doi: 10.1002/hep.32557. Epub 2022 May 19. PMID: 35503709

The intention to get COVID-19 **vaccine** and **vaccine** uptake among cancer patients: An extension of the theory of planned behaviour (TPB).
Servidio R, Malvaso A, Vizza D, Valente M, Campagna MR, Iacono ML, Martin LR, Bruno F. Support Care Cancer. 2022 Oct;30(10):7973-7982. doi: 10.1007/s00520-022-07238-5. Epub 2022 Jun 25. PMID: 35752690

Meningococcal B **vaccine**-associated papillophlebitis and cilioretinal artery occlusion.
Parvus M, Pakravan M, Charoenkijkajorn C, Edmond J, Spinetti A, Lee AG. Can J Ophthalmol. 2022 Oct;57(5):e182-e184. doi: 10.1016/j.jcjo.2022.01.015. Epub 2022 Feb 4. PMID: 35123946

Incidence and Risk Factors of Immediate Hypersensitivity Reactions and Immunization Stress-Related Responses With COVID-19 mRNA **Vaccine**.
Imai K, Tanaka F, Kawano S, Esaki K, Arakawa J, Nishiyama T, Seno S, Hatanaka K, Sugiura T, Kodama Y, Yamada S, Iwamoto S, Takeshima S, Abe N, Kamae C, Aono S, Ito T, Yamamoto T, Mizuguchi Y. J Allergy Clin Immunol Pract. 2022 Oct;10(10):2667-2676.e10. doi: 10.1016/j.jaip.2022.07.027. Epub 2022 Aug 8. PMID: 35953016

mRNA and Viral Vector COVID-19 Vaccines Do Not Affect Male Fertility: A Prospective Study.
Massarotti C, Stigliani S, Maccarini E, Bovis F, Ferraro MF, Gazzo I, Anserini P, Scaruffi P. World J Mens Health. 2022 Oct;40(4):561-569. doi: 10.5534/wjmh.220055. Epub 2022 Aug 16. PMID: 36047075

Dendritic cell-based **vaccine**: the state-of-the-art **vaccine** platform for COVID-19 management.
Chavda VP, Patel AB, Vora LK, Apostolopoulos V, Uhal BD. Expert Rev Vaccines. 2022 Oct;21(10):1395-1403. doi: 10.1080/14760584.2022.2110076. Epub 2022 Aug 9. PMID: 35929957

Cardiac MRI Findings in COVID-19 **Vaccine**-Related Myocarditis: A Pooled Analysis of 468 Patients.
Samimisedeh P, Jafari Afshar E, Shafiabadi Hassani N, Rastad H. J Magn Reson Imaging. 2022 Oct;56(4):971-982. doi: 10.1002/jmri.28268. Epub 2022 May 25. PMID: 35612967

SARS-CoV-2 **vaccine** safe for young patients.
Onuora S. Nat Rev Rheumatol. 2022 Oct;18(10):552. doi: 10.1038/s41584-022-00831-2. PMID: 35953559

Impact of **Vaccine** Hesitancy on Onset, Severity and Type of Self-reported Adverse Events: A French Cross-Sectional Survey.
Khouri C, Larabi A, Verger P, Gauna F, Cracowski JL, Ward J. Drug Saf. 2022 Oct;45(10):1049-1056. doi: 10.1007/s40264-022-01220-0. Epub 2022 Aug 16. PMID: 35972651

Awareness of and Support for HPV Vaccination Among Pacific Islander Women in Southern California.
Mouttapa M, Cunningham M, Tanjasiri SP. J Cancer Educ. 2022 Oct;37(5):1372-1377. doi: 10.1007/s13187-021-01965-9. Epub 2021 Feb 4. PMID: 33539008

Trends and prospects in oral cancer **vaccine**.
Sarode GS, Kumari N, Gophane R, Ghone U, Sharma N, Sarode SC. Oral Oncol. 2022 Oct;133:106051. doi: 10.1016/j.oraloncology.2022.106051. Epub 2022 Aug 5. PMID: 35939917

Hybrid M13 bacteriophage-based **vaccine** platform for personalized cancer immunotherapy.
Dong X, Pan P, Ye JJ, Zhang QL, Zhang XZ. Biomaterials. 2022 Oct;289:121763. doi: 10.1016/j.biomaterials.2022.121763. Epub 2022 Aug 26. PMID: 36055175

Treatment, outcome and re-vaccination of patients with SARS-CoV-2 **vaccine**-associated immune thrombocytopenia.

Ruzicka M, Wurm S, Lindner L, Dreyling M, von Bergwelt-Baildon M, Boeck S, Giessen-Jung C, Milani V, Stemmler JH, Subklewe M, Weigert O, Spiekermann K. Infection. 2022 Oct 4:1-8. doi: 10.1007/s15010-022-01909-5. Online ahead of print. PMID: 36195695

Health economic analysis of **vaccine** options for the polio eradication endgame: 2022-2036.
Thompson KM, Kalkowska DA, Badizadegan K. Expert Rev Vaccines. 2022 Oct 5:1-8. doi: 10.1080/14760584.2022.2128108. Online ahead of print. PMID: 36154436

The Impact of Childhood and Parental Vaccination on SARS-CoV-2 Infection Rates in Children.
Yigit M, Ince YE, Kalayci F, Santaflioglu B, Kurt F, Ozkaya-Parlakay A, Dibek Misirlioglu E, Senel E. Pediatr Infect Dis J. 2022 Oct 1;41(10):841-845. doi: 10.1097/INF.0000000000003625. Epub 2022 Jun 28. PMID: 35763687

Eosinophils Recruited During Pulmonary Vaccination Regulate Mucosal Antibody Production.
Prince L, Martín-Faivre L, Villeret B, Sanchez-Guzman D, Le Guen P, Sallenave JM, Garcia-Verdugo I. Am J Respir Cell Mol Biol. 2022 Oct 4. doi: 10.1165/rcmb.2022-0236OC. Online ahead of print. PMID: 36194580

How a generally well-accepted measles **vaccine** mandate may lead to inequities and decreased **vaccine** uptake: a preregistered survey study in Germany.
Neufeind J, Schmid-Küpke N, Rehfuess E, Betsch C, Wichmann O. BMC Public Health. 2022 Oct 3;22(1):1846. doi: 10.1186/s12889-022-14075-y. PMID: 36192739

Nanocarriers based on bacterial membrane materials for cancer **vaccine** delivery.
Zhao X, Zhao R, Nie G. Nat Protoc. 2022 Oct;17(10):2240-2274. doi: 10.1038/s41596-022-00713-7. Epub 2022 Jul 25. PMID: 35879454

Safety-Related Outcomes of Novel mRNA COVID-19 Vaccines in Pregnancy.
Nakahara A, Biggio JR, Elmayan A, Williams FB. Am J Perinatol. 2022 Oct;39(13):1484-1488. doi: 10.1055/a-1745-1168. Epub 2022 Jan 19. PMID: 35045574

Estimating **vaccine** effectiveness against SARS-CoV-2 infection, hospitalization and death from ecologic data in Costa Rica.
Fantin R, Herrero R, Hildesheim A, Barboza-Solís C, Aparicio A, Prevots DR, Pfeiffer RM, Gail MH; RESPIRA Study Group. BMC Infect Dis. 2022 Oct 2;22(1):767. doi: 10.1186/s12879-022-07740-5. PMID: 36184587

Time and labour costs of preventive health care, including vaccinations, in Finnish child health clinics.
Nieminen H, Hakulinen T, Puumalainen T, Sirén P, Palmu AA. PLoS One. 2022 Oct 3;17(10):e0270835. doi: 10.1371/journal.pone.0270835. eCollection 2022. PMID: 36190966

A social ecological approach to identify the barriers and facilitators to COVID-19 vaccination acceptance: A scoping review.
Lun P, Gao J, Tang B, Yu CC, Jabbar KA, Low JA, George PP. PLoS One. 2022 Oct 3;17(10):e0272642. doi: 10.1371/journal.pone.0272642. eCollection 2022. PMID: 36191018

Past, present, and future of Lyme disease vaccines: antigen engineering approaches and mechanistic insights.
Chen WH, Strych U, Bottazzi ME, Lin YP. Expert Rev Vaccines. 2022 Oct;21(10):1405-1417. doi: 10.1080/14760584.2022.2102484. Epub 2022 Jul 22. PMID: 35836340

Community health worker intervention improves early childhood vaccination rates: results from a propensity-score matching evaluation.
Wightman P, McCue K, Sabo S, Annorbah R, Jiménez D, Pilling V, Butler M, Celaya MF, Rumann S. BMC Public Health. 2022 Oct 4;22(1):1854. doi: 10.1186/s12889-022-14239-w. PMID: 36195944

Immune epitopes identification and designing of a multi-epitope **vaccine** against bovine leukemia virus: a molecular dynamics and immune simulation approaches.
Samad A, Meghla NS, Nain Z, Karpiński TM, Rahman MS. Cancer Immunol Immunother. 2022 Oct;71(10):2535-2548. doi: 10.1007/s00262-022-03181-w. Epub 2022 Mar 16. PMID: 35294591

Seizures following COVID-19 vaccination in Mexico: A nationwide observational study.
Núñez I, García-Grimshaw M, Castillo Valencia CY, Aguilera Callejas DE, Moya Alfaro ML, Saniger-Alba MDM, Gutiérrez-Romero A, Carrillo-Mezo R, Ceballos-Liceaga SE, Baptista-Rosas RC, López-Gatell H, Reyes-Terán G, Díaz-Ortega JL, Arauz A, Valdés-Ferrer SI, Hernández-Vanegas LE. Epilepsia. 2022 Oct;63(10):e144-e149. doi: 10.1111/epi.17390. Epub 2022 Aug 20. PMID: 35943891

Neutralizing antibody activity, safety and immunogenicity of human anti-rabies virus monoclonal antibody (Ormutivimab) in Chinese healthy adults: A phase IIb randomized, double-blind, parallel-controlled study.
Li L, Li Y, Bai Y, Li G, Zhang J, Yang L, Zhao W, Zhao W, Luo F, Zhao Q, Zhang Z, Liu Y, Li S, Lu Q, Wang H, Zhang J, Zhang Y, Gao J, Shi N. Vaccine. 2022 Oct 6;40(42):6153-6162. doi: 10.1016/j.vaccine.2022.09.022. Epub 2022 Sep 16. PMID: 36123259

Effectiveness of a pay-it-forward intervention compared with user-paid vaccination to improve influenza **vaccine** uptake and community engagement among children and older adults in China: a quasi-experimental pragmatic trial.
Wu D, Jin C, Bessame K, Tang FF, Ong JJ, Wang Z, Xie Y, Jit M, Larson HJ, Chantler T, Lin L, Gong W, Yang F, Jing F, Wei S, Cheng W, Zhou Y, Ren N, Qiu S, Bao J, Wen L, Yang Q, Tian J, Tang W, Tucker JD. Lancet Infect Dis. 2022 Oct;22(10):1484-1492. doi: 10.1016/S1473-3099(22)00346-2. Epub 2022 Jul 19. PMID: 35868342

Immunogenicity and protective efficacy of a prototype pneumococcal bioconjugate **vaccine**.
Aceil J, Paschall AV, Knoot CJ, Robinson LS, Scott NE, Feldman MF, Harding CM, Avci FY. Vaccine. 2022 Oct 6;40(42):6107-6113. doi: 10.1016/j.vaccine.2022.09.018. Epub 2022 Sep 15. PMID: 36115800

Safety and immunogenicity of the Na-APR-1 hookworm **vaccine** in infection-naïve adults.
Diemert DJ, Zumer M, Campbell D, Grahek S, Li G, Peng J, Elena Bottazzi M, Hotez P, Bethony J. Vaccine. 2022 Oct 6;40(42):6084-6092. doi: 10.1016/j.vaccine.2022.09.017. Epub 2022 Sep 14. PMID: 36114129

Safety and Immunogenicity of Cell-Based Quadrivalent Influenza **Vaccine**: A Randomized Trial.

Essink BJ, Heeringa M, Jeanfreau RJ, Finn D, Matassa V, Edelman J, Hohenboken M, Molrine D. Pediatrics. 2022 Oct 10:e2022057509. doi: 10.1542/peds.2022-057509. Online ahead of print. PMID: 36214072

Ethnic homophily affects **vaccine** prioritization strategies.
Kadelka C, Islam MR, McCombs A, Alston J, Morton N. J Theor Biol. 2022 Oct 5:111295. doi: 10.1016/j.jtbi.2022.111295. Online ahead of print. PMID: 36208667

Effectiveness and durability of BNT162b2 **vaccine** against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study.
Tartof SY, Slezak JM, Puzniak L, Hong V, Frankland TB, Xie F, Ackerson BK, Valluri SR, Jodar L, McLaughlin JM. Lancet Respir Med. 2022 Oct 7:S2213-2600(22)00354-X. doi: 10.1016/S2213-2600(22)00354-X. Online ahead of print. PMID: 36216013

Pediatric and adolescent COVID-19 vaccination side effects: A retrospective cohort study of the Iranian teenage group in 2021.
Tavakoli N, Nafissi N, Shokri S, Fallahpour M, Soleimani S, Riahi T, Kalantari S, Javan A, Goodarzi A, Valizadeh R. J Med Virol. 2022 Oct;94(10):4890-4900. doi: 10.1002/jmv.27962. Epub 2022 Jul 5. PMID: 35758760

Differential **vaccine**-induced kinetics of humoral and cellular immune responses in SARS-CoV-2 naive and convalescent health care workers.
Smit W, Thijsen S, van der Kieft R, van Tol S, Reimerink J, Reusken C, Rümke L, Bossink A, Limonard G, Heron M. Pathog Dis. 2022 Oct 3;80(1):ftac035. doi: 10.1093/femspd/ftac035. PMID: 36089571

Potential role of vaccines in elimination of Plasmodium vivax.
White M, Chitnis CE. Parasitol Int. 2022 Oct;90:102592. doi: 10.1016/j.parint.2022.102592. Epub 2022 Apr 28. PMID: 35489701

A novel **vaccine** based on SARS-CoV-2 $CD4^+$ and $CD8^+$ T cell conserved epitopes from variants Alpha to Omicron.
Palatnik-de-Sousa I, Wallace ZS, Cavalcante SC, Ribeiro MPF, Silva JABM, Cavalcante RC, Scheuermann RH, Palatnik-de-Sousa CB. Sci Rep. 2022 Oct 6;12(1):16731. doi: 10.1038/s41598-022-21207-2. PMID: 36202985

CLL-461 Humoral Response to COVID-19 **Vaccine**: A Challenge in CLL.
Capasso A, Albi E, Schiattone L, Martini F, Sant'Antonio E, Scarfò L, Ranghetti P, Frenquelli M, Campanella A, Perotta E, Heltai S, Colia M, Ghia P. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S279-S280. doi: 10.1016/S2152-2650(22)01348-9. PMID: 36163894

Improving Pneumococcal Vaccination Rates in an Inpatient Pediatric Diabetic Population.
Mirza A, Jagadish A, Trimble K, Olanrewaju A. Ochsner J. 2022 Fall;22(3):239-243. doi: 10.31486/toj.22.0036. PMID: 36189088

Outbreak of SARS-CoV-2 in a teenage discotheque in Northern Ireland-November 2021.
McAleavey P, Rainey E, McKaig C, Richardson C, Anderson C, Tilley C, Kmiecik ED, Dallat M, Stevens H, Sheridan P, Bennett D. Public Health. 2022 Oct;211:81-84. doi: 10.1016/j.puhe.2022.06.023. Epub 2022 Jun 28. PMID: 36055066

Malaysian public preferences and decision making for COVID-19 vaccination: A discrete choice experiment.
Teh HS, Woon YL, Leong CT, Hing NYL, Mien TYS, Roope LSJ, Clarke PM, Lim LL, Buckell J. Lancet Reg Health West Pac. 2022 Oct;27:100534. doi: 10.1016/j.lanwpc.2022.100534. Epub 2022 Aug 9. PMID: 35966625

Comparative efficacy evaluation of different CSF vaccines in pigs with CSF maternally derived antibodies.
Chen N, Wang Q, Hu Y, Sun Y, Li J, Wu H, Xu L, Liu H, Yang C, Chen X, Deng Y, Xia Y, Zhang Q, Cheng S, Fan A, Chen G. Vet Microbiol. 2022 Oct;273:109541. doi: 10.1016/j.vetmic.2022.109541. Epub 2022 Aug 8. PMID: 36027683

Sociodemographic predictors of COVID-19 **vaccine** hesitancy and leading concerns with COVID-19 vaccines among pregnant women at a South Texas clinic.
Sutanto MY, Hosek MG, Stumpff SK, Neuhoff BK, Hernandez BS, Wang Z, Ramsey PS, Boyd AR. J Matern Fetal Neonatal Med. 2022 Oct 4:1-7. doi: 10.1080/14767058.2022.2128652. Online ahead of print. PMID: 36195447

A specific Leishmania infantum polyepitope **vaccine** triggers Th1-type immune response and protects against experimental visceral leishmaniasis.
Lopes Valentim Di Paschoale Ostolin T, Rodrigues Gusmão M, Augusto Siqueira Mathias F, Mirelle de Oliveira Cardoso J, Mendes Roatt B, Dian de Oliveira Aguiar-Soares R, Conceição Ruiz J, de Melo Resende D, Cristiane Fortes de Brito R, Barbosa Reis A. Cell Immunol. 2022 Oct;380:104592. doi: 10.1016/j.cellimm.2022.104592. Epub 2022 Sep 5. PMID: 36084402

Viral subpopulation variability in different batches of Infectious bronchitis virus (IBV) vaccines based on GI-23 lineage: Implications for the field.
Legnardi M, Cecchinato M, Homonnay Z, Dauphin G, Koutoulis KC, Tucciarone CM, Franzo G. Virus Res. 2022 Oct 2;319:198877. doi: 10.1016/j.virusres.2022.198877. Epub 2022 Jul 22. PMID: 35872282

DNA vaccines targeting amyloid-β oligomer ameliorate cognitive deficits of aged APP/PS1/tau triple-transgenic mouse models of Alzheimer's disease.
Sha S, Xing XN, Wang T, Li Y, Zhang RW, Shen XL, Cao YP, Qu L. Neural Regen Res. 2022 Oct;17(10):2305-2310. doi: 10.4103/1673-5374.337054. PMID: 35259854

RBD-mRNA **vaccine** induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.
Shi J, Zheng J, Zhang X, Tai W, Odle AE, Perlman S, Du L. Transl Res. 2022 Oct;248:11-21. doi: 10.1016/j.trsl.2022.04.007. Epub 2022 Apr 28. PMID: 35489692

Longitudinal mapping of hepatitis B **vaccine**-induced B-cell linear epitopes in healthy individuals.
Zhong S, Liu Z, Zhou Y, Zhang T, Fu X, Guo L, Gu S, Tang L, Hou J, Li Y. J Med Virol. 2022 Oct;94(10):4993-5006. doi: 10.1002/jmv.27926. Epub 2022 Jun 16. PMID: 35676468

Pan-genomic analyses of 47 complete genomes of the *Rickettsia* genus and prediction of new **vaccine** targets and virulence factors of the species.
Felice AG, Alves LG, Freitas ASF, Rodrigues TCV, Jaiswal AK, Tiwari S, Gomes LGR, Miranda FM, Ramos RTJ, Azevedo V, Oliveira LC, Oliveira CJ, Soares SDC, Benevides LJ. J Biomol Struct Dyn. 2022 Oct;40(16):7496-7510. doi: 10.1080/07391102.2021.1898473. Epub 2021 Mar 15. PMID: 33719856

Clinician perspectives on pediatric COVID-19 vaccination: A qualitative study in central and western, Massachusetts.
Ryan GW, Goulding M, Borg A, Minkah P, Hermann S, Fisher L, Rosal MC, Lemon SC. Prev Med Rep. 2022 Oct;29:101966. doi: 10.1016/j.pmedr.2022.101966. Epub 2022 Sep 1. PMID: 36065256

Optimizing the Live Attenuated Influenza A **Vaccine** Backbone for High-Risk Patient Groups.
Bonifacio JPPL, Williams N, Garnier L, Hugues S, Schmolke M, Mazel-Sanchez B. J Virol. 2022 Oct 3:e0087122. doi: 10.1128/jvi.00871-22. Online ahead of print. PMID: 36190240

Imperfect Immunization Communication on School District Websites: A Mixed-Methods Review.
Navin MC, Attwell K. J Sch Nurs. 2022 Oct;38(5):459-466. doi: 10.1177/1059840520970886. Epub 2020 Nov 6. PMID: 33153397

Therapeutic human papilloma virus vaccination in patients at risk for cervical dysplasia.
Florence AM, Fogel J, Mozey M, Dave S, O'Dell H, Fatehi M. Minerva Obstet Gynecol. 2022 Oct 4. doi: 10.23736/S2724-606X.22.05141-7. Online ahead of print. PMID: 36193830

Modeling a sustainable **vaccine** supply chain for a healthcare system.
Chowdhury NR, Ahmed M, Mahmud P, Paul SK, Liza SA. J Clean Prod. 2022 Oct 10;370:133423. doi: 10.1016/j.jclepro.2022.133423. Epub 2022 Aug 12. PMID: 35975192

What explains racial/ethnic inequities in the uptake of differentiated influenza vaccines?
Mahmud SM, Pabla G, Righolt CH, Loiacono MM, Thommes E, Chit A. Prev Med. 2022 Oct;163:107236. doi: 10.1016/j.ypmed.2022.107236. Epub 2022 Sep 1. PMID: 36058382

Decoding the Human Genetic and Immunological Basis of COVID-19 mRNA **Vaccine**-Induced Myocarditis.
Bolze A, Mogensen TH, Zhang SY, Abel L, Andreakos E, Arkin LM, Borghesi A, Brodin P, Hagin D, Novelli G, Okada S, Peter J, Renia L, Severe K, Tiberghien P, Vinh DC; COVID human genetic effort, Cirulli ET, Casanova JL, Hsieh EWY. J Clin Immunol. 2022 Oct 8:1-6. doi: 10.1007/s10875-022-01372-9. Online ahead of print. PMID: 36207567

Immunogenicity decay and case incidence six months post Sinovac-CoronaVac **vaccine** in autoimmune rheumatic diseases patients.
Silva CA, Medeiros-Ribeiro AC, Kupa LVK, Yuki EFN, Pasoto SG, Saad CGS, Fusco SRG, Pereira RMR, Shinjo SK, Halpern ASR, Borba EF, Souza FHC, Guedes LKN, Miossi R, Bonfiglioli KR, Domiciano DS, Shimabuco AY, Andrade DCO, Seguro LPC, Fuller R, Sampaio-Barros PD, Assad APL, Moraes JCB, Goldenstein-Schainberg C, Giardini HAM, Silva HC, Martins VAO, Villamarin LEB, Novellino RS, Sales LP, Araújo CSR, Silva MSR, Filho DMN, Lopes MH, Duarte AJS, Kallas EG, Aikawa NE, Bonfa E. Nat Commun. 2022 Oct 3;13(1):5801. doi: 10.1038/s41467-022-33042-0. PMID: 36192386

BNT162b2 **vaccine** effectiveness in chronic kidney disease patients-an observational study.
Bielopolski D, Libresco G, Barda N, Dagan N, Steinmetz T, Yahav D, Charytan DM, Balicer RD, Rozen-Zvi B. Clin Kidney J. 2022 Jul 4;15(10):1838-1846. doi: 10.1093/ckj/sfac166. eCollection 2022 Oct. PMID: 36147707

Reasons for and insights about HPV vaccination refusal among ultra-Orthodox Jewish mothers.
Zach R, Bentwich ME. Dev World Bioeth. 2022 Oct 6. doi: 10.1111/dewb.12372. Online ahead of print. PMID: 36201654

COVID-19 vaccination hesitancy in pregnant and breastfeeding women and strategies to increase vaccination compliance: a systematic review and meta-analysis.
Bianchi FP, Stefanizzi P, Di Gioia MC, Brescia N, Lattanzio S, Tafuri S. Expert Rev Vaccines. 2022 Oct;21(10):1443-1454. doi: 10.1080/14760584.2022.2100766. Epub 2022 Jul 20. PMID: 35818804

The effect of COVID 19 vaccination on kidney recipients.
Marzieh L, Elahe P, Habib R, Maryam P, Arefeh J, Elnaz E, Sanaz D. Transpl Immunol. 2022 Oct;74:101658. doi: 10.1016/j.trim.2022.101658. Epub 2022 Jun 28. PMID: 35777613

Efficacy, Usability, and Acceptability of a Chatbot for Promoting COVID-19 Vaccination in Unvaccinated or Booster-Hesitant Young Adults: Pre-Post Pilot Study.
Luk TT, Lui JHT, Wang MP. J Med Internet Res. 2022 Oct 4;24(10):e39063. doi: 10.2196/39063. PMID: 36179132

Psoriasis exacerbation after COVID-19 vaccines: A brief report of the reported cases.
El-Qushayri AE, Nardone B. Dermatol Ther. 2022 Oct 6:e15900. doi: 10.1111/dth.15900. Online ahead of print. PMID: 36200490

A newly discovered PD-L1 B-cell epitope peptide **vaccine** (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell **vaccine** (B-Vaxx).
Guo L, Overholser J, Darby H, Ede NJ, Kaumaya PTP. Oncoimmunology. 2022 Oct 5;11(1):2127691. doi: 10.1080/2162402X.2022.2127691. eCollection 2022. PMID: 36211807

The impact of financial incentives on COVID-19 vaccination intention among a sample of U.S. adults.
Andresen JA, Harris JN, Mauro C, Zimet GD, Rosenthal SL. Prev Med Rep. 2022 Oct;29:101962. doi: 10.1016/j.pmedr.2022.101962. Epub 2022 Sep 1. PMID: 36065257

General practice experiences of Australia’s COVID-19 **vaccine** rollout: lessons for primary care reform.
Wright M, Hoffman R, Petrozzi MJ, Wise S. Aust Health Rev. 2022 Oct;46(5):595-604. doi: 10.1071/AH22121. PMID: 36116826

Third dose of mRNA COVID-19 **vaccine** and response: Correspondence.
Sookaromdee P, Wiwanitkit V. Liver Int. 2022 Oct;42(10):2342. doi: 10.1111/liv.15370. Epub 2022 Jul 30. PMID: 35854427

Protection and antibody levels 35 years after primary series with hepatitis B **vaccine** and response to a booster dose.
Bruce MG, Bruden D, Hurlburt D, Morris J, Bressler S, Thompson G, Lecy D, Rudolph K, Bulkow L, Hennessy T, Simons BC, Weng MK, Nelson N, McMahon BJ. Hepatology. 2022 Oct;76(4):1180-1189. doi: 10.1002/hep.32474. Epub 2022 May 19. PMID: 35320592

Radiotherapy activity in the COVID 19 pandemic: Brazil's operational national-level study.
Moraes FY, Gouveia AG, Lima RP, Bratti VF, Hamamura AC, Viani GA. J Cancer Policy. 2022 Oct 7:100367. doi: 10.1016/j.jcpo.2022.100367. Online ahead of print. PMID: 36216270

Myth and Misinformation on COVID-19 **Vaccine**: The Possible Impact on Vaccination Refusal Among People of Northeast Ethiopia: A Community-Based Research.
Kalayou MH, Awol SM. Risk Manag Healthc Policy. 2022 Oct 1;15:1859-1868. doi: 10.2147/RMHP.S366730. eCollection 2022. PMID: 36213385

Preparation and pre-clinical evaluation of flagellin-adjuvanted NOM **vaccine** candidate formulated with Spike protein against SARS-CoV-2 in mouse model.
Farshidi N, Ghaedi T, Hassaniazad M, Eftekhar E, Gouklani H, Farshidi H, Asadi Karam MR, Shahbazi B, Kalani M, Ahmadi K. Microb Pathog. 2022 Oct;171:105736. doi: 10.1016/j.micpath.2022.105736. Epub 2022 Aug 24. PMID: 36030048

COVID-19 **vaccine** development, production and regulatory oversight in African countries.
Makenga G, Booy R, Oloo PN, Auerbach J. Bull World Health Organ. 2022 Oct 1;100(10):651-652. doi: 10.2471/BLT.22.287958. Epub 2022 Sep 2. PMID: 36188025

Time for Resolution of COVID-19 **Vaccine**-Related Axillary Lymphadenopathy and Associated Factors.
Lane EG, Eisen CS, Drotman MB, Dodelzon K, Mema E, Thomas C, Prince MR. AJR Am J Roentgenol. 2022 Oct;219(4):559-568. doi: 10.2214/AJR.22.27687. Epub 2022 May 18. PMID: 35583425

Shades of doubt: Measuring and classifying vaccination confidence in Europe.
Rughiniș C, Vulpe SN, Flaherty MG, Vasile S. Vaccine. 2022 Oct 7:S0264-410X(22)01147-1. doi: 10.1016/j.vaccine.2022.09.039. Online ahead of print. PMID: 36216651

Waning of **vaccine** effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study.
Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, Lewis N, Natarajan K, Stenehjem E, Grannis SJ, Han J, McEvoy C, Ong TC, Naleway AL, Reese SE, Embi PJ, Dascomb K, Klein NP, Griggs EP, Liao IC, Yang DH, Fadel WF, Grisel N, Goddard K, Patel P, Murthy K, Birch R, Valvi NR, Arndorfer J, Zerbo O, Dickerson M, Raiyani C, Williams J, Bozio CH, Blanton L, Link-Gelles R, Barron MA, Gaglani M, Thompson MG, Fireman B. BMJ. 2022 Oct 3;379:e072141. doi: 10.1136/bmj-2022-072141. PMID: 36191948

Booster vaccination against SARS-CoV-2 induces potent immune responses in people with HIV.
Fidler S, Fox J, Tipoe T, Longet S, Tipton T, Abeywickrema M, Adele S, Alagaratnam J, Ali M, Aley PK, Aslam S, Balasubramanian A, Bara A, Bawa T, Brown A, Brown H, Cappuccini F, Davies S, Fowler J, Godfrey L, Goodman AL, Hilario K, Hackstein CP, Mathew M, Mujadidi YF, Packham A, Petersen C, Plested E, Pollock KM, Ramasamy MN, Robinson H, Robinson N, Rongkard P, Sanders H, Serafimova T,

Spence N, Waters A, Woods D, Zacharopoulou P, Barnes E, Dunachie S, Goulder P, Klenerman P, Winston A, Hill AVS, Gilbert SC, Carroll M, Pollard AJ, Lambe T, Ogbe A, Frater J. Clin Infect Dis. 2022 Oct 5:ciac796. doi: 10.1093/cid/ciac796. Online ahead of print. PMID: 36196614

A universal SARS-CoV DNA **vaccine** inducing highly cross-reactive neutralizing antibodies and T cells.
Appelberg S, Ahlén G, Yan J, Nikouyan N, Weber S, Larsson O, Höglund U, Aleman S, Weber F, Perlhamre E, Apro J, Gidlund EK, Tuvesson O, Salati S, Cadossi M, Tegel H, Hober S, Frelin L, Mirazimi A, Sällberg M. EMBO Mol Med. 2022 Oct 10;14(10):e15821. doi: 10.15252/emmm.202215821. Epub 2022 Sep 2. PMID: 35986481

A high level of **vaccine** knowledge increases people's behavioral risks for contracting COVID-19 in Japan.
Takahashi S, Yamada S, Sasaki S, Takahashi N, Nohara M, Kawachi I. Soc Sci Med. 2022 Oct;310:115256. doi: 10.1016/j.socscimed.2022.115256. Epub 2022 Aug 11. PMID: 36029712

COVID-19 **Vaccine**-Related Adverse Events in Solid Cancer Patients Treated with Immunotherapy.
Bouleftour W, Bonjean P, Grangeon K, Magné N. Cancer Invest. 2022 Oct;40(9):760-766. doi: 10.1080/07357907.2022.2121966. Epub 2022 Sep 14. PMID: 36062881

Drivers of and barriers to routine adult vaccination: A systematic literature review.
Eiden AL, Barratt J, Nyaku MK. Hum Vaccin Immunother. 2022 Oct 5:2127290. doi: 10.1080/21645515.2022.2127290. Online ahead of print. PMID: 36197070

Psychometric validation of a chinese version of COVID-19 **vaccine** hesitancy scale: a cross-sectional study.
Huang Y, Wu Y, Dai Z, Xiao W, Wang H, Si M, Wang W, Gu X, Ma L, Li L, Zhang S, Yang C, Yu Y, Qiao Y, Su X. BMC Infect Dis. 2022 Oct 1;22(1):765. doi: 10.1186/s12879-022-07746-z. PMID: 36183087

Insight into the first multi-epitope-based peptide subunit **vaccine** against avian influenza A virus (H5N6): An immunoinformatics approach.
Mia MM, Hasan M, Ahmed S, Rahman MN. Infect Genet Evol. 2022 Oct;104:105355. doi: 10.1016/j.meegid.2022.105355. Epub 2022 Aug 22. PMID: 36007760

Country immunization policies for refugees across 20 low-middle income and 20 high-income countries.
Elharake JA, Omer SB, Schwartz JL. Vaccine. 2022 Oct 6;40(42):6017-6022. doi: 10.1016/j.vaccine.2022.09.032. Epub 2022 Sep 16. PMID: 36123257

Parents' Acceptance of COVID-19 Compared to Human Papillomavirus Vaccines.
Footman A, Kanney N, Niccolai LM, Zimet GD, Overton ET, Davies SL, Van Der Pol B. J Adolesc Health. 2022 Oct 5:S1054-139X(22)00555-9. doi: 10.1016/j.jadohealth.2022.07.015. Online ahead of print. PMID: 36208985

Linear Darier disease after COVID-19 infection.
Burch A, Long T, Garofola C. JAAD Case Rep. 2022 Oct;28:136-137. doi: 10.1016/j.jdcr.2022.08.017. Epub 2022 Aug 20. PMID: 36035746

The urgency of legal regulations existence in case of COVID-19 vaccination refusal in Indonesia.
Firdaus SU. J Forensic Leg Med. 2022 Oct;91:102401. doi: 10.1016/j.jflm.2022.102401. Epub 2022 Jul 30. PMID: 35932531

Toll-like receptor (TLR) agonists as a driving force behind next-generation **vaccine** adjuvants and cancer therapeutics.
Kaur A, Baldwin J, Brar D, Salunke DB, Petrovsky N. Curr Opin Chem Biol. 2022 Oct;70:102172. doi: 10.1016/j.cbpa.2022.102172. Epub 2022 Jul 1. PMID: 35785601

Safety and immunogenicity of parvovirus B19 virus-like particle **vaccine** lacking phospholipase A2 activity.
Suzuki H, Noguchi T, Matsugu N, Suzuki A, Kimura S, Onishi M, Kosaka M, Miyazato P, Morita E, Ebina H. Vaccine. 2022 Oct 6;40(42):6100-6106. doi: 10.1016/j.vaccine.2022.09.009. Epub 2022 Sep 14. PMID: 36114131

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.
Bockstal V, Shukarev G, McLean C, Goldstein N, Bart S, Gaddah A, Anumenden D, Stoop JN, Marit de Groot A, Pau MG, Hendriks J, De Rosa SC, Cohen KW, McElrath MJ, Callendret B, Luhn K, Douoguih M, Robinson C. PLoS One. 2022 Oct 5;17(10):e0274906. doi: 10.1371/journal.pone.0274906. eCollection 2022. PMID: 36197845

Measuring psychosocial determinants of vaccination behavior in healthcare professionals: validation of the Pro-VC-Be short-form questionnaire.
Garrison A, Fressard L, Karlsson L, Soveri A, Fasce A, Lewandowsky S, Schmid P, Gagneur A, Dubé E, Verger P. Expert Rev Vaccines. 2022 Oct;21(10):1505-1514. doi: 10.1080/14760584.2022.2108800. Epub 2022 Aug 8. PMID: 35938710

In situ photothermal nano-**vaccine** based on tumor cell membrane-coated black phosphorus-Au for photo-immunotherapy of metastatic breast tumors.
Huang D, Wu T, Lan S, Liu C, Guo Z, Zhang W. Biomaterials. 2022 Oct;289:121808. doi: 10.1016/j.biomaterials.2022.121808. Epub 2022 Sep 16. PMID: 36137415

Virulence factors of Leishmania parasite: Their paramount importance in unraveling novel **vaccine** candidates and therapeutic targets.
Kumari D, Mahajan S, Kour P, Singh K. Life Sci. 2022 Oct 1;306:120829. doi: 10.1016/j.lfs.2022.120829. Epub 2022 Jul 22. PMID: 35872004

How long-term metal and lead exposure among foundry workers affect COVID-19 infection outcomes in Jordan.
Saadh M. Environ Sci Pollut Res Int. 2022 Oct;29(46):70408-70412. doi: 10.1007/s11356-022-20845-3. Epub 2022 May 19. PMID: 35589897

Covid-19 **vaccine** dissemination: A public health ethical evaluation of Pennsylvania's plan during Phase 1A.
Richardson CL, Wright MS, Pinto CN. Ethics Med Public Health. 2022 Oct;24:100815. doi: 10.1016/j.jemep.2022.100815. Epub 2022 Jun 17. PMID: 35757376

Genomic characterization of peste des petits ruminants **vaccine** seed "45G37/35-k", Russia.
Kwiatek O, Libeau G, Guendouz S, Corbanini C, Gogin A, Lunitsin A, Sindryakova I, Koblasov D, Bataille A. Vet Res. 2022 Oct 8;53(1):79. doi: 10.1186/s13567-022-01099-w. PMID: 36209143

Cutting Edge: High-Dose Live Attenuated Influenza Vaccines Elicit Pulmonary Tissue-Resident Memory CD8$^+$ T Cells in the Face of Pre-Existing Humoral Immunity.
Zheng MZM, Fritzlar S, Wang Z, Tan TK, Kedzierska K, Townsend A, Reading PC, Wakim LM. J Immunol. 2022 Oct 5:ji2200577. doi: 10.4049/jimmunol.2200577. Online ahead of print. PMID: 36198421

Association between Vaccination with the BNT162b2 mRNA Coronavirus Disease 2019 **Vaccine** and Noninfectious Uveitis: A Population-Based Study.
Tomkins-Netzer O, Sar S, Barnett-Griness O, Friedman B, Shyriaieva H, Saliba W. Ophthalmology. 2022 Oct;129(10):1087-1095. doi: 10.1016/j.ophtha.2022.05.015. Epub 2022 May 25. PMID: 35643168

Safety and Immunogenicity After a Three-Dose SARS-CoV-2 **Vaccine** Schedule in Allogeneic Stem Cell Transplant Recipients.
Kimura M, Ferreira VH, Kothari S, Pasic I, Mattsson JI, Kulasingam V, Humar A, Mah A, Delisle JS, Ierullo M, Majchrzak-Kita B, Kumar D, Hosseini-Moghaddam SM. Transplant Cell Ther. 2022 Oct;28(10):706.e1-706.e10. doi: 10.1016/j.jtct.2022.07.024. Epub 2022 Jul 29. PMID: 35914727

Pilot study to determine effect of an altruism intervention focusing on herd immunity to enhance influenza vaccination rates.
Marlowe E, Pranikoff S, Borsheim B, Salafian K, Halvorson EE, Kram DE. Vaccine. 2022 Oct 6:S0264-410X(22)01194-X. doi: 10.1016/j.vaccine.2022.09.074. Online ahead of print. PMID: 36210252

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.
Bockstal V, Shukarev G, McLean C, Goldstein N, Bart S, Gaddah A, Anumenden D, Stoop JN, Marit de Groot A, Pau MG, Hendriks J, De Rosa SC, Cohen KW, McElrath MJ, Callendret B, Luhn K, Douoguih M, Robinson C. PLoS One. 2022 Oct 5;17(10):e0274906. doi: 10.1371/journal.pone.0274906. eCollection 2022. PMID: 36197845

Measuring psychosocial determinants of vaccination behavior in healthcare professionals: validation of the Pro-VC-Be short-form questionnaire.
Garrison A, Fressard L, Karlsson L, Soveri A, Fasce A, Lewandowsky S, Schmid P, Gagneur A, Dubé E, Verger P. Expert Rev Vaccines. 2022 Oct;21(10):1505-1514. doi: 10.1080/14760584.2022.2108800. Epub 2022 Aug 8. PMID: 35938710

In situ photothermal nano-**vaccine** based on tumor cell membrane-coated black phosphorus-Au for photo-immunotherapy of metastatic breast tumors.
Huang D, Wu T, Lan S, Liu C, Guo Z, Zhang W. Biomaterials. 2022 Oct;289:121808. doi: 10.1016/j.biomaterials.2022.121808. Epub 2022 Sep 16. PMID: 36137415

Virulence factors of Leishmania parasite: Their paramount importance in unraveling novel **vaccine** candidates and therapeutic targets.

Kumari D, Mahajan S, Kour P, Singh K. Life Sci. 2022 Oct 1;306:120829. doi: 10.1016/j.lfs.2022.120829. Epub 2022 Jul 22. PMID: 35872004

How long-term metal and lead exposure among foundry workers affect COVID-19 infection outcomes in Jordan.
Saadh M. Environ Sci Pollut Res Int. 2022 Oct;29(46):70408-70412. doi: 10.1007/s11356-022-20845-3. Epub 2022 May 19. PMID: 35589897

Covid-19 **vaccine** dissemination: A public health ethical evaluation of Pennsylvania's plan during Phase 1A.
Richardson CL, Wright MS, Pinto CN. Ethics Med Public Health. 2022 Oct;24:100815. doi: 10.1016/j.jemep.2022.100815. Epub 2022 Jun 17. PMID: 35757376

Genomic characterization of peste des petits ruminants **vaccine** seed "45G37/35-k", Russia.
Kwiatek O, Libeau G, Guendouz S, Corbanini C, Gogin A, Lunitsin A, Sindryakova I, Koblasov D, Bataille A. Vet Res. 2022 Oct 8;53(1):79. doi: 10.1186/s13567-022-01099-w. PMID: 36209143

Cutting Edge: High-Dose Live Attenuated Influenza Vaccines Elicit Pulmonary Tissue-Resident Memory CD8$^+$ T Cells in the Face of Pre-Existing Humoral Immunity.
Zheng MZM, Fritzlar S, Wang Z, Tan TK, Kedzierska K, Townsend A, Reading PC, Wakim LM. J Immunol. 2022 Oct 5:ji2200577. doi: 10.4049/jimmunol.2200577. Online ahead of print. PMID: 36198421

Association between Vaccination with the BNT162b2 mRNA Coronavirus Disease 2019 **Vaccine** and Noninfectious Uveitis: A Population-Based Study.
Tomkins-Netzer O, Sar S, Barnett-Griness O, Friedman B, Shyriaieva H, Saliba W. Ophthalmology. 2022 Oct;129(10):1087-1095. doi: 10.1016/j.ophtha.2022.05.015. Epub 2022 May 25. PMID: 35643168

Pilot study to determine effect of an altruism intervention focusing on herd immunity to enhance influenza vaccination rates.
Marlowe E, Pranikoff S, Borsheim B, Salafian K, Halvorson EE, Kram DE. Vaccine. 2022 Oct 6:S0264-410X(22)01194-X. doi: 10.1016/j.vaccine.2022.09.074. Online ahead of print. PMID: 36210252

Identifying optimal vaccination scenarios to reduce varicella zoster virus transmission and reactivation.
Bakker KM, Eisenberg MC, Woods RJ, Martinez ME. BMC Med. 2022 Oct 8;20(1):387. doi: 10.1186/s12916-022-02534-7. PMID: 36209074

A SARS-CoV-2 oral **vaccine** development strategy based on the attenuated Salmonella type III secretion system.
Wu L, Li L, Yin X, Li C, Xin W, Liu L, Hua Z. J Appl Microbiol. 2022 Oct;133(4):2484-2500. doi: 10.1111/jam.15720. Epub 2022 Jul 31. PMID: 35858677

Personal and contextual determinants of COVID-19 vaccination intention: a vignette study.
Morbée S, Waterschoot J, Yzerbyt V, Klein O, Luminet O, Schmitz M, Van den Bergh O, Van Oost P, De Craene S, Vansteenkiste M. Expert Rev Vaccines. 2022 Oct;21(10):1475-1485. doi: 10.1080/14760584.2022.2105212. Epub 2022 Jul 29. PMID: 35876102

CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 **Vaccine** in Patients With CLL.
Bryer E, Paul S, Chen J, Pleyer C, Wiestner A, Sun C. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S270-S271. doi: 10.1016/S2152-2650(22)01330-1. PMID: 36163876

The quantification of **vaccine** uptake in the Nordic countries and impact on key indicators of COVID-19 severity and healthcare stress level via age range comparative analysis.
Islind AS, Óskarsdóttir M, Cot C, Cacciapaglia G, Sannino F. Sci Rep. 2022 Oct 7;12(1):16891. doi: 10.1038/s41598-022-21055-0. PMID: 36207410

"We don't routinely check vaccination background in adults": a national qualitative study of barriers and facilitators to **vaccine** delivery and uptake in adult migrants through UK primary care.
Carter J, Mehrotra A, Knights F, Deal A, Crawshaw AF, Farah Y, Goldsmith LP, Wurie F, Ciftci Y, Majeed A, Hargreaves S. BMJ Open. 2022 Oct 10;12(10):e062894. doi: 10.1136/bmjopen-2022-062894. PMID: 36216433

Understanding Human Factors Challenges on the Front Lines of Mass COVID-19 Vaccination Clinics: Human-Systems Modelling Study.
Tennant R, Tetui M, Grindrod K, Burns CM. JMIR Hum Factors. 2022 Oct 6. doi: 10.2196/39670. Online ahead of print. PMID: 36219839

High performance anion exchange chromatographic and colorimetric methods for quality assessment of total and free polysaccharide content in *Haemophilus influenzae* type b conjugate **vaccine** containing lactose.
Hussein AR, Rezk MR, Fathalla FAA, El-Saharty YS, Nadim AH. Anal Methods. 2022 Oct 6;14(38):3757-3765. doi: 10.1039/d2ay00937d. PMID: 36106712

NVX-CoV2373 vaccination induces functional SARS-CoV-2-specific CD4+ and CD8+ T cell responses.
Rydyznski Moderbacher C, Kim C, Mateus J, Plested J, Zhu M, Cloney-Clark S, Weiskopf D, Sette A, Fries L, Glenn G, Crotty S. J Clin Invest. 2022 Oct 3;132(19):e160898. doi: 10.1172/JCI160898. PMID: 35943810

A third dose of the unmodified COVID-19 mRNA **vaccine** CVnCoV enhances quality and quantity of immune responses.
Lenart K, Hellgren F, Ols S, Yan X, Cagigi A, Cerveira RA, Winge I, Hanczak J, Mueller SO, Jasny E, Schwendt K, Rauch S, Petsch B, Loré K. Mol Ther Methods Clin Dev. 2022 Oct 6. doi: 10.1016/j.omtm.2022.10.001. Online ahead of print. PMID: 36217434

The US needs to prepare to introduce the novel oral polio **vaccine**.
Schwalbe N, Varma JK. BMJ. 2022 Oct 4;379:o2388. doi: 10.1136/bmj.o2388. PMID: 36195323

Combination therapy between prophylactic and therapeutic human papillomavirus (HPV) vaccines with special emphasis on implementation of nanotechnology.
Gohar A, Ali AA, Elkhatib WF, El-Sayyad GS, Elfadil D, Noreddin AM. Microb Pathog. 2022 Oct;171:105747. doi: 10.1016/j.micpath.2022.105747. Epub 2022 Sep 5. PMID: 36064102

Subacute thyroiditis after anti-SARS-CoV-2 (Ad5-nCoV) **vaccine**.
Flores Rebollar A. Enferm Infecc Microbiol Clin (Engl Ed). 2022 Oct;40(8):459-460. doi: 10.1016/j.eimce.2022.05.008. Epub 2022 May 19. PMID: 35637121

A combination **vaccine** against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core.
Shi R, Zeng J, Xu L, Wang F, Duan X, Wang Y, Wu Z, Yu D, Huang Q, Yao YG, Yan J. EBioMedicine. 2022 Oct 4;85:104297. doi: 10.1016/j.ebiom.2022.104297. Online ahead of print. PMID: 36206623

Torque teno virus DNA load as a predictive marker of antibody response to a three-dose regimen of COVID-19 mRNA-based **vaccine** in lung transplant recipients.
Gallais F, Renaud-Picard B, Solis M, Laugel E, Soulier E, Caillard S, Kessler R, Fafi-Kremer S. J Heart Lung Transplant. 2022 Oct;41(10):1429-1439. doi: 10.1016/j.healun.2022.07.008. Epub 2022 Jul 16. PMID: 35953352

A pan-genotype hepatitis C virus viral vector **vaccine** generates T cells and neutralizing antibodies in mice.
Donnison T, McGregor J, Chinnakannan S, Hutchings C, Center RJ, Poumbourios P, Klenerman P, Drummer HE, Barnes E. Hepatology. 2022 Oct;76(4):1190-1202. doi: 10.1002/hep.32470. Epub 2022 May 19. PMID: 35313015

PfSPZ-CVac malaria **vaccine** demonstrates safety among malaria-experienced adults: A randomized, controlled phase 1 trial.
Coulibaly D, Kone AK, Traore K, Niangaly A, Kouriba B, Arama C, Zeguime A, Dolo A, Lyke KE, Plowe CV, Abebe Y, Potter GE, Kennedy JK, Galbiati SM, Nomicos E, Deye GA, Richie TL, James ER, Kc N, Sim BKL, Hoffman SL, Doumbo OK, Thera MA, Laurens MB; DMID 15-0052 PfSPZ-CVac Study Team. EClinicalMedicine. 2022 Jul 30;52:101579. doi: 10.1016/j.eclinm.2022.101579. eCollection 2022 Oct. PMID: 35928033

Immunoinformatic screening of Marburgvirus epitopes and computational investigations of epitope-allele complexes.
Baral P, Pavadai E, Zhou Z, Xu Y, Tison CK, Pokhrel R, Gerstman BS, Chapagain PP. Int Immunopharmacol. 2022 Oct;111:109109. doi: 10.1016/j.intimp.2022.109109. Epub 2022 Aug 1. PMID: 35926269

Amplitudes and kinetic of antibodies after second and third doses of BNT162b2 **vaccine** in nonagenarians and centenarians with and without prior SARS-CoV-2 infection.
Tuaillon E, Pisoni A, Gamon L, Henry S, Anne-Marie Mondain, Pastor P, Van de Perre P, Bousquet J, Picot MC, Blain H. Clin Microbiol Infect. 2022 Oct;28(10):1393-1395. doi: 10.1016/j.cmi.2022.05.025. Epub 2022 May 31. PMID: 35659927

Immunogenicity and safety of an enterovirus 71 **vaccine** in children aged 36-71 months: A double-blind, randomised, similar **vaccine**-controlled, non-inferiority phase III trial.
Tong Y, Zhang X, Chen J, Chen W, Wang Z, Li Q, Duan K, Wei S, Yang B, Qian X, Li J, Hang L, Deng S, Li X, Guo C, Shen H, Liu Y, Deng P, Xie T, Li Q, Li L, Du H, Mao Q, Gao F, Lu W, Guan X, Huang J, Li X, Chen X. EClinicalMedicine. 2022 Jul 29;52:101596. doi: 10.1016/j.eclinm.2022.101596. eCollection 2022 Oct. PMID: 35923425

The spike hypothesis in **vaccine**-induced adverse effects: questions and answers.
Cosentino M, Marino F. Trends Mol Med. 2022 Oct;28(10):797-799. doi: 10.1016/j.molmed.2022.07.009. Epub 2022 Sep 12. PMID: 36114089

Pregnancy during COVID-19: social contact patterns and **vaccine** coverage of pregnant women from CoMix in 19 European countries.
Wong KLM, Gimma A, Paixao ES; CoMix Europe Working Group, Faes C, Beutels P, Hens N, Jarvis CI, Edmunds WJ. BMC Pregnancy Childbirth. 2022 Oct 8;22(1):757. doi: 10.1186/s12884-022-05076-1. PMID: 36209078

Vaccines against chicken coccidiosis with particular reference to previous decade: progress, challenges, and opportunities.
Zaheer T, Abbas RZ, Imran M, Abbas A, Butt A, Aslam S, Ahmad J. Parasitol Res. 2022 Oct;121(10):2749-2763. doi: 10.1007/s00436-022-07612-6. Epub 2022 Aug 4. PMID: 35925452

Follow-up of COVID-19 **Vaccine**-related Axillary Lymphadenopathy before 12 Weeks Is Unnecessary.
Moy L, Kim E. Radiology. 2022 Oct;305(1):54-55. doi: 10.1148/radiol.220962. Epub 2022 Apr 26. PMID: 35471114

[Subacute thyroiditis after anti-SARS-CoV-2 (Ad5-nCoV) **vaccine**].
Flores Rebollar A. Enferm Infecc Microbiol Clin. 2022 Oct;40(8):459-460. doi: 10.1016/j.eimc.2021.10.015. Epub 2021 Nov 18. PMID: 34812213

Measuring the effects of misinformation exposure and beliefs on behavioural intentions: a COVID-19 vaccination study.
de Saint Laurent C, Murphy G, Hegarty K, Greene CM. Cogn Res Princ Implic. 2022 Oct 1;7(1):87. doi: 10.1186/s41235-022-00437-y. PMID: 36183027

The effectiveness of mRNA vaccines to prevent SARS-CoV-2 infection and hospitalisation for COVID-19 according to the time elapsed since their administration in health professionals in the Valencian Autonomous Community (Spain).
Chico-Sánchez P, Gras-Valentí P, Algado-Sellés N, Jiménez-Sepúlveda N, Vanaclocha H, Peiró S, Burgos JS, Berenguer A, Navarro D, Sánchez-Payá J; Valencian vaccine research program (ProVaVac) study group. Prev Med. 2022 Oct;163:107237. doi: 10.1016/j.ypmed.2022.107237. Epub 2022 Aug 31. PMID: 36057393

Clinical observation and analysis of skin reactions caused by COVID-19 vaccination.
Li Y, Fan L, Mao Q, Luan X, Wang Z, Zeng N, Cheng Y, Li Y, Xia Q, Lu Z, Lu Q, Min W, Luo D. Dermatol Ther. 2022 Oct;35(10):e15746. doi: 10.1111/dth.15746. Epub 2022 Aug 10. PMID: 36190010

Knowledge, attitudes, perceptions, and COVID-19 hesitancy in a large public university in Mexico city during the early vaccination rollout.
Mongua-Rodríguez N, Rodríguez-Álvarez M, De-la-Rosa-Zamboni D, Jiménez-Corona ME, Castañeda-Cediel ML, Miranda-Novales G, Cruz-Pacheco G, Ferreira-Guerrero E, Ferreyra-Reyes L, Delgado-Sánchez G, Martínez-Hernández M, Cruz-Salgado A, Pérez-Padilla R, Ponce-de-León S, García-García L. BMC Public Health. 2022 Oct 4;22(1):1853. doi: 10.1186/s12889-022-14225-2. PMID: 36195873

Isolated popliteal artery lesion due to giant cell vasculitis post COVID-19 mRNA **vaccine** and COVID-19 asymptomatic infection.
Gabrielli R, Siani A, Smedile G, Rizzo AR, De Vivo G, Accrocca F, Bartoli S. Vascular. 2022 Oct 6:17085381221126234. doi: 10.1177/17085381221126234. Online ahead of print. PMID: 36200437

Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster **vaccine** against COVID-19: a phase 2/3 trial.
Chalkias S, Eder F, Essink B, Khetan S, Nestorova B, Feng J, Chen X, Chang Y, Zhou H, Montefiori D, Edwards DK, Girard B, Pajon R, Dutko FJ, Leav B, Walsh SR, Baden LR, Miller JM, Das R. Nat Med. 2022 Oct 6. doi: 10.1038/s41591-022-02031-7. Online ahead of print. PMID: 36202997

A next generation BCG **vaccine** moves forward.
Dockrell HM. Lancet Infect Dis. 2022 Oct;22(10):1404-1406. doi: 10.1016/S1473-3099(22)00287-0. Epub 2022 Jun 27. PMID: 35772448

Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV: A systematic review and meta-analysis.
Staadegaard L, Rönn MM, Soni N, Bellerose ME, Bloem P, Brisson M, Maheu-Giroux M, Barnabas RV, Drolet M, Mayaud P, Dalal S, Boily MC. EClinicalMedicine. 2022 Aug 3;52:101585. doi: 10.1016/j.eclinm.2022.101585. eCollection 2022 Oct. PMID: 35936024

Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective.
Wang C, Yu M, Zhang W. Cancer Lett. 2022 Oct 7:215945. doi: 10.1016/j.canlet.2022.215945. Online ahead of print. PMID: 36216148

The kinetics of IgG subclasses and contributions to neutralizing activity against SARS-CoV-2 wild-type strain and variants in healthy adults immunized with inactivated **vaccine**.
Chen W, Zhang L, Li J, Bai S, Wang Y, Zhang B, Zheng Q, Chen M, Zhao W, Wu J. Immunology. 2022 Oct;167(2):221-232. doi: 10.1111/imm.13531. Epub 2022 Jul 6. PMID: 35751471

Immunogenicity of COVID-19 mRNA vaccines in hemodialysis patients: Systematic review and meta-analysis.
Falahi S, Sayyadi H, Kenarkoohi A. Health Sci Rep. 2022 Oct 3;5(6):e874. doi: 10.1002/hsr2.874. eCollection 2022 Nov. PMID: 36210877

COVID **vaccine** booster doses for omicron variants.
Burki T. Lancet Respir Med. 2022 Oct;10(10):936. doi: 10.1016/S2213-2600(22)00361-7. Epub 2022 Sep 2. PMID: 36063833

SARS-CoV-2 **vaccine** as a potential trigger for narcolepsy.
Mungmunpuntipantip R, Wiwanitkit V. J Clin Sleep Med. 2022 Oct 1;18(10):2519. doi: 10.5664/jcsm.10176. PMID: 35866225

Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of **Vaccine**-Related Adverse Events: A Survey From China.
Tian WN, Huang YH, Dai C. Inflamm Bowel Dis. 2022 Oct 3;28(10):e134-e136. doi: 10.1093/ibd/izac118. PMID: 35666245

Characterization of US State COVID-19 **Vaccine** Incentive Programs.
Hogan CM, Parzuchowski AS, Lyu X, Goldstick J, Resnicow K. JAMA Netw Open. 2022 Oct 3;5(10):e2235328. doi: 10.1001/jamanetworkopen.2022.35328. PMID: 36206001

Factors Associated with Intention to Receive the COVID-19 **Vaccine**: A Cross-sectional National Study.
Kasting ML, Macy JT, Grannis SJ, Wiensch AJ, Lavista Ferres JM, Dixon BE. JMIR Public Health Surveill. 2022 Oct 9. doi: 10.2196/37203. Online ahead of print. PMID: 36219842

Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccines.
Elliott T, Cheeseman HM, Evans AB, Day S, McFarlane LR, O'Hara J, Kalyan M, Amini F, Cole T, Winston A, Fidler S, Pollock KM, Harker JA, Shattock RJ. PLoS Pathog. 2022 Oct 4;18(10):e1010885. doi: 10.1371/journal.ppat.1010885. Online ahead of print. PMID: 36194628

Sheep vaccinated against paratuberculosis have increased levels of B cells infiltrating the intestinal tissue.
Pooley HB, Whittington RJ, Begg DJ, Purdie AC, Plain KM, de Silva K. Vet Immunol Immunopathol. 2022 Oct;252:110482. doi: 10.1016/j.vetimm.2022.110482. Epub 2022 Sep 6. PMID: 36122535

Assessment of Immediate Allergic Reactions After Immunization With the Pfizer BNT162b2 **Vaccine** Using Intradermal Skin Testing With the COVID-19 Vaccines.
Shavit R, Maoz-Segal R, Offengenden I, Yahia SH, Maayan DM, Lifshitz Y, Niznik S, Deutch M, Elbaz E, Genaim H, Iancovici-Kidon M, Agmon-Levin N. J Allergy Clin Immunol Pract. 2022 Oct;10(10):2677-2684. doi: 10.1016/j.jaip.2022.08.010. Epub 2022 Aug 13. PMID: 35973526

Effectiveness of an inactivated Covid-19 **vaccine** with homologous and heterologous boosters against Omicron in Brazil.
Ranzani OT, Hitchings MDT, de Melo RL, de França GVA, Fernandes CFR, Lind ML, Torres MSS, Tsuha DH, David LCS, Said RFC, Almiron M, de Oliveira RD, Cummings DAT, Dean NE, Andrews JR, Ko AI, Croda J. Nat Commun. 2022 Oct 6;13(1):5536. doi: 10.1038/s41467-022-33169-0. PMID: 36202800

Microneedle Transdermal Drug Delivery Systems for Allergen-Specific Immunotherapy, Skin Disease Treatment, and **Vaccine** Development.
Park CO, Kim HL, Park JW. Yonsei Med J. 2022 Oct;63(10):881-891. doi: 10.3349/ymj.2022.0092. PMID: 36168240

Corrigendum to 'Thrombosis patterns and clinical outcome of COVID-19 **vaccine**-induced immune thrombotic thrombocytopenia: A Systematic Review and Meta-Analysis' International Journal of Infectious Diseases, Volume 119, June 2022, Page 130-139.
Kim AY, Woo W, Yon DK, Lee SW, Yang JW, Kim JH, Park S, Koyanagi A, Kim MS, Lee S, Shin JI, Smith L. Int J Infect Dis. 2022 Oct;123:166. doi: 10.1016/j.ijid.2022.08.025. Epub 2022 Sep 15. PMID: 36116211

Comparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease receiving haemodialysis: A prospective, observational cohort study.
Martin P, Gleeson S, Clarke CL, Thomson T, Edwards H, Spensley K, Mortimer P, McIntyre S, Cox A, Pickard G, Lightstone L, Thomas D, McAdoo SP, Kelleher P, Prendecki M, Willicombe M. Lancet Reg Health Eur. 2022 Oct;21:100478. doi: 10.1016/j.lanepe.2022.100478. Epub 2022 Sep 10. PMID: 36105885

Effect of **vaccine** program on IgG antibody titers for measles, rubella, varicella, and mumps in young adults in Japan: Survey between 2018 and 2021.
Miyazaki H, Yamanaka G, Furukawa K, Ichiki M. J Infect Chemother. 2022 Oct;28(10):1410-1414. doi: 10.1016/j.jiac.2022.06.016. Epub 2022 Jun 29. PMID: 35779802

Putting a twist in syphilis **vaccine** development.
Grillová L. Nat Rev Microbiol. 2022 Oct;20(10):577. doi: 10.1038/s41579-022-00784-z. PMID: 35902764

The potential rationale of COVID-19 **vaccine**-induced myopericarditis.
Au TY, Assavarittirong C. J Med Virol. 2022 Oct;94(10):4586-4587. doi: 10.1002/jmv.27910. Epub 2022 Jun 11. PMID: 35655335

Adenoviral-Based Cancer Vaccines Promote Anti-PD-1 Treatment Efficacy.
[No authors listed] Cancer Discov. 2022 Oct 5;12(10):OF11. doi: 10.1158/2159-8290.CD-RW2022-152. PMID: 36018032

The Quest to Eradicate HPV-Related Oropharyngeal Carcinoma: An Opportunity Not to Miss.
Lalonde CS, Teng Y, Burtness BA, Ferris RL, Ahmed R, Saba NF. J Natl Cancer Inst. 2022 Oct 6;114(10):1333-1337. doi: 10.1093/jnci/djac098. PMID: 35567531

Effect of the of 10-valent pneumococcal conjugate **vaccine** in Nepal 4 years after introduction: an observational cohort study.
Shrestha S, Gurung M, Amatya P, Bijukchhe S, Bose AS, Carter MJ, Gautam MC, Gurung S, Hinds J, Kandasamy R, Kelly S, Khadka B, Maskey P, Mujadidi YF, O'Reilly PJ, Pokhrel B, Pradhan R, Shah GP, Shrestha S, Wahl B, O'Brien KL, Knoll MD, Murdoch DR, Kelly DF, Thorson S, Voysey M, Pollard AJ; PneumoNepal study group. Lancet Glob Health. 2022 Oct;10(10):e1494-e1504. doi: 10.1016/S2214-109X(22)00281-9. PMID: 36113533

Engineered flavivirus vaccines control induction of crossreactive infection-enhancing and -neutralizing antibodies.
Yamanaka A, Rattanaamnuaychai P, Matsuda M, Suzuki R, Matsuura Y, Tatsumi M, Konishi E. Vaccine. 2022 Oct 6;40(42):6004-6011. doi: 10.1016/j.vaccine.2022.09.012. Epub 2022 Sep 13. PMID: 36109279

Identification of Antigenic Properties of Acinetobacter baumannii Proteins as Novel Putative **Vaccine** Candidates Using Reverse Vaccinology Approach.
Piri-Gharaghie T, Doosti A, Mirzaei SA. Appl Biochem Biotechnol. 2022 Oct;194(10):4892-4914. doi: 10.1007/s12010-022-03995-5. Epub 2022 Jun 7. PMID: 35670904

Hypersensitivity Lymphohistiocytic Myocarditis After Moderna mRNA-1273 **Vaccine**.
Kounis NG, Mplani V, Kouni S, Plotas P, Koniari I. Am J Clin Pathol. 2022 Oct 6;158(4):555-556. doi: 10.1093/ajcp/aqac090. PMID: 35938624

Nanomedicine for advanced cancer immunotherapy.
Diep YN, Kim TJ, Cho H, Lee LP. J Control Release. 2022 Oct 8:S0168-3659(22)00674-5. doi: 10.1016/j.jconrel.2022.10.004. Online ahead of print. PMID: 36220487

Lactobacillus casei displaying Clostridium perfringens NetB antigen protects chickens against necrotic enteritis.
Shamshirgaran MA, Golchin M, Mohammadi E. Appl Microbiol Biotechnol. 2022 Oct;106(19-20):6441-6453. doi: 10.1007/s00253-022-12155-y. Epub 2022 Sep 5. PMID: 36063180

A scoping review of literature exploring factors affecting **vaccine** uptake within Roma communities across Europe.
Cronin A, Ibrahim N. Expert Rev Vaccines. 2022 Oct;21(10):1429-1442. doi: 10.1080/14760584.2022.2104715. Epub 2022 Aug 1. PMID: 35877604

Incidence of Monkeypox Among Unvaccinated Persons Compared with Persons Receiving ≥1 JYNNEOS **Vaccine** Dose - 32 U.S. Jurisdictions, July 31-September 3, 2022.
Payne AB, Ray LC, Kugeler KJ, Fothergill A, White EB, Canning M, Farrar JL, Feldstein LR, Gundlapalli AV, Houck K, Kriss JL, Lewis NM, Sims E, Smith DK, Spicknall IH, Nakazawa Y, Damon IK, Cohn AC, Payne DC. MMWR Morb Mortal Wkly Rep. 2022 Oct 7;71(40):1278-1282. doi: 10.15585/mmwr.mm7140e3. PMID: 36201401

Integrated Multicultural Media Campaign to Increase COVID-19 Education and Vaccination Among Californians, 2021.
Dominguez ME, Macias-Carlos D, Montoya JA, Plant A, Neffa-Creech D. Am J Public Health. 2022 Oct;112(10):1389-1393. doi: 10.2105/AJPH.2022.306974. Epub 2022 Aug 11. PMID: 35952332

Immune Response to SARS-CoV-2 Third **Vaccine** in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines.
Isnardi CA, Cerda OL, Landi M, Cruces L, Schneeberger EE, Calle Montoro C, Alfaro MA, Roldán BM, Gómez Vara AB, Giorgis P, Ezquer RA, Crespo Rocha MG, Reyes Gómez CR, de Los Ángeles Correa M, Rosemffet MG, Abarza VC, Catalan Pellet S, Perandones M, Reimundes C, Longueira Y, Turk G, Quiroga MF, Laufer N, Quintana R, de la Vega MC, Kreplak N, Pifano M, Maid P, Pons-Estel GJ, Citera G. J Rheumatol. 2022 Oct 1:jrheum.220469. doi: 10.3899/jrheum.220469. Online ahead of print. PMID: 36182107

Safety and immunogenicity of live, attenuated intranasal Bordetella pertussis **vaccine** (BPZE1) in healthy adults.
Buddy Creech C, Jimenez-Truque N, Kown N, Sokolow K, Brady EJ, Yoder S, Solovay K, Rubin K, Noviello S, Hensel E, Selamawi S, Bakare A, Makowski M, Lu K. Vaccine. 2022 Oct 8:S0264-410X(22)01196-3. doi: 10.1016/j.vaccine.2022.09.075. Online ahead of print. PMID: 36220716

Effects of prenatal dietary rumen-protected choline supplementation during late gestation on calf growth, metabolism, and **vaccine** response.
Swartz TH, Bradford BJ, Lemke M, Mamedova LK, Agnew R, Fehn J, Owczarzak E, McGill JL, Estes KA. J Dairy Sci. 2022 Oct 4:S0022-0302(22)00574-4. doi: 10.3168/jds.2022-22239. Online ahead of print. PMID: 36207180

How aging impacts **vaccine** efficacy: known molecular and cellular mechanisms and future directions.
Chen J, Deng JC, Goldstein DR. Trends Mol Med. 2022 Oct 7:S1471-4914(22)00243-X. doi: 10.1016/j.molmed.2022.09.008. Online ahead of print. PMID: 36216643

Research note: effects of different anticoccidial regimens on the growth performance, hematological parameters, immune response, and intestinal coccidial lesion scores of yellow-feathered broilers.
Lei T, Wu D, Song Z, Ren Y, Yu Q, Qi C, Xiao P, Gong J. Poult Sci. 2022 Oct;101(10):102019. doi: 10.1016/j.psj.2022.102019. Epub 2022 Jun 24. PMID: 35973348

Model-based evaluation of the impact of prophylactic vaccination applied to Ebola epidemics in Sierra Leone and Democratic Republic of Congo.
Potluri R, Kumar A, Oriol-Mathieu V, Van Effelterre T, Metz L, Bhandari H. BMC Infect Dis. 2022 Oct 4;22(1):769. doi: 10.1186/s12879-022-07723-6. PMID: 36192683

[Expert opinion on strategies to improve vaccination coverage against seasonal influenza].
Velicia Peñas C, Del Campo Pérez VM, Rivero Calle I, Armenteros Del Olmo L, Pérez Rodríguez MT, Gestal Otero JJ. Rev Esp Quimioter. 2022 Oct;35(5):435-443. doi: 10.37201/req/031.2022. Epub 2022 Jun 21. PMID: 35726347

Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers.
Brunner WM, Freilich D, Victory J, Krupa N, Scribani MB, Jenkins P, Lasher EG, Fink A, Shah A, Cross P, Bush V, Peek LJ, Pestano GA, Gadomski AM. Int J Infect Dis. 2022 Oct;123:183-191. doi: 10.1016/j.ijid.2022.08.022. Epub 2022 Aug 28. PMID: 36044963

Vaccine Effectiveness of CanSino (Adv5-nCoV) Coronavirus Disease 2019 (COVID-19) **Vaccine** Among Childcare Workers-Mexico, March-December 2021.
Richardson VL, Camacho Franco MA, Bautista Márquez A, Martínez Valdez L, Castro Ceronio LE, Cruz Cruz V, Gharpure R, Lafond KE, Yau TS, Azziz-Baumgartner E, Hernández Ávila M. Clin Infect Dis. 2022 Oct 3;75(Supplement_2):S167-S173. doi: 10.1093/cid/ciac488. PMID: 35717650

Dataset from a proteomics analysis of tumor antigens shared between an allogenic tumor cell lysate **vaccine** and pancreatic tumor tissue.
Stingl C, Lau SP, van der Burg SH, Aerts JG, van Eijck CHJ, Luider TM. Data Brief. 2022 Jul 25;44:108490. doi: 10.1016/j.dib.2022.108490. eCollection 2022 Oct. PMID: 35959468

Urticarial vasculitis triggered by SARS-CoV-2 **vaccine** (mRNA **vaccine**).
Daldoul M, Korbi M, Bellalah A, Ben Fadhel N, Belhadjali H, Zili J. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):e743-e744. doi: 10.1111/jdv.18253. Epub 2022 Jun 3. PMID: 35604050

Effect of mandating vaccination on COVID-19 cases in colleges and universities.
Ghaffarzadegan N. Int J Infect Dis. 2022 Oct;123:41-45. doi: 10.1016/j.ijid.2022.08.004. Epub 2022 Aug 17. PMID: 35985570

Predicting effectiveness of the V114 **vaccine** against invasive pneumococcal disease in children.
Ryman J, Weaver J, Yee KL, Sachs JR. Expert Rev Vaccines. 2022 Oct;21(10):1515-1521. doi: 10.1080/14760584.2022.2112179. Epub 2022 Aug 25. PMID: 35997125

Higher antibody responses after mRNA-based **vaccine** compared to inactivated **vaccine** against SARS-CoV-2 in Behcet's syndrome.

Ozdede A, Nohut OK, Atli Z, Tok YT, Guner S, Yilmaz E, Ucar D, Uygunoglu U, Hamuryudan V, Seyahi E. Rheumatol Int. 2022 Oct;42(10):1741-1750. doi: 10.1007/s00296-022-05164-7. Epub 2022 Jul 2. PMID: 35779083

Sublingual immunisation with GBS serotype III capsular polysaccharide-tetanus toxoid conjugate **vaccine** induces systemic and mucosal antibody responses which are opsonophagocytic and inhibit GBS colonisation of vaginal epithelial cells.
Deifallah Yousif M, Felek A, Saydam M, Wilson S, Murdan S, Mawas F. Vaccine. 2022 Oct 6;40(42):6055-6063. doi: 10.1016/j.vaccine.2022.08.064. Epub 2022 Sep 9. PMID: 36096970

Development of a road map to scale up the uptake and utilization of influenza **vaccine** in 22 countries of Eastern Mediterranean Region.
Chughtai AA, Mohammed S, Al Ariqi L, McCarron M, Bresee J, Abubakar A, Khan W. Vaccine. 2022 Oct 5:S0264-410X(22)01159-8. doi: 10.1016/j.vaccine.2022.09.051. Online ahead of print. PMID: 36208976

COVID-19 Vaccination Hesitancy and Its Association With Altered Presentation of Primary Rhegmatogenous Retinal Detachment.
Mundae R, Wagley S, Ryan EH, Parke DW 3rd, Mittra RA, Tang PH. Am J Ophthalmol. 2022 Oct;242:7-17. doi: 10.1016/j.ajo.2022.05.013. Epub 2022 May 21. PMID: 35609676

Immunization with inactivated whole virus particle influenza virus vaccines improves the humoral response landscape in cynomolgus macaques.
Chua BY, Sekiya T, Koutsakos M, Nomura N, Rowntree LC, Nguyen THO, McQuilten HA, Ohno M, Ohara Y, Nishimura T, Endo M, Itoh Y, Habel JR, Selva KJ, Wheatley AK, Wines BD, Hogarth PM, Kent SJ, Chung AW, Jackson DC, Brown LE, Shingai M, Kedzierska K, Kida H. PLoS Pathog. 2022 Oct 7;18(10):e1010891. doi: 10.1371/journal.ppat.1010891. Online ahead of print. PMID: 36206307

Correction to: COVID-19 **Vaccine** Administration and Hesitation Among Psychiatric Emergency Services Patients.
Mitchell L, Wilkosz M, Fuehrlein B. Community Ment Health J. 2022 Oct;58(7):1385. doi: 10.1007/s10597-022-00971-5. PMID: 35389155

Public health opportunities resulting from sufficient HPV **vaccine** supply and a single-dose vaccination schedule.
Kreimer AR, Cernuschi T, Rees H, Brotherton JML, Porras C, Schiller J. J Natl Cancer Inst. 2022 Oct 4:djac189. doi: 10.1093/jnci/djac189. Online ahead of print. PMID: 36194015

[Immune responses induced by subunit **vaccine** of Ag85B-ESAT-6 delivered by mucosal route to Mycobacterium tuberculosis].
Ning H, Zhang F, Kang J, Wang L, Lu Y, Ren R, Bai L, Liang X, Xie Y, Bai Y. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2022 Oct;38(10):886-892. PMID: 36163619

Heterologous booster COVID-19 vaccination elicited potent immune responses in HCWs.
Saltoğlu N, Dinç HÖ, Balkan İİ, Can G, Özbey D, Beytur AN, Keskin E, Budak B, Aydoğan O, Mete B, Karaali R, Ergin S, Kocazeybek B. Diagn Microbiol Infect Dis. 2022 Oct;104(2):115758. doi: 10.1016/j.diagmicrobio.2022.115758. Epub 2022 Jul 1. PMID: 35878507

Efficacy of passive immunization in broiler chicks via an inactivated *Escherichia coli* autogenous **vaccine** administered to broiler breeder hens.
Keita A, Le Devendec L, Amelot M, Puterflam J, Lucas C, Bougeard S, Delannoy S, Schouler C, Fach P, Lucas P, Souillard R, Kempf I. Avian Pathol. 2022 Oct;51(5):445-456. doi: 10.1080/03079457.2022.2084362. Epub 2022 Aug 5. PMID: 35634647

Effects of coronavirus pandemic on expanded program on immunization in weija gbawe municipality (Accra-Ghana).
Kissi J, Owusu-Marfo J, Osei E, Dzamvivie K, Akorfa Anku V, Naa Lamiokor Lamptey J. Hum Vaccin Immunother. 2022 Oct 4:2129830. doi: 10.1080/21645515.2022.2129830. Online ahead of print. PMID: 36194867

Modelling optimal vaccination strategies against COVID-19 in a context of Gamma variant predominance in Brazil.
Ferreira LS, de Almeida GB, Borges ME, Simon LM, Poloni S, Bagattini ÂM, da Rosa MQM, Diniz Filho JAF, Kuchenbecker RS, Camey SA, Kraenkel RA, Coutinho RM, Toscano CM. Vaccine. 2022 Oct 3:S0264-410X(22)01216-6. doi: 10.1016/j.vaccine.2022.09.082. Online ahead of print. PMID: 36210250

Barriers and facilitators to the future uptake of regular COVID-19 booster vaccinations among young adults in the UK.
Williams L, Gallant A, Brown L, Corrigan K, Crowe K, Hendry E. Hum Vaccin Immunother. 2022 Oct 4:2129238. doi: 10.1080/21645515.2022.2129238. Online ahead of print. PMID: 36194693

COVID-19 mRNA **vaccine**-induced adverse effects: unwinding the unknowns.
Trougakos IP, Terpos E, Alexopoulos H, Politou M, Paraskevis D, Scorilas A, Kastritis E, Andreakos E, Dimopoulos MA. Trends Mol Med. 2022 Oct;28(10):800-802. doi: 10.1016/j.molmed.2022.07.008. Epub 2022 Sep 12. PMID: 36114090

A Cross-Sectional Study of Untoward Reactions Following Homologous and Heterologous COVID-19 Booster Immunizations in Recipients Seventeen Years of Age and Older.
Tamburro M, Ripabelli G, D'Amico A, De Dona R, Iafigliola M, Parente A, Samprati N, Santagata A, Adesso C, Natale A, Di Palma MA, Cannizzaro F, Sammarco ML. J Community Health. 2022 Oct;47(5):814-821. doi: 10.1007/s10900-022-01112-5. Epub 2022 Jun 25. PMID: 35750980

Active Post-Licensure Safety Surveillance for Recombinant Zoster **Vaccine** Using Electronic Health Record Data.
Nelson JC, Ulloa-Pérez E, Yu O, Cook AJ, Jackson ML, Belongia EA, Daley MF, Harpaz R, Kharbanda EO, Klein NP, Naleway AL, Tseng HF, Weintraub ES, Duffy J, Yih WK, Jackson LA. Am J Epidemiol. 2022 Oct 4:kwac170. doi: 10.1093/aje/kwac170. Online ahead of print. PMID: 36193854

Neutralizing Antibody Responses Among Residents and Staff of Long-Term Care Facilities in the State of New Jersey During the First Wave of the COVID-19 Pandemic.
Friedman SM, Li J, Thomas P, Gurumurthy M, Siderits R, Nepomich A, Lifshitz E. J Community Health. 2022 Oct 5:1-9. doi: 10.1007/s10900-022-01142-z. Online ahead of print. PMID: 36197535

Absence of active systemic anaphylaxis in guinea pigs upon intramuscular injection of inactivated SARS-CoV-2 **vaccine** (Vero cells).

Huang Z, Li Y, Yi H, Wu Z, Li C, Du T, Yang J, Wang Y, Jiang Q, Fan S, Liao Y, Zhang Y, Jiang G, Ma K, Li Q. Immunopharmacol Immunotoxicol. 2022 Oct;44(5):633-640. doi: 10.1080/08923973.2022.2073889. Epub 2022 May 11. PMID: 35506627

Outreach Medicine as an Experiential Teaching Tool to Improve Veterinary Student and Client Education.
Kim J, Rinke EJ, Matusicky ME, Millward LM. J Vet Med Educ. 2022 Oct;49(5):560-567. doi: 10.3138/jvme-2020-0128. Epub 2021 Aug 2. PMID: 34342523

IgG4 related pleural disease: Recurrent pleural effusion after COVID-19 vaccination.
Tasnim S, Al-Jobory O, Hallak A, Bharadwaj T, Patel M. Respirol Case Rep. 2022 Sep 18;10(10):e01026. doi: 10.1002/rcr2.1026. eCollection 2022 Oct. PMID: 36187460

IBCL-054 The Effects of an mRNA COVID-19 **Vaccine** Booster on Immune Responses in Cancer-Bearing Veterans.
Frankel A, Capozzola T, Andrabi R, Ahn C, Burton D. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S383-S384. doi: 10.1016/S2152-2650(22)01548-8. PMID: 36164097

Impact of a Multi-Level, Multi-Component, System Intervention on HPV Vaccination in a Federally Qualified Health Center.
Glenn BA, Nonzee NJ, Herrmann AK, Crespi CM, Haroutunian GG, Sundin P, Chang LC, Singhal R, Taylor VM, Bastani R. Cancer Epidemiol Biomarkers Prev. 2022 Oct 4;31(10):1952-1958. doi: 10.1158/1055-9965.EPI-22-0156. PMID: 35914738

Serological responses to Anthrax **Vaccine** Precipitated (AVP) increase with time interval between booster doses.
Dyson EH, Simpson AJH, Gwyther RJ, Cuthbertson H, Patient DH, Matheson M, Gregg A, Hepburn MJ, Hallis B, Williamson ED. Vaccine. 2022 Oct 6;40(42):6163-6178. doi: 10.1016/j.vaccine.2022.08.052. Epub 2022 Sep 22. PMID: 36153153

CT-157 Another Rare Case of COVID-19 **Vaccine** Induced Acquired Hemophilia.
Ismail AM. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S435. doi: 10.1016/S2152-2650(22)01649-4. PMID: 36164200

COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: **Vaccine** safety in idiopathic inflammatory myopathies.
Gil-Vila A, Ravichandran N, Selva-O'Callaghan A, Sen P, Nune A, Gaur PS, Gonzalez RA, Lilleker JB, Joshi M, Agarwal V, Kardes S, Kim M, Day J, Makol A, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, Nikiphorou E, Tan AL, Chatterjee T, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Kuwana M, Distler O, Chinoy H, Agarwal V, Aggarwal R, Gupta L; and the COVAD Study Group. Muscle Nerve. 2022 Oct;66(4):426-437. doi: 10.1002/mus.27681. Epub 2022 Aug 8. PMID: 35869701

COVID-19 vaccinations: An overview of the Italian national health system's online communication from a citizen perspective.
Pirrotta L, Guidotti E, Tramontani C, Bignardelli E, Venturi G, De Rosis S. Health Policy. 2022 Oct;126(10):970-979. doi: 10.1016/j.healthpol.2022.08.001. Epub 2022 Aug 4. PMID: 35987784

Predicting a Positive Antibody Response After 2 SARS-CoV-2 mRNA Vaccines in Transplant Recipients: A Machine Learning Approach With External Validation.
Alejo JL, Mitchell J, Chiang TP, Chang A, Abedon AT, Werbel WA, Boyarsky BJ, Zeiser LB, Avery RK, Tobian AAR, Levan ML, Warren DS, Massie AB, Moore LW, Guha A, Huang HJ, Knight RJ, Gaber AO, Ghobrial RM, Garonzik-Wang JM, Segev DL, Bae S. Transplantation. 2022 Oct 1;106(10):e452-e460. doi: 10.1097/TP.0000000000004259. Epub 2022 Jul 21. PMID: 35859275

Effectiveness and Durability of the BNT162b2 **Vaccine** against Omicron Sublineages in South Africa.
Collie S, Nayager J, Bamford L, Bekker LG, Zylstra M, Gray G. N Engl J Med. 2022 Oct 6;387(14):1332-1333. doi: 10.1056/NEJMc2210093. Epub 2022 Sep 14. PMID: 36103455

Immunogenicity of ChAdOx1-nCoV-19 **vaccine** in solid malignancy patients by treatment regimen versus healthy controls: A prospective, multicenter observational study.
Teeyapun N, Luangdilok S, Pakvisal N, Sainamthip P, Mingmalairak S, Poovorawan N, Sitthideatphaiboon P, Parinyanitikul N, Sriuranpong V, Namkanisorn T, Inthasuwan P, Angspatt P, Wongchanapat P, Bamrungnam A, Leeleakpai N, Uttha S, Jaichum S, Kongkaew P, Suksanong C, Veranitinun R, Prasomphol A, Sartsuk C, Patcharajutanon C, Preaprang S, Choengsamor H, Phongwan R, Preeyasaksa C, Phaibulvatanapong E, Suntronwong N, Yorsaeng R, Vichaiwattana P, Wanlapakorn N, Kerr SJ, Poovorawan Y, Wanchaijiraboon P, Tanasanvimon S. EClinicalMedicine. 2022 Oct;52:101608. doi: 10.1016/j.eclinm.2022.101608. Epub 2022 Aug 11. PMID: 35971500

A pigeon paramyxovirus type 1 isolated from racing pigeon as an inactivated **vaccine** candidate provides effective protection.
Zhang Y, Wang W, Li Y, Liu J, Wang W, Bai J, Yang Z, Liu H, Xiao S. Poult Sci. 2022 Oct;101(10):102097. doi: 10.1016/j.psj.2022.102097. Epub 2022 Aug 1. PMID: 36055029

Post COVID-19 vaccination: AusVaxSafety survey participation and adverse events - a community-based regional Queensland study.
Hamilton E, Oversby S, Kitchener S, Ratsch A. Aust N Z J Public Health. 2022 Oct 3. doi: 10.1111/1753-6405.13300. Online ahead of print. PMID: 36190203

Scarier than the flu shot? : The social determinants of shingles and influenza vaccinations among U.S. older adults.
Vogelsang EM, Polonijo AN. Vaccine. 2022 Oct 8:S0264-410X(22)01183-5. doi: 10.1016/j.vaccine.2022.09.061. Online ahead of print. PMID: 36220715

Parents' attitude towards pneumococcal **vaccine**: an online survey from Jordan.
Al-Iede M, Khanfar AN, Alshrouf MA, Azzam MI, Haddad TA, Khanfar ON, Al-Tarawneh ZM, Aleidi SM. J Int Med Res. 2022 Oct;50(10):3000605221128151. doi: 10.1177/03000605221128151. PMID: 36200323

Factors associated with intention to receive vaccines for bacterial sexually transmitted infections among young HPV-vaccinated Canadian women.
de Waal A, Racey CS, Donken R, Plotnikoff K, Dobson S, Smith L, Grennan T, Sadarangani M, Ogilvie G. Can J Public Health. 2022 Oct;113(5):776-785. doi: 10.17269/s41997-022-00648-2. Epub 2022 May 26. PMID: 35616872

A Prospective Observational Study on BBV152 Coronavirus **Vaccine** Use in Adolescents and Comparison with Adults: Interim Results of the First Real-World Safety Analysis.
Kaur U, K L A, Chauhan M, Joshi A, Das A, Kansal S, Jaisawal V, Patwardhan K, Chakrabarti SS. Drug Saf. 2022 Oct;45(10):1099-1109. doi: 10.1007/s40264-022-01226-8. Epub 2022 Aug 27. PMID: 36030299

A study on seroconversion following first & second doses of ChAdOx1 nCoV-19 **vaccine** in Central Kerala.
Varghese SM, Mateethra GC, George G, Chandran VS, John GM, Varghese LT, Mammen NK, Vinayak V. Indian J Med Res. 2022 Oct 3. doi: 10.4103/ijmr.ijmr_1917_21. Online ahead of print. PMID: 36204929

Reactivation of minimal change disease after Pfizer **vaccine** against COVID-19.
Marampudi S, Beshai R, Banker G. J Osteopath Med. 2022 Jun 15;122(10):499-501. doi: 10.1515/jom-2022-0064. eCollection 2022 Oct 1. PMID: 35700437

Neutralizing antibodies and cellular immune response after two doses of inactivated SARS-CoV-2 **vaccine** in China.
Yan LN, Zhao ZX, Wang ZD, Xiao X, Liu PP, Zhang WK, Gu XL, Li B, Yu LP, Yu XJ. Expert Rev Vaccines. 2022 Oct;21(10):1465-1473. doi: 10.1080/14760584.2022.2104714. Epub 2022 Jul 29. PMID: 35861138

Chitosan-polymer based nanovaccine as promising immersion **vaccine** against Aeromonas veronii challenge in red tilapia (Oreochromis sp.).
Sukkarun P, Kitiyodom S, Yostawornkul J, Chaiin P, Yata T, Rodkhum C, Boonrungsiman S, Pirarat N. Fish Shellfish Immunol. 2022 Oct;129:30-35. doi: 10.1016/j.fsi.2022.08.035. Epub 2022 Aug 18. PMID: 35988712

Stress-induced immunosuppression affecting avian influenza virus **vaccine** immune response through miR-20a-5p/NR4A3 pathway in chicken.
Tian Y, Wang Q, Han J, Wen J, Wu Y, Man C. Vet Microbiol. 2022 Oct;273:109546. doi: 10.1016/j.vetmic.2022.109546. Epub 2022 Aug 17. PMID: 35994844

Prevaccine Human Papillomavirus Status in Invasive and Intraepithelial Lesions of the Vulva in New Zealand Women.
Bigby SM, Eva LJ, Tous S, de Sanjosé S, Bosch X, Alemany L, Chang KCT, Jones RW. J Low Genit Tract Dis. 2022 Oct 1;26(4):323-327. doi: 10.1097/LGT.0000000000000687. Epub 2022 Aug 5. PMID: 35930419

Accelerated DNA **vaccine** regimen provides protection against Crimean-Congo hemorrhagic fever virus challenge in a macaque infection model.
Hawman DW, Meade-White K, Shanna Leventhal, Appelberg S, Ahlén G, Nikouyan N, Clancy C, Smith B, Hanley P, Lovaglio J, Mirazimi A, Sällberg M, Feldmann H. Mol Ther. 2022 Oct 1:S1525-0016(22)00605-0. doi: 10.1016/j.ymthe.2022.09.016. Online ahead of print. PMID: 36184852

Comparative full genome sequence analysis of wild-type and chicken embryo origin **vaccine**-like infectious laryngotracheitis virus field isolates from Canada.
Elshafiee EA, Hassan MSH, Provost C, Gagnon CA, Ojkic D, Abdul-Careem MF. Infect Genet Evol. 2022 Oct;104:105350. doi: 10.1016/j.meegid.2022.105350. Epub 2022 Aug 14. PMID: 35977653

Vaccine nationalism among the public: A cross-country experimental evidence of own-country bias towards COVID-19 vaccination.

Barceló J, Sheen GC, Tung HH, Wu WC. Soc Sci Med. 2022 Oct;310:115278. doi: 10.1016/j.socscimed.2022.115278. Epub 2022 Aug 15. PMID: 35994879

A randomised phase II trial of a trivalent ganglioside **vaccine** targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery.
Rosenbaum E, Chugh R, Ryan CW, Agulnik M, Milhem MM, George S, Jones RL, Chmielowski B, Van Tine BA, Tawbi H, Elias AD, Read WL, Budd GT, Qin LX, Rodler ET, Hirman J, Weiden P, Bennett CM, Livingston PO, Ragupathi G, Hansen D, D'Angelo SP, Tap WD, Schwartz GK, Maki RG, Carvajal RD. Eur J Cancer. 2022 Oct 7;176:155-163. doi: 10.1016/j.ejca.2022.09.003. Online ahead of print. PMID: 36215947

Single-dose HPV **vaccine** immunity: is there a role for non-neutralizing antibodies?
Quang C, Chung AW, Frazer IH, Toh ZQ, Licciardi PV. Trends Immunol. 2022 Oct;43(10):815-825. doi: 10.1016/j.it.2022.07.011. Epub 2022 Aug 20. PMID: 35995705 Review.

Effectiveness of Second mRNA COVID-19 Booster **Vaccine** in Immunocompromised Persons and Long-Term Care Facility Residents.
Kim YY, Choe YJ, Kim J, Kim RK, Jang EJ, Park SK, Lim DS, Yi S, Lee S, Kwon GY, Shin JY, Choi SY, Jeong MJ, Park YJ. Emerg Infect Dis. 2022 Oct 3;28(11). doi: 10.3201/eid2811.220918. Online ahead of print. PMID: 36191615

Expanding COVID-19 **vaccine** access to underserved populations through implementation of mobile vaccination units.
Gupta PS, Mohareb AM, Valdes C, Price C, Jollife M, Regis C, Munshi N, Taborda E, Lautenschlager M, Fox A, Hanscom D, Kruse G, LaRocque R, Betancourt J, Taveras EM. Prev Med. 2022 Oct;163:107226. doi: 10.1016/j.ypmed.2022.107226. Epub 2022 Aug 25. PMID: 36029925

A systematic review of live **vaccine** outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero.
Goulden B, Chua N, Parker E, Giles I. Rheumatology (Oxford). 2022 Oct 6;61(10):3902-3906. doi: 10.1093/rheumatology/keac141. PMID: 35258557

BNT162b2 Covid-19 **vaccine** does not affect fertility as explored in a pilot study of women undergoing IVF treatment.
Safrai M, Kremer E, Atias E, Ben-Meir A. Minerva Obstet Gynecol. 2022 Oct 4. doi: 10.23736/S2724-606X.22.05148-X. Online ahead of print. PMID: 36193832

CMR Imaging 6 Months After Myocarditis Associated with the BNT162b2 mRNA COVID-19 **Vaccine**.
Amir G, Rotstein A, Razon Y, Beyersdorf GB, Barak-Corren Y, Godfrey ME, Lakovsky Y, Yaeger-Yarom G, Yarden-Bilavsky H, Birk E. Pediatr Cardiol. 2022 Oct;43(7):1522-1529. doi: 10.1007/s00246-022-02878-0. Epub 2022 Mar 23. PMID: 35320390

Immunoinformatics analysis to design novel epitope based **vaccine** candidate targeting the glycoprotein and nucleoprotein of Lassa mammarenavirus (LASMV) using strains from Nigeria.

Abass OA, Timofeev VI, Sarkar B, Onobun DO, Ogunsola SO, Aiyenuro AE, Aborode AT, Aigboje AE, Omobolanle BN, Imolele AG, Abiodun AA. J Biomol Struct Dyn. 2022 Oct;40(16):7283-7302. doi: 10.1080/07391102.2021.1896387. Epub 2021 Mar 15. PMID: 33719908

Segmentation of intentions towards COVID-19 **vaccine** acceptance through political and health behaviour explanatory models.
Rountree C, Prentice G. Ir J Med Sci. 2022 Oct;191(5):2369-2383. doi: 10.1007/s11845-021-02852-4. Epub 2021 Nov 26. PMID: 34826039

Vaccine-Induced Myocarditis in Two Intern Doctors in the Same Night Shift.
Canakci ME, Sevik OE, Dereli G, Mert KU, Acar N. Prehosp Disaster Med. 2022 Oct;37(5):698-700. doi: 10.1017/S1049023X22001078. Epub 2022 Jul 19. PMID: 35851434

Strengthened belief in **vaccine** effectiveness predicted increased COVID-19 vaccination intention and behaviour: Results from a nationally representative longitudinal survey of U.S. adults from July 2020 to April/May 2021.
Kikut A, Clark D, Jesch E, Hornik R. Vaccine. 2022 Oct 6;40(42):6035-6041. doi: 10.1016/j.vaccine.2022.08.046. Epub 2022 Aug 26. PMID: 36088194

A bacterially expressed triple-type chimeric **vaccine** against human papillomavirus types 51, 69, and 26.
Yu M, Chi X, Huang S, Wang Z, Chen J, Qian C, Han F, Cao L, Li J, Sun H, Zhou L, Li T, Wang Y, Zheng Q, Yu H, Zhang J, Xia N, Li S, Gu Y. Vaccine. 2022 Oct 6;40(42):6141-6152. doi: 10.1016/j.vaccine.2022.09.010. Epub 2022 Sep 16. PMID: 36117002

Subcutaneous panniculitis-like T-cell lymphoma after COVID-19 vaccination.
Kreher MA, Ahn J, Werbel T, Motaparthi K. JAAD Case Rep. 2022 Oct;28:18-20. doi: 10.1016/j.jdcr.2022.08.006. Epub 2022 Aug 10. PMID: 35966352

Effect of an Escherichia coli F4/F18 bivalent oral live **vaccine** on gut health and performance of healthy weaned pigs.
Correa F, Luise D, Amatucci L, Palumbo F, Virdis S, Negrini C, Clavenzani P, Vecchi M, Mazzoni M, Bosi P, Trevisi P. Animal. 2022 Oct 7;16(11):100654. doi: 10.1016/j.animal.2022.100654. Online ahead of print. PMID: 36215797

Subacute thyroiditis after SARS-CoV2 **vaccine**: possible relapse after boosting.
Teti C, Nazzari E, Graziani G, Bagnasco M. J Endocrinol Invest. 2022 Oct;45(10):2019-2020. doi: 10.1007/s40618-022-01856-w. Epub 2022 Jul 5. PMID: 35790684

Pruritic annular erythematous eruption after receiving the COVID-19 **vaccine**.
Cross DE, Garritano J, Zubek AE, Little AJ. Int J Womens Dermatol. 2022 Jul 12;8(3):e033. doi: 10.1097/JW9.0000000000000033. eCollection 2022 Oct. PMID: 35837337

Collective Value Promotes the Willingness to Share Provaccination Messages on Social Media in China: Randomized Controlled Trial.
Fu C, Lyu X, Mi M. JMIR Form Res. 2022 Oct 4;6(10):e35744. doi: 10.2196/35744. PMID: 36067417

Influenza Vaccination Receipt in Pediatric Patients With Cancer or Sickle Cell Disease.
Yarnall JN, Mertens A, Yee M, Orenstein E, Lai KW, Wasilewski-Masker K. J Pediatr Hematol Oncol. 2022 Oct 3. doi: 10.1097/MPH.0000000000002559. Online ahead of print. PMID: 36219461

Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial.
Cotton MF, Madhi SA, Luabeya AK, Tameris M, Hesseling AC, Shenje J, Schoeman E, Hatherill M, Desai S, Kapse D, Brückner S, Koen A, Jose L, Moultrie A, Bhikha S, Walzl G, Gutschmidt A, Kotze LA, Allies DL, Loxton AG, Shaligram U, Abraham M, Johnstone H, Grode L, Kaufmann SHE, Kulkarni PS. Lancet Infect Dis. 2022 Oct;22(10):1472-1483. doi: 10.1016/S1473-3099(22)00222-5. Epub 2022 Jun 27. PMID: 35772447

Artificial intelligence-assisted colorimetric lateral flow immunoassay for sensitive and quantitative detection of COVID-19 neutralizing antibody.
Tong H, Cao C, You M, Han S, Liu Z, Xiao Y, He W, Liu C, Peng P, Xue Z, Gong Y, Yao C, Xu F. Biosens Bioelectron. 2022 Oct 1;213:114449. doi: 10.1016/j.bios.2022.114449. Epub 2022 Jun 8. PMID: 35696869

A qualitative study of factors influencing COVID-19 **vaccine** hesitancy among South Asians in London.
Chandok RS, Madar P, Majeed A. JRSM Open. 2022 Oct 4;13(10):20542704221123430. doi: 10.1177/20542704221123430. eCollection 2022 Oct. PMID: 36213844

The Percentage of Hesitation and Factors Associated with Acceptance or Refusal for COVID-19 Vaccination: Does Education About Vaccines by Allergist Affect Personal Decision?
Sayaca N, Cansiz KA, Yildirim E, Öztürk B, Kirmaz C. Rev Fr Allergol (2009). 2022 Oct 3. doi: 10.1016/j.reval.2022.09.004. Online ahead of print. PMID: 36213873

Longitudinal neutralization activities on authentic Omicron variant provided by 3 doses of BBIBP-CorV vaccination during one year.
Lai DY, Xue JB, He P, Jiang HW, Li Y, Ma ML, Hong W, Yu JP, Wei HP, Tao SC. Proteomics. 2022 Oct 7:e2200306. doi: 10.1002/pmic.202200306. Online ahead of print. PMID: 36205637

Covid19 vaccination-associated portal vein thrombosis-An interdisciplinary clinical challenge.
Bogovic N, Doenecke A, Hart C, Lürken L, Heimerl S, Eissnert C, Schlitt HJ, Bitterer F. Clin Res Hepatol Gastroenterol. 2022 Oct;46(8):101932. doi: 10.1016/j.clinre.2022.101932. Epub 2022 Apr 30. PMID: 35504460

Immunogenicity and safety of one-dose human papillomavirus **vaccine** compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial.
Watson-Jones D, Changalucha J, Whitworth H, Pinto L, Mutani P, Indangasi J, Kemp T, Hashim R, Kamala B, Wiggins R, Songoro T, Connor N, Mbwanji G, Pavon MA, Lowe B, Mmbando D, Kapiga S, Mayaud P, de SanJosé S, Dillner J, Hayes RJ, Lacey CJ, Baisley K. Lancet Glob Health. 2022 Oct;10(10):e1473-e1484. doi: 10.1016/S2214-109X(22)00309-6. PMID: 36113531

Comment on: "SARS CoV-2 **vaccine** AND rituximab, timing is probably a key for a better **vaccine** response" by Verhoeven et al. Joint Bone Spine 2021;88:105258.
De Marchi G, Fabris M, Domenis R, Curcio F, De Vita S, Quartuccio L. Joint Bone Spine. 2022 Oct;89(5):105408. doi: 10.1016/j.jbspin.2022.105408. Epub 2022 May 13. PMID: 35577050

Humoral response after SARS-CoV-2 mRNA vaccination in patients with prostate cancer using steroids.
Ishii N, Hatakeyama S, Yoneyama T, Tanaka R, Narita T, Fujita N, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C. Urol Oncol. 2022 Oct;40(10):451.e1-451.e8. doi: 10.1016/j.urolonc.2022.07.015. Epub 2022 Aug 1. PMID: 36008254

Cellular and Humoral Response to the Fourth BNT162b2 mRNA COVID-19 **Vaccine** Dose in Patients with CLL.
Benjamini O, Gershon R, Haim EB, Lustig Y, Cohen H, Doolman R, Kedmi M, Ribakovsky E, Kneller A, Hod T, Erez N, Levy I, Rahav G, Avigdor A. Eur J Haematol. 2022 Oct 7. doi: 10.1111/ejh.13878. Online ahead of print. PMID: 36208015

Determination of the efficacy of using a serine protease gene as a DNA **vaccine** to protect against Vibrio parahaemolyticus infection in Litopenaeus vannamei.
Madsari N, Maskaew S, Obchoei S, Kwankaew P, Senghoi W, Utarabhand P, Runsaeng P. Dev Comp Immunol. 2022 Oct;135:104459. doi: 10.1016/j.dci.2022.104459. Epub 2022 Jun 1. PMID: 35660488

Effect of Outreach Messages on Adolescent Well Child Visits and COVID-19 **Vaccine** Rates: An RCT.
Burkhardt MC, Berset AE, Xu Y, Mescher A, Brinkman WB. J Pediatr. 2022 Oct 3:S0022-3476(22)00857-5. doi: 10.1016/j.jpeds.2022.09.035. Online ahead of print. PMID: 36202236

Clinical study on the efficacy of hepatitis B vaccination in hepatitis C virus related chronic liver diseases in Egypt.
Hassnine AA, Saber MA, Fouad YM, Sarhan H, Elsayed MM, Zaki ZM, Abdelraheem EM, Abdelhalim SM, Elsayed AM. Virus Res. 2022 Oct 6:198953. doi: 10.1016/j.virusres.2022.198953. Online ahead of print. PMID: 36209916

DNA **vaccine** dual-expressing viral hemorrhagic septicemia virus glycoprotein and C-C motif chemokine ligand 19 induces the expression of immune-related genes in zebrafish (Danio rerio).
Kim JY, Kim HJ, Park JS, Kwon SR. J Microbiol. 2022 Oct;60(10):1032-1038. doi: 10.1007/s12275-022-2231-8. Epub 2022 Aug 1. PMID: 35913595

Exploring Cultural Factors of Human Papillomavirus Vaccination Acceptance in African Americans: An Integrative Review.
Henderson RL, Zoucha R, Colbert A, Braxter BJ. J Transcult Nurs. 2022 Oct 5:10436596221125899. doi: 10.1177/10436596221125899. Online ahead of print. PMID: 36197072

Counselling of non-communicable diseases' patients for COVID-19 **vaccine** uptake in Jordan: Evaluating the intervention.
Al-Shaikh A, Mahmoud RI, Boukerdenna H, Muthu N, Aidyralieva C, Bellizzi S. Vaccine. 2022 Oct 3:S0264-410X(22)01214-2. doi: 10.1016/j.vaccine.2022.09.083. Online ahead of print. PMID: 36216648

Safety and Efficacy of the NVX-CoV2373 COVID-19 **Vaccine** at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial.
Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, Chadwick DR, Clark R, Cosgrove CA, Galloway J, Goodman AL, Heer A, Higham A, Iyengar S, Jeanes C, Kalra PA, Kyriakidou C, Bradley JM, Munthali C, Minassian AM, McGill F, Moore P, Munsoor I, Nicholls H, Osanlou O, Packham J, Pretswell CH, Francisco Ramos AS, Saralaya D, Sheridan RP, Smith R, Soiza RL, Swift PA, Thomson EC, Turner J,

Viljoen ME, Fries L, Cho I, McKnight I, Glenn G, Rivers EJ, Robertson A, Alves K, Smith K, Toback S. Clin Infect Dis. 2022 Oct 10:ciac803. doi: 10.1093/cid/ciac803. Online ahead of print. PMID: 36210481

Construction of Streptococcus agalactiae sialic acid mutant and evaluation of its potential as a live attenuated **vaccine** in Nile tilapia (Oreochromis niloticus).
Hao J, Wang S, Wei Z, Zhang Q, Wu Z, Lin Y, Yang J, Zhang J, Zhang D, Li A. J Appl Microbiol. 2022 Oct;133(4):2403-2416. doi: 10.1111/jam.15706. Epub 2022 Jul 27. PMID: 35801502

School Health Service Provider Perceptions on Facilitated Interactive Role-Play Around HPV **Vaccine** Recommendation.
Rosen BL, Real FJ, Bishop JM, McDonald SL, Klein M, Kahn JA, Kreps GL. J Cancer Educ. 2022 Oct;37(5):1286-1295. doi: 10.1007/s13187-020-01949-1. Epub 2021 Jan 2. PMID: 33387266

Retrospective review COVID-19 **vaccine** induced thrombotic thrombocytopenia and cerebral venous thrombosis-what can we learn from the immune response.
Franceschi AM, Petrover DR, McMahon TM, Libman RB, Giliberto L, Clouston SAP, Castillo M, Kirsch C. Clin Imaging. 2022 Oct;90:63-70. doi: 10.1016/j.clinimag.2022.06.020. Epub 2022 Jul 15. PMID: 35926315

Heterologous COVID-19 vaccination as a strategy to accelerate mass immunization.
Klastrup V, Stærke NB, Søgaard OS. Clin Microbiol Infect. 2022 Oct;28(10):1316-1318. doi: 10.1016/j.cmi.2022.06.032. Epub 2022 Jul 16. PMID: 35843563

Comment on "Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit **Vaccine**, and Live-Attenuated **Vaccine**".
Giannelos N, Nishimwe ML, Lecrenier N. Pharmacoeconomics. 2022 Oct;40(10):1011-1012. doi: 10.1007/s40273-022-01184-0. Epub 2022 Sep 26. PMID: 36163540

Authors' Reply to Comment on "Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison Between No Vaccination, the Adjuvanted Subunit **Vaccine**, and Live-Attenuated **Vaccine**".
Bilcke J, Beutels P. Pharmacoeconomics. 2022 Oct;40(10):1013-1014. doi: 10.1007/s40273-022-01186-y. Epub 2022 Sep 26. PMID: 36163539

Sex-differential non-specific effects of adjuvanted and non-adjuvanted rabies vaccines versus placebo on all-cause mortality in dogs (NERVE-Dog study): a study protocol for a randomized controlled trial with a nested case-control study.
Knobel DL, Conan A, Toka FN, Arega SM, Byaruhanga C, Ogola E, Muok EMO, Crafford JE, Leisewitz AL, Quan M, Thrall MA. BMC Vet Res. 2022 Oct 1;18(1):363. doi: 10.1186/s12917-022-03455-6. PMID: 36183113

CLL-211 Humoral Immune Response Following COVID-19 Vaccination in Patients With Chronic Lymphocytic Leukemia (CLL) and Indolent Non-Hodgkin Lymphoma (NHL): Results From a Large, Single-Center Observational Study.
St-Pierre F, Doukas P, Boyer J, Nieves M, Ma S. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S273. doi: 10.1016/S2152-2650(22)01335-0. PMID: 36163881

Randomized clinical trial of BCG **vaccine** in patients with convalescent COVID-19: Clinical evolution, adverse events, and humoral immune response.
Jalalizadeh M, Buosi K, Dionato FAV, Dal Col LSB, Giacomelli CF, Ferrari KL, Pagliarone AC, Leme PAF, Maia CL, Yadollahvandmiandoab R, Trinh QD, Franchini KG, Bajgelman MC, Reis LO. J Intern Med. 2022 Oct;292(4):654-666. doi: 10.1111/joim.13523. Epub 2022 Jun 3. PMID: 35599154

Production of a viral surface protein in Nannochloropsis oceanica for fish vaccination against infectious pancreatic necrosis virus.
Rout SS, de Grahl I, Yu X, Reumann S. Appl Microbiol Biotechnol. 2022 Oct;106(19-20):6535-6549. doi: 10.1007/s00253-022-12106-7. Epub 2022 Sep 7. PMID: 36069927

Histopathologically TMA-like distribution of multiple organ thromboses following the initial dose of the BNT162b2 mRNA **vaccine** (Comirnaty, Pfizer/BioNTech): an autopsy case report.
Kaimori R, Nishida H, Uchida T, Tamura M, Kuroki K, Murata K, Hatakeyama K, Ikeda Y, Amemiya K, Nishizono A, Daa T, Mori S. Thromb J. 2022 Oct 6;20(1):61. doi: 10.1186/s12959-022-00418-7. PMID: 36203145

Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease.
Bhagat S, Yadav N, Shah J, Dave H, Swaraj S, Tripathi S, Singh S. Expert Rev Anti Infect Ther. 2022 Oct;20(10):1275-1298. doi: 10.1080/14787210.2021.1835469. Epub 2020 Dec 7. PMID: 33043740

The growing threat of wild poliovirus 1 and **vaccine**-derived cases in the COVID-19 era.
Franco-Paredes C, Rodriguez-Morales AJ, Henao-Martínez AF, Carrasco P, Tuells J. Lancet Infect Dis. 2022 Oct;22(10):1412-1414. doi: 10.1016/S1473-3099(22)00548-5. Epub 2022 Aug 16. PMID: 35985345

Acute kidney injury after Pfizer COVID-19 **vaccine** due to crescentic fibrillary glomerulonephritis.
Al-Sawalmeh K, Pandes M, Niño JA, Avila-Casado C. Clin Nephrol. 2022 Oct;98(4):205-208. doi: 10.5414/CN110855. PMID: 35900077

Hepatitis E virus (HEV) open reading frame 2: Role in pathogenesis and diagnosis in HEV infections.
Sayed IM, Karam-Allah Ramadan H, Hafez MHR, Elkhawaga AA, El-Mokhtar MA. Rev Med Virol. 2022 Oct 9:e2401. doi: 10.1002/rmv.2401. Online ahead of print. PMID: 36209386

A rare case of cortical blindness following vaccination against SARS-CoV-2.
Mahajan A, Phuljhele S. Indian J Ophthalmol. 2022 Oct;70(10):3721-3723. doi: 10.4103/ijo.IJO_1619_22. PMID: 36190083

Prevalence of rheumatoid arthritis following COVID-19 **vaccine**: An autoimmune disorder.
Rai A, Aashish, Priya, Karmani S, Abbas W, Khatri G. Ann Med Surg (Lond). 2022 Oct;82:104628. doi: 10.1016/j.amsu.2022.104628. Epub 2022 Sep 9. PMID: 36101843

Very low risk of monkeypox among staff and students after exposure to a confirmed case in educational settings, England, May to July 2022.
Ladhani SN, Aiano F, Edwards DS, Perkins S, Khan WM, Iyanger N, Whittaker E, Cohen JM, Ho D, Hopkins S, Ramsay ME, Chow JY. Euro Surveill. 2022 Oct;27(40). doi: 10.2807/1560-7917.ES.2022.27.40.2200734. PMID: 36205169

Regeneration of Capto Core 700 resin through high throughput and laboratory scale studies and impact on production of a SARS-CoV-2 **vaccine** candidate.
Konstantinidis S, Reinhart SR, Castagna C, Poplyk MR, Rustandi RR, Flor KL, Acevedo-Skrip J, Thompson R, Wang CJ, Wang SC, Winters MA. Biotechnol J. 2022 Oct;17(10):e2200191. doi: 10.1002/biot.202200191. Epub 2022 Jul 28. PMID: 35771570

Full seroconversion in initial non-responders with higher antibody levels after heterologous COVID-19 vaccination schedule.
Wagner A, Ohradanova-Repic A, Gebetsberger L, Tajti G, Kundi M, Stockinger H, Wiedermann U, Grabmeier-Pfistershammer K. Immunol Lett. 2022 Oct;250:1-6. doi: 10.1016/j.imlet.2022.09.001. Epub 2022 Sep 13. PMID: 36108774

Retinal venous occlusion in a child following Corbevax COVID-19 vaccination.
Nangia P, Prakash VJ, Dutta Majumder P. Indian J Ophthalmol. 2022 Oct;70(10):3713-3715. doi: 10.4103/ijo.IJO_1927_22. PMID: 36190080

Multisite Integrated Health System Utilizes Proactive Community Strategies to Address **Vaccine** Hesitancy and Create Positive Change.
Stamps DC, Caldwell ED. Nurse Lead. 2022 Oct;20(5):509-516. doi: 10.1016/j.mnl.2022.01.010. Epub 2022 Apr 28. PMID: 35502181

Omicron-specific mRNA **vaccine** elicits potent immune responses in mice, hamsters, and nonhuman primates.
Wu Y, Shen Y, Wu N, Zhang X, Chen S, Yang C, Zhou J, Wu Y, Chen D, Wang L, Wang C, Zhang H, Xia N, Chiu S, Wang Y. Cell Res. 2022 Oct;32(10):949-952. doi: 10.1038/s41422-022-00706-x. Epub 2022 Aug 1. PMID: 35915244

Immunity to a third BNT162B2 COVID-19 **vaccine** after heart transplantation: Bridging the knowledge gap to end the pandemic for organ transplant recipients.
Haidar G. J Heart Lung Transplant. 2022 Oct;41(10):1426-1428. doi: 10.1016/j.healun.2022.07.004. Epub 2022 Jul 11. PMID: 35933295

Thrombocytopenia and pneumonitis associated with BNT16B2b2 mRNA COVID-19 **vaccine**: A case report.
Kojima Y, Takeyabu K, Satoh M, Konno S. Clin Infect Pract. 2022 Nov;16:100204. doi: 10.1016/j.clinpr.2022.100204. Epub 2022 Oct 5. PMID: 36212609

mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based **vaccine** formulations.
Carreño JM, Singh G, Tcheou J, Srivastava K, Gleason C, Muramatsu H, Desai P, Aberg JA, Miller RL, Study Group P, Pardi N, Simon V, Krammer F. Vaccine. 2022 Oct 6;40(42):6114-6124. doi: 10.1016/j.vaccine.2022.08.024. Epub 2022 Sep 15. PMID: 36115801

Constrictive pericarditis following inactivated virus COVID-19 **vaccine**: a case report with review of the literature.

Hajsadeghi S, Gholizadeh Mesgarha M, Saberi Shahrbabaki E, Pishgahi M, Ebadi Fard Azar A, Pour Mohammad A. Radiol Case Rep. 2022 Aug 5;17(10):3774-3778. doi: 10.1016/j.radcr.2022.07.021. eCollection 2022 Oct. PMID: 35950151

Answer to De Marchi et al. Joint Bone Spine 2022;89:105408.
Verhoeven F, Lepiller Q, Hecquet S, Prati C, Wendling D. Joint Bone Spine. 2022 Oct;89(5):105412. doi: 10.1016/j.jbspin.2022.105412. Epub 2022 May 20. PMID: 35605879

Attitudes of mothers of pre-adolescent girls on HPV **vaccine** in Italy. Do we need a turning point?
Calagna G, Granese R, Giallombardo V, Capra G, Perino A, Schiattarella A, Trucchi C, Caridi G. Minerva Obstet Gynecol. 2022 Oct 4. doi: 10.23736/S2724-606X.22.05153-3. Online ahead of print. PMID: 36193834

A bivalent SARS-CoV-2 monoclonal antibody combination does not affect the immunogenicity of a vector-based COVID-19 **vaccine** in macaques.
Nkolola JP, Yu J, Wan H, Chang A, McMahan K, Anioke T, Jacob-Dolan C, Powers O, Ye T, Chandrashekar A, Sellers D, Barrett J, Loo YM, Esser MT, Carnahan RH, Crowe JE Jr, Barouch DH. Sci Transl Med. 2022 Oct 5;14(665):eabo6160. doi: 10.1126/scitranslmed.abo6160. Epub 2022 Oct 5. PMID: 35857623

A broadly protective **vaccine** against cutaneous human papillomaviruses.
Mariz FC, Balz K, Dittrich M, Zhang Y, Yang F, Zhao X, Bolchi A, Ottonello S, Müller M. NPJ Vaccines. 2022 Oct 10;7(1):116. doi: 10.1038/s41541-022-00539-0. PMID: 36216845

Adverse events following immunization of elderly with COVID-19 inactivated virus **vaccine** (CoronaVac) in Southeastern Brazil: an active surveillance study.
Miyaji KT, Itto LYU, Jacintho LC, Sales ACR, Hiratsuka M, Leonel FC, Higa-Taniguchi KT, Picone CM, Lara AN, Rodrigues CCM, Lopes MH, Sartori AMC. Rev Inst Med Trop Sao Paulo. 2022 Oct 3;64:e56. doi: 10.1590/S1678-9946202264056. eCollection 2022. PMID: 36197371

Quality of life and sexual function analysis in a group of Italian postmenopausal women after COVID-19 vaccination.
Yacoub V, Carletti V, Grilli D, Morgani C, Palazzetti P, Zullo MA, Luffarelli P, Valensise HCC, Schiavi MC. Gynecol Endocrinol. 2022 Oct 6:1-4. doi: 10.1080/09513590.2022.2132224. Online ahead of print. PMID: 36203336

Factors Associated With COVID-19 **Vaccine** Response in Transplant Recipients: A Systematic Review and Meta-analysis.
Li J, Ayada I, Wang Y, den Hoed CM, Kamar N, Peppelenbosch MP, de Vries AC, Li P, Pan Q. Transplantation. 2022 Oct 1;106(10):2068-2075. doi: 10.1097/TP.0000000000004256. Epub 2022 Jun 28. PMID: 35761439

Optimization of an adenovirus-vectored zoster **vaccine** production process with chemically defined medium and a perfusion system.
Nie J, Sun Y, Ren H, Huang L, Feng K, Li Y, Bai Z. Biotechnol Lett. 2022 Oct 1:1-12. doi: 10.1007/s10529-022-03302-6. Online ahead of print. PMID: 36183022

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola **vaccine** (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials.
Simon JK, Kennedy SB, Mahon BE, Dubey SA, Grant-Klein RJ, Liu K, Hartzel J, Coller BG, Welebob C, Hanson ME, Grais RF. Vaccine. 2022 Oct 5:S0264-410X(22)01145-8. doi: 10.1016/j.vaccine.2022.09.037. Online ahead of print. PMID: 36208978

Lethal Toxic Epidermal Necrolysis probably induced by Sinopharm COVID-19 **vaccine**.
Seck B, Dieye A, Diallo M. Rev Fr Allergol (2009). 2022 Oct;62(6):590-592. doi: 10.1016/j.reval.2022.07.001. Epub 2022 Jul 13. PMID: 35855853

Typhoid **vaccine** does not impact feelings of social connection or social behavior in a randomized crossover trial among middle-aged female breast cancer survivors.
Madison AA, Way B, Ratner KG, Renna M, Andridge R, Peng J, Rosie Shrout M, Sheridan J, Lustberg M, Ramaswamy B, Wesolowski R, VanDeusen JB, Williams NO, Sardesai SD, Noonan AM, Reinbolt RE, Stover DG, Cherian MA, Malarkey WB, Kiecolt-Glaser JK. Brain Behav Immun. 2022 Oct 5;107:124-131. doi: 10.1016/j.bbi.2022.09.021. Online ahead of print. PMID: 36208853

COVID **vaccine** recommendations in dermatologic patients on immunosuppressive agents: Lessons learned from pandemic.
Aryanian Z, Balighi K, Afshar ZM, Zamanian MH, Razavi Z, Hatami P. J Cosmet Dermatol. 2022 Oct 10. doi: 10.1111/jocd.15448. Online ahead of print. PMID: 36214611

Guillain-Barrè syndrome following COVID-19 **vaccine** mRNA-1273: a case report.
Masuccio FG, Comi C, Solaro C. Acta Neurol Belg. 2022 Oct;122(5):1369-1371. doi: 10.1007/s13760-021-01838-4. Epub 2021 Nov 12. PMID: 34767184

Effectiveness of Booster and Influenza Vaccines against COVID-19 among Healthcare Workers, Taiwan.
Sim JY, Wu PS, Cheng CF, Chao YC, Yu CH. Emerg Infect Dis. 2022 Oct;28(10):2126-2130. doi: 10.3201/eid2810.221134. Epub 2022 Aug 29. PMID: 36037810

Efficacy of an accelerated vaccination schedule against hepatitis E virus infection in pregnant rabbits.
Zhang F, Yang Z, Dai C, He Q, Liang Z, Liu T, Huang W, Wang Y, Wang L, Wang L. J Med Virol. 2022 Oct 6. doi: 10.1002/jmv.28193. Online ahead of print. PMID: 36202778

The persistence of anti-Spike antibodies following two SARS-CoV-2 **vaccine** doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study.
Christensen IE, Jyssum I, Tveter AT, Sexton J, Tran TT, Mjaaland S, Kro GB, Kvien TK, Warren DJ, Jahnsen J, Munthe LA, Haavardsholm EA, Vaage JT, Grødeland G, Lund-Johansen F, Jørgensen KK, Syversen SW, Goll GL, Provan SA. BMC Med. 2022 Oct 5;20(1):378. doi: 10.1186/s12916-022-02587-8. PMID: 36199139

Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) **Vaccine** for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States.
Lewis NM, Self WH, Gaglani M, Ginde AA, Douin DJ, Keipp Talbot H, Casey JD, Mohr NM, Zepeski A, Ghamande SA, McNeal TA, Shapiro NI, Gibbs KW, Files DC, Hager DN, Shehu A, Prekker ME, Erickson HL, Gong MN, Mohamed A, Johnson NJ, Srinivasan V, Steingrub JS, Peltan ID, Brown SM, Martin ET, Monto AS, Khan A, Busse LW, Lohuis CCT, Duggal A, Wilson JG, Gordon AJ, Qadir N, Chang SY, Mallow

C, Rivas C, Babcock HM, Kwon JH, Exline MC, Lauring AS, Halasa N, Chappell JD, Grijalva CG, Rice TW, Rhoads JP, Jones ID, Stubblefield WB, Baughman A, Womack KN, Lindsell CJ, Hart KW, Zhu Y, Adams K, Patel MM, Tenforde MW; IVY Network Collaborators. Clin Infect Dis. 2022 Oct 3;75(Supplement_2):S159-S166. doi: 10.1093/cid/ciac439. PMID: 35675695

Heterologous booster with inhaled Adenovirus vector COVID-19 **vaccine** generated more neutralizing antibodies against different SARS-CoV-2 variants.
Zhong J, Liu S, Cui T, Li J, Zhu F, Zhong N, Huang W, Zhao Z, Wang Z. Emerg Microbes Infect. 2022 Oct 5:1-18. doi: 10.1080/22221751.2022.2132881. Online ahead of print. PMID: 36197655

Cross protective efficacy of the Non-Neurotropic live attenuated herpes simplex virus type 1 **vaccine** VC-2 is enhanced by intradermal vaccination and deletion of glycoprotein G.
Stanfield BA, Bravo FJ, Dixon DA, Chouljenko VN, Kousoulas KG, Bernstein DI. Vaccine. 2022 Oct 6;40(42):6093-6099. doi: 10.1016/j.vaccine.2022.09.015. Epub 2022 Sep 14. PMID: 36114130

Poor **vaccine** responsiveness towards third-dose mRNA **vaccine** of COVID-19 in Japanese older people.
Hagiya H, Hikita T, Habu T, Asada M, Yorifuji T, Toyooka S, Otsuka F, Nakayama M. J Infect. 2022 Oct;85(4):436-480. doi: 10.1016/j.jinf.2022.07.007. Epub 2022 Jul 11. PMID: 35835411

Effectiveness of a fourth dose of mRNA COVID-19 **vaccine** against all-cause mortality in long-term care facility residents and in the oldest old: A nationwide, retrospective cohort study in Sweden.
Nordström P, Ballin M, Nordström A. Lancet Reg Health Eur. 2022 Oct;21:100466. doi: 10.1016/j.lanepe.2022.100466. Epub 2022 Jul 13. PMID: 35855494

Exploring the ethical complexity of pediatric organ transplant candidates and COVID-19 vaccination: Tensions between autonomy and beneficence, children and parents.
Lara Carrion L, Bramstedt KA. Pediatr Transplant. 2022 Oct 9:e14408. doi: 10.1111/petr.14408. Online ahead of print. PMID: 36210480

Antigenic variability of Vibrio anguillarum serotype O2a: A hurdle for **vaccine** efficacy against vibriosis in Oncorhynchus mykiss.
Sepúlveda D, Hansen MJ, Dalsgaard I, Skov J, Lorenzen N. Fish Shellfish Immunol. 2022 Oct 3:S1050-4648(22)00638-6. doi: 10.1016/j.fsi.2022.09.072. Online ahead of print. PMID: 36202204

Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and **vaccine**.
Breccia M, Piciocchi A, Messina M, Soddu S, De Stefano V, Bellini M, Iurlo A, Martino B, Siragusa S, Albano F, Mora B, Fazi P, Vignetti M, Guglielmelli P, Palandri F. Leukemia. 2022 Oct;36(10):2548-2550. doi: 10.1038/s41375-022-01675-1. Epub 2022 Aug 13. PMID: 35963940

Effectiveness of COVID-19 Viral Vector Ad.26.COV2.S **Vaccine** and Comparison with mRNA Vaccines in Cirrhosis.
John BV, Sidney Barritt A 4th, Moon A, Taddei TH, Kaplan DE, Dahman B, Doshi A, Deng Y, Mansour N, Ioannou G, Martin P, Chao HH. Clin Gastroenterol Hepatol. 2022 Oct;20(10):2405-2408.e3. doi: 10.1016/j.cgh.2022.05.038. Epub 2022 Jun 16. PMID: 35716904

Correction to "Hyper inflammatory syndrome following COVID-19 mRNA **vaccine** in children: A national post-authorization pharmacovigilance study".
Ouldali N, Bagheri H, Salvo F, Antona D, Pariente A, Leblanc C, Tebacher M, Micallef J, Levy C, Cohen R, Javouhey E, Bader-Meunier B, Ovaert C, Renolleau S, Hentgen V, Kone-Paut I, Deschamps N, De Pontual L, Iriart X, Guen CG, Angoulvant F, Belot A; French Covid-19 Paediatric Inflammation Consortium; French Pharmacovigilance network. Lancet Reg Health Eur. 2022 Oct;21:100468. doi: 10.1016/j.lanepe.2022.100468. Epub 2022 Aug 10. PMID: 35967266

Acceptance of coronavirus disease 2019 vaccination among postpartum women during delivery hospitalization.
Kouba I, Yaghoubian Y, Rochelson B, Shan W, Combs A, Nimaroff M, Blitz MJ. J Matern Fetal Neonatal Med. 2022 Oct 9:1-4. doi: 10.1080/14767058.2022.2131386. Online ahead of print. PMID: 36210157

Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Residents of US Nursing Homes Before and During the Delta Variant Predominance, December 2020-November 2021.
Hatfield KM, Baggs J, Wolford H, Fang M, Sattar AA, Montgomery KS, Jin S, Jernigan J, Pilishvili T. Clin Infect Dis. 2022 Oct 3;75(Supplement_2):S147-S154. doi: 10.1093/cid/ciac562. PMID: 35856635

Antibody titers after a third dose of the SARS-CoV-2 BNT162b2 **vaccine** in immunocompromised adults in Greece: Is a fourth dose necessary?
Kontopoulou K, Nakas CT, Belai C, Papazisis G. J Med Virol. 2022 Oct;94(10):5056-5060. doi: 10.1002/jmv.27954. Epub 2022 Jul 1. PMID: 35739059

Comparing one dose of HPV **vaccine** in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV **vaccine** in historical cohorts: an immunobridging analysis of a randomised controlled trial.
Baisley K, Kemp TJ, Kreimer AR, Basu P, Changalucha J, Hildesheim A, Porras C, Whitworth H, Herrero R, Lacey CJ, Schiller JT, Lucas E, Mutani P, Dillner J, Indangasi J, Muwonge R, Hayes RJ, Pinto LA, Watson-Jones D. Lancet Glob Health. 2022 Oct;10(10):e1485-e1493. doi: 10.1016/S2214-109X(22)00306-0. PMID: 36113532

Thrombotic thrombocytopenic purpura after vaccination for COVID-19: lesson for the clinical nephrologist.
Özcan F, Brinkhoff A, Kiziler F, Bramlage P, Hollenbeck M. J Nephrol. 2022 Oct 1:1-3. doi: 10.1007/s40620-022-01466-y. Online ahead of print. PMID: 36181624

Fatal intracerebral haemorrhage associated with thrombosis with thrombocytopenia syndrome after ChAdOx1-S **vaccine**.
Gómez-Roldós A, González-Sánchez M, Vales-Montero M, Vázquez-Alen P, Fernández-Bullido Y, Iglesias-Mohedano AM, Díaz-Otero F, García-Pastor A, Gil-Núñez A. Rev Neurol. 2022 Oct 1;75(7):199-202. doi: 10.33588/rn.7507.2021323. PMID: 36169326

The introduction of mutations in the wild type coxsackievirus B3 (CVB3) IRES RNA leads to different levels of in vitro reduced replicative and translation efficiencies.
Gharbi J, Almalki MA, Ben M'hadheb M. PLoS One. 2022 Oct 3;17(10):e0274162. doi: 10.1371/journal.pone.0274162. eCollection 2022. PMID: 36190999

Guillain-Barré syndrome following Covid-19 immunization: a report of two cases.
Bax F, Gigli GL, Belgrado E, Brunelli L, Valente M. Acta Neurol Belg. 2022 Oct;122(5):1365-1367. doi: 10.1007/s13760-021-01798-9. Epub 2021 Oct 1. PMID: 34599482

Long-term protective immunity to goatpox in goats after a single immunization with a live attenuated goatpox **vaccine**.
Bhanuprakash V, Hosamani M, Venkatesan G, Singh RK. Arch Virol. 2022 Oct;167(10):2035-2040. doi: 10.1007/s00705-022-05505-8. Epub 2022 Jun 26. PMID: 35752986

Validation and use of a serum bactericidal antibody assay for Neisseria meningitidis serogroup X in a seroprevalence study in Niger, West Africa.
Katz S, Townsend-Payne K, Louth J, Lee-Jones L, Trotter C, Dan Dano I, Borrow R; MenAfriCar Consortium. Vaccine. 2022 Oct 6;40(42):6042-6047. doi: 10.1016/j.vaccine.2022.08.013. Epub 2022 Sep 8. PMID: 36089429

Letter to the Editor Regarding: "Myocarditis and Cardiac Complications Associated With COVID-19 and mRNA Vaccination" by Holland et al., Heart Lung Circ. 2022;31(7):924-33.
Lampejo T, Durkin SM. Heart Lung Circ. 2022 Oct;31(10):e129-e130. doi: 10.1016/j.hlc.2022.05.049. Epub 2022 Aug 14. PMID: 35977862

Three doses of mRNA COVID-19 **vaccine** protects from SARS-CoV-2 infections in Japan.
Hotta K, Suzuki E, Ichihara E, Kiura K. J Intern Med. 2022 Oct;292(4):687-689. doi: 10.1111/joim.13526. Epub 2022 Jun 3. PMID: 35612543

The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022.
Sridhar S, Chicz RM, Warren W, Tartaglia J, Savarino S, Gurunathan S, Toussaint JF. Nat Commun. 2022 Oct 2;13(1):5794. doi: 10.1038/s41467-022-33549-6. PMID: 36184631

Updated report of COVID-19 **vaccine** safety monitoring in Japan: Booster shots and paediatric vaccinations.
Yamaguchi T, Iwagami M, Ishiguro C, Fujii D, Yamamoto N, Sakai H, Tsuboi T, Umeda H, Kinoshita N, Iguchi T, Oka A, Morio T, Nakai K, Hayashi S, Tsuruta S. Lancet Reg Health West Pac. 2022 Sep 21;27:100600. doi: 10.1016/j.lanwpc.2022.100600. eCollection 2022 Oct. PMID: 36160728

Could Partnerships with Places of Worship Improve COVID-19 **Vaccine** Access in the US?
Schellenberg SJ, Rydland KJ, Temps WH, Lehmann LS, Hauser JM. J Gen Intern Med. 2022 Oct;37(13):3522-3524. doi: 10.1007/s11606-022-07711-1. Epub 2022 Jul 26. PMID: 35882709

The role of treatment with plasma exchange therapy in two pediatric toxic epidermal necrolysis cases related to COVID-19.
Varol F, Can YY, Sahin E, Durak C, Kilic A, Sahin C, Gursoy F, Akin T. J Clin Apher. 2022 Oct;37(5):516-521. doi: 10.1002/jca.21997. Epub 2022 Jul 6. PMID: 35792366

Neutralizing SARS-CoV-2 Spike Antibodies against Omicron in Paired Samples after Two or Three Doses of mRNA **Vaccine**.

Debes AK, Xiao S, Egbert ER, Caturegli P, Gadala A, Colantuoni E, Sitaras I, Pekosz A, Milstone AM. Microbiol Spectr. 2022 Oct 3:e0204622. doi: 10.1128/spectrum.02046-22. Online ahead of print. PMID: 36190405

White House Advisor Nahid Bhadelia, MD, MALD, on COVID-19 in Resource-Limited Nations-Undercounted Deaths, **Vaccine** Inequity, and More.
Abbasi J. JAMA. 2022 Oct 5. doi: 10.1001/jama.2022.13663. Online ahead of print. PMID: 36197671

Cardiac Magnetic Resonance Imaging Midterm Follow Up of COVID-19 **Vaccine**-Associated Myocarditis.
Cavalcante JL, Shaw KE, Gössl M. JACC Cardiovasc Imaging. 2022 Oct;15(10):1821-1824. doi: 10.1016/j.jcmg.2022.01.008. Epub 2022 Mar 16. PMID: 36202461

Production of a high purity, C-tagged hepatitis B surface antigen fusion protein VLP **vaccine** for malaria expressed in Pichia pastoris under cGMP conditions.
Mukhopadhyay E, Brod F, Angell-Manning P, Green N, Tarrant RD, Detmers FJ, Bolam EJ, Baleanu IN, Hobson M, Whale G, Morris SJ, Ashfield R, Gilbert SC, Jin J, Draper SJ, Moyle SP, Berrie EL, Hill AVS. Biotechnol Bioeng. 2022 Oct;119(10):2784-2793. doi: 10.1002/bit.28181. Epub 2022 Jul 22. PMID: 35822551

The relationship between anti-spike SARS-CoV-2 antibody levels and risk of breakthrough COVID-19 among fully vaccinated adults.
Asamoah-Boaheng M, Goldfarb DM, Karim ME, O'Brien SF, Wall N, Drews SJ, Barakauskas V, Jassem AN, Grunau B. J Infect Dis. 2022 Oct 5:jiac403. doi: 10.1093/infdis/jiac403. Online ahead of print. PMID: 36197948

Effect of educational intervention for compliance of school adolescents with the human papillomavirus **vaccine**.
Ferreira HLOC, Siqueira CM, Sousa LB, Nicolau AIO, Lima TM, Aquino PS, Pinheiro AKB. Rev Esc Enferm USP. 2022 Oct 7;56:e20220082. doi: 10.1590/1980-220X-REEUSP-2022-0082en. eCollection 2022. PMID: 36219589

Correspondence on "Immunogenicity of COVID-19 **Vaccine** Doses in Patients With Inflammatory Bowel Disease".
Sookaromdee P, Wiwanitkit V. Inflamm Bowel Dis. 2022 Oct 3;28(10):e142. doi: 10.1093/ibd/izac108. PMID: 35639935

Different anti-SARS-CoV-2 **vaccine** response under B- and T-cell targeted therapies versus anti-cytokine therapies in patients with inflammatory arthritides.
Felten R, Geoffroy M, Bolko L, Duret PM, Desmurs M, Fan A, Couderc M, Laurent M, Ardizzone M, Ahmed-Yahia S, Javier RM, Meyer A, Chatelus E, Sordet C, Pijnenburg L, Sibilia J, Soubrier M, Gottenberg JE, Salmon JH. Joint Bone Spine. 2022 Oct;89(5):105391. doi: 10.1016/j.jbspin.2022.105391. Epub 2022 Apr 28. PMID: 35490948

Durability of Booster mRNA **Vaccine** against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants.
Qu P, Faraone JN, Evans JP, Zheng YM, Yu L, Ma Q, Carlin C, Lozanski G, Saif LJ, Oltz EM, Gumina RJ, Liu SL. N Engl J Med. 2022 Oct 6;387(14):1329-1331. doi: 10.1056/NEJMc2210546. Epub 2022 Sep 7. PMID: 36069925

Presence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies Among Vietnamese Healthcare Workers by Dosing Interval for ChAdOx1 nCoV-19 **Vaccine**.
Vu DM, Vu DTB, Do TTT, Olmsted AE, Dao BH, Thai TT, Nguyen CL, Le NTT, Le TA, Bui HTT, Pham TN, Moore MR. Clin Infect Dis. 2022 Oct 3;75(Supplement_2):S174-S181. doi: 10.1093/cid/ciac493. PMID: 35723271

COVID-19 Update: Novavax **vaccine** authorized for adolescents 12-17 years old.
[No authors listed] Med Lett Drugs Ther. 2022 Oct 3;64(1660):e160. PMID: 36206168

Risk for uveitis relapse after COVID-19 vaccination.
Zhong Z, Wu Q, Lai Y, Dai L, Gao Y, Liao W, Feng X, Yang P. J Autoimmun. 2022 Oct 4;133:102925. doi: 10.1016/j.jaut.2022.102925. Online ahead of print. PMID: 36209692

Corrigendum to "Estimating the burden of adult hospitalized RSV infection including special populations". [**Vaccine** 40(31) (2022) 4121-4127].
Nowalk MP, D'Agostino H, Dauer K, Stiegler M, Zimmerman RK, Balasubramani GK. Vaccine. 2022 Oct 6;40(42):6187. doi: 10.1016/j.vaccine.2022.09.027. Epub 2022 Sep 10. PMID: 36100491

Targeting eosinophils by active vaccination against interleukin-5 reduces basophil counts in horses with insect bite hypersensitivity in the 2nd year of vaccination.
Rhiner T, Fettelschoss V, Schoster A, Birkmann K, Fettelschoss-Gabriel A. Vet J. 2022 Oct;288:105896. doi: 10.1016/j.tvjl.2022.105896. Epub 2022 Sep 17. PMID: 36126798

Autoimmune hepatitis (AIH) following coronavirus (COVID-19) **vaccine**-No longer exclusive to mRNA **vaccine**?
Shahrani S, Sooi CY, Hilmi IN, Mahadeva S. Liver Int. 2022 Oct;42(10):2344-2345. doi: 10.1111/liv.15350. Epub 2022 Jul 15. PMID: 35762286

Immunogenicity and safety of high-dose quadrivalent influenza **vaccine** in older adults in Taiwan: A phase III, randomized, multi-center study.
Chen JY, Hsieh SM, Hwang SJ, Liu CS, Li X, Fournier M, Yeh TY, Yin JK, Samson SI. Vaccine. 2022 Oct 7:S0264-410X(22)01200-2. doi: 10.1016/j.vaccine.2022.09.078. Online ahead of print. PMID: 36216650

Sweet syndrome after the first dose of SARS-CoV-2 **vaccine** (Pfizer-BioNTech).
Kim MJ, Kim JW, Na JI. Dermatol Ther. 2022 Oct 9:e15915. doi: 10.1111/dth.15915. Online ahead of print. PMID: 36209375

Motivational interviewing approach and COVID-19 **vaccine** hesitancy: Correspondence.
Mungmunpuntipantip R, Wiwanitkit V. J Pediatr Nurs. 2022 Oct 6;67:168. doi: 10.1016/j.pedn.2022.09.019. Online ahead of print. PMID: 36209633

COVID-19 **vaccine**-induced adverse events predict immunogenicity among recipients of allogeneic hematopoietic stem cell transplantation.
Wiktorin HG, Einarsdottir S, Törnell A, Arabpour M, Issdisai N, Waldenström J, Ringlander J, Lindh M, Lagging M, Hellstrand K, Martner A. Haematologica. 2022 Oct 1;107(10):2492-2495. doi: 10.3324/haematol.2022.280813. PMID: 35734932

Immunogenicity After a Heterologous BNT262b2 Versus Homologous Booster in Kidney Transplant Recipients Receiving 2 Doses of CoronaVac **Vaccine**: A Prospective Cohort Study.
Medina-Pestana J, Almeida Viana L, Nakamura MR, Lucena EF, Granato CFH, Dreige YC, Amorim LVP, Chow CYZ, Demarchi Foresto R, Roberto Requião-Moura L, Tedesco-Silva H, Cristelli MP. Transplantation. 2022 Oct 1;106(10):2076-2084. doi: 10.1097/TP.0000000000004260. Epub 2022 Aug 5. PMID: 35939382

Immunize the HPV **Vaccine** Rumors: Effects of Inoculation Messages and Tone of Voice on Parental Intention to Vaccinate Their Children.
Park E, Kim S, Cameron GT. J Community Health. 2022 Oct;47(5):790-799. doi: 10.1007/s10900-022-01100-9. Epub 2022 Jun 21. PMID: 35727435

Antibody efficacy of inactivated **vaccine** boosters (CoronaVac) against Omicron variant from a 15-month follow-up study.
Yin Y, Li X, Qian C, Cheng B, Lu F, Shen T. J Infect. 2022 Oct;85(4):e119-e121. doi: 10.1016/j.jinf.2022.06.018. Epub 2022 Jun 26. PMID: 35760302

COVID-19 booster uptake among US adults: Assessing the impact of **vaccine** attributes, incentives, and context in a choice-based experiment.
Raman S, Kriner D, Ziebarth N, Simon K, Kreps S. Soc Sci Med. 2022 Oct;310:115277. doi: 10.1016/j.socscimed.2022.115277. Epub 2022 Aug 15. PMID: 36001917

The clinical course of patients with previous acute and recurrent pericarditis receiving the BNT162b2 **vaccine**.
Wasserstrum Y, Nadav S, Segev A, Lotan D, Freimark D, Arad M. Int J Cardiol Heart Vasc. 2022 Jul 18;42:101084. doi: 10.1016/j.ijcha.2022.101084. eCollection 2022 Oct. PMID: 35873860

Editorial Comment: Prolonged Resolution of COVID-19 **Vaccine**-Related Axillary Lymphadenopathy Necessitates a Long Imaging Follow-Up Interval.
Perry H. AJR Am J Roentgenol. 2022 Oct;219(4):567. doi: 10.2214/AJR.22.28019. Epub 2022 Jun 1. PMID: 35642766

Needle-free, spirulina-produced Plasmodium falciparum circumsporozoite vaccination provides sterile protection against pre-erythrocytic malaria in mice.
Saveria T, Parthiban C, Seilie AM, Brady C, Martinez A, Manocha R, Afreen E, Zhao H, Krzeszowski A, Ferrara J, Paddock T, Roberts J, Stone BC, Tasch M, Murphy SC. NPJ Vaccines. 2022 Oct 4;7(1):113. doi: 10.1038/s41541-022-00534-5. PMID: 36195607

Effectiveness of maternal pertussis vaccination in Singapore: A test-negative case-control study.
Chong CY, Tan NW, Yung CF, Li J, Kam KQ, Nadua K, Maiwald M, Sultana R, Thoon KC. Vaccine. 2022 Oct 8:S0264-410X(22)01219-1. doi: 10.1016/j.vaccine.2022.09.087. Online ahead of print. PMID: 36216649

Author Correction: Development of the H3N2 influenza microneedle **vaccine** for cross-protection against antigenic variants.
Shin Y, Kim J, Seok JH, Park H, Cha HR, Ko SH, Lee JM, Park MS, Park JH. Sci Rep. 2022 Oct 3;12(1):16540. doi: 10.1038/s41598-022-20913-1. PMID: 36192424

Immunogenicity and protection against Glaesserella parasuis serotype 13 infection after vaccination with recombinant protein LolA in mice.
Guo Z, Jia Y, Huang C, Zhou Y, Chen X, Yin R, Guo Y, Wang L, Yuan J, Wang J, Yan P, Yin R. J Vet Med Sci. 2022 Oct 10. doi: 10.1292/jvms.22-0203. Online ahead of print. PMID: 36216558

Three-Dose Primary Series of Inactivated COVID-19 **Vaccine** for Persons Living with HIV, Hong Kong.
Chan DPC, Wong NS, Wong BCK, Chan JMC, Lee SS. Emerg Infect Dis. 2022 Oct;28(10):2130-2132. doi: 10.3201/eid2810.220691. Epub 2022 Sep 1. PMID: 36048772

No significant influence of pre-vaccination antipyretic use on specific antibody response to a BNT162b2 **vaccine** booster against COVID-19.
Tani N, Ikematsu H, Goto T, Gondo K, Yanagihara Y, Kurata Y, Oishi R, Minami J, Onozawa K, Nagano S, Kuwano H, Akashi K, Shimono N, Chong Y. Vaccine X. 2022 Dec;12:100224. doi: 10.1016/j.jvacx.2022.100224. Epub 2022 Oct 3. PMID: 36213591

Regression of sarcoidosis skin lesions after receiving the Moderna anti-coronavirus disease 2019 **vaccine**.
Canu D, Doutre MS. J Dermatol. 2022 Oct;49(10):e378-e380. doi: 10.1111/1346-8138.16438. Epub 2022 May 19. PMID: 35588231

Before blaming a COVID **vaccine** for cytotoxic lesions of the corpus callosum all other differentials must be ruled out.
Finsterer J. Neuroradiology. 2022 Oct;64(10):1917-1918. doi: 10.1007/s00234-022-03022-8. Epub 2022 Jul 18. PMID: 35843986

Efficacy of bivalent *CEACAM6/4*-1BBL genetic **vaccine** combined with anti-PD1 antibody in MC38 tumor model of mice.
Li Y, Zhu X, You J, Zhang B, Huang X, Jin C. Heliyon. 2022 Sep 28;8(10):e10775. doi: 10.1016/j.heliyon.2022.e10775. eCollection 2022 Oct. PMID: 36212004

The Effect of the COVID-19 **Vaccine** on Facial Aesthetic Injectables and Suspension Threads Among Patients Treated by the Philippine Dermatological Society (PDS) Dermatologists.
Dim-Jamora KCC, Gulmatico-Flores Z, Rescober-Valencia MC, Lacson S, Ingente-Tablante M, Robredo-Vitas IG, Ang-Tiu C, Sy-Alvarado FMS, Ferrariz TS, Espinoza-Thaebtharm A. J Cosmet Dermatol. 2022 Oct 6. doi: 10.1111/jocd.15417. Online ahead of print. PMID: 36200924

Central retinal artery occlusion after vaccination with whole virion inactivated SARSCoV- 2 **vaccine** Covaxin.
Thakar M, Bhattacharya S. Indian J Ophthalmol. 2022 Oct;70(10):3716-3718. doi: 10.4103/ijo.IJO_1148_22. PMID: 36190081

Measuring impact of vaccination among wildlife: The case of bait **vaccine** campaigns for classical swine fever epidemic among wild boar in Japan.
Matsuyama R, Yamamoto T, Hayama Y, Omori R. PLoS Comput Biol. 2022 Oct 6;18(10):e1010510. doi: 10.1371/journal.pcbi.1010510. eCollection 2022 Oct. PMID: 36201410

Unremarkable antibody responses against various infectious agents after inoculation with the BNT162b2 COVID-19 **vaccine**.

Kozawa K, Miura H, Kawamura Y, Higashimoto Y, Ihira M, Yoshikawa T. J Med Virol. 2022 Oct;94(10):4583-4585. doi: 10.1002/jmv.27895. Epub 2022 Jun 9. PMID: 35641431

Pityriasis rubra pilaris (type I) following administration of the BNT162b2 mRNA COVID-19 **vaccine**: Successful treatment with ustekinumab and acitretin.
Gamonal SBL, Marques NCV, Pereira HMB, Gamonal ACC. Dermatol Ther. 2022 Oct 5:e15899. doi: 10.1111/dth.15899. Online ahead of print. PMID: 36196603

Immunogenicity of a third dose of inactivated COVID-19 **vaccine** in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: A cross-sectional study.
Yan Y, Davgadorj C, Lyu C, Zhang S, Qiu Y. J Infect. 2022 Oct;85(4):e109-e111. doi: 10.1016/j.jinf.2022.06.032. Epub 2022 Jul 5. PMID: 35803384

Induction of protein specific antibody by carbonated hydroxy apatite as a candidate for mucosal **vaccine** adjuvant.
Anggraeni R, Ana ID, Agustina D, Martien R. Dent Mater J. 2022 Oct 2;41(5):710-723. doi: 10.4012/dmj.2021-254. Epub 2022 Jul 20. PMID: 35858789

Atrial fibrillation after vaccination for COVID-19: analysis of the **vaccine** adverse event reporting system.
Kumar A, Shariff M, Bhat V, DeSimone C, Deshmukh A. J Interv Card Electrophysiol. 2022 Oct;65(1):1-2. doi: 10.1007/s10840-022-01263-4. Epub 2022 Jun 8. PMID: 35674855

Preexisting anti-PF4 antibodies are not further triggered upon vaccination with SARS-CoV-2 vector vaccines in a cohort of 400 health care workers.
Angelika W, Erika GS, Michael K, Hannes S, Ingrid P, Sabine EH, Peter Q, Oswald W, Ursula W, Katharina GP. Thromb Res. 2022 Oct;218:142-144. doi: 10.1016/j.thromres.2022.08.005. Epub 2022 Aug 11. PMID: 36037550

COVID-19 morbidity decreases with tixagevimab-cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-**vaccine** responders.
Kaminski H, Gigan M, Vermorel A, Charrier M, Guirle L, Jambon F, Lacapère A, Ménard C, Moreau K, Neau-Cransac M, Novion M, Pribat F, Taton B, Borde S, Burguet L, Martinez C, Jasiek M, D'Halluin P, Lafon ME, Merville P, Couzi L. Kidney Int. 2022 Oct;102(4):936-938. doi: 10.1016/j.kint.2022.07.008. Epub 2022 Jul 20. PMID: 35870641

Comment on: COVID-19 **vaccine** hesitancy in inflammatory arthritis patients: serial surveys from a large longitudinal national Australian cohort.
Mungmunpuntipantip R, Wiwanitkit V. Rheumatology (Oxford). 2022 Oct 4:keac572. doi: 10.1093/rheumatology/keac572. Online ahead of print. PMID: 36193990

Quality of antibody responses by adults and young children to 13-valent pneumococcal conjugate vaccination and Streptococcus pneumoniae colonisation.
Wolf AS, Mitsi E, Jones S, Jochems SP, Roalfe L, Thindwa D, Meiring JE, Msefula J, Bonomali F, Makhaza Jere T, Mbewe M, Collins AM, Gordon SB, Gordon MA, Ferreira DM, French N, Goldblatt D, Heyderman RS, Swarthout TD. Vaccine. 2022 Oct 6:S0264-410X(22)01190-2. doi: 10.1016/j.vaccine.2022.09.069. Online ahead of print. PMID: 36210249

Effectiveness of Coronavirus Disease 2019 (COVID-19) mRNA Vaccines Against Infection During an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta (B.1.351) Variant in a Skilled Nursing Facility: Virginia, March-April 2021.
Moline HL, Keaton A, Rice W, Varghese J, Deng L, Waters A, Barringer A, Winston D, Fields V, Slifka KJ, Verani JR, Schrag SJ, Jernigan J, Tate JE, Fleming-Dutra KE. Clin Infect Dis. 2022 Oct 3;75(Supplement_2):S155-S158. doi: 10.1093/cid/ciac526. PMID: 35758873

Predicting the long-term impact of rotavirus vaccination in 112 countries from 2006 to 2034: A transmission modeling analysis.
Kraay ANM, Steele MK, Baker JM, Hall EW, Deshpande A, Saidzosa BF, Mukaratirwa A, Boula A, Mpabalwani EM, Kiulia NM, Tsolenyanu E, Enweronu-Laryea C, Abebe A, Beyene B, Tefera M, Willilo R, Batmunkh N, Pastore R, Mwenda JM, Antoni S, Cohen AL, Pitzer VE, Lopman BA. Vaccine. 2022 Oct 6:S0264-410X(22)01193-8. doi: 10.1016/j.vaccine.2022.09.072. Online ahead of print. PMID: 36210251

Immunogenicity of the BNT162b2 COVID-19 **vaccine** as a third dose (booster) following two doses of different primary series regimens in Thailand.
Wanlapakorn N, Suntronwong N, Kanokudom S, Assawakosri S, Nilyanimit P, Yorsaeng R, Chansaenroj J, Poovorawan Y. Pathog Glob Health. 2022 Oct;116(7):395-397. doi: 10.1080/20477724.2022.2108646. Epub 2022 Aug 3. PMID: 35920191

Response to letter to the editor regarding *"Acute onset ocular myasthenia gravis after vaccination with the Oxford-AstraZeneca COVID-19 **vaccine**".*
Maher DI, Hogarty D, Ben Artsi E. Orbit. 2022 Oct;41(5):662-663. doi: 10.1080/01676830.2022.2087234. Epub 2022 Jun 10. PMID: 35686598

Seroconversion among rituximab-treated patients following SARS-CoV-2 **vaccine** supplemental dose.
Rose E, Magliulo D, Kyttaris VC. Clin Immunol. 2022 Oct 8:109144. doi: 10.1016/j.clim.2022.109144. Online ahead of print. PMID: 36220613

Is a single dose of ChAdOx1 nCoV-19 **vaccine** (AZD1222) enough for people with prior SARS-CoV-2 infection or baseline seropositive status?
Deswal V, Phogat R, Sharma P, Kataria S, Soin A. Int J Infect Dis. 2022 Oct;123:143-144. doi: 10.1016/j.ijid.2022.06.051. Epub 2022 Jul 3. PMID: 35793757

The impact of enterovirus A71 vaccination program on hand, foot, and mouth disease in Guangdong, China: A longitudinal surveillance study.
Xiao J, Zhu Q, Yang F, Zeng S, Zhu Z, Gong D, Li Y, Zhang L, Li B, Zeng W, Li X, Rong Z, Hu J, He G, Sun J, Lu J, Liu T, Ma W, Sun L. J Infect. 2022 Oct;85(4):428-435. doi: 10.1016/j.jinf.2022.06.020. Epub 2022 Jun 26. PMID: 35768049

Reply to "A case of symmetrical drug-related intertriginous and flexural exanthema-like eruption associated with Pfizer COVID-19 vaccination" by Manaa et al.
Camela E, Scalvenzi M, Megna M, Potestio L, Guerrasio G, Fornaro L, Fabbrocini G, Costa C. Dermatol Ther. 2022 Oct 1:e15881. doi: 10.1111/dth.15881. Online ahead of print. PMID: 36181410

Immune transcriptome and antibody response in adult-onset Still's disease with mild flare following administration of mRNA **vaccine** BNT162b2.

Knabl L, Lee HK, Walter M, Furth PA, Hennighausen L. Rheumatology (Oxford). 2022 Oct 6;61(10):e305-e307. doi: 10.1093/rheumatology/keac281. PMID: 35532082

Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: A randomized trial.
Niyomnaitham S, Toh ZQ, Licciardi PV, Wongprompitak P, Srisutthisamphan K, Copeland KK, Chokephaibulkit K. J Infect. 2022 Oct;85(4):436-480. doi: 10.1016/j.jinf.2022.06.014. Epub 2022 Jun 18. PMID: 35728642

Shorter duration of protection and lower geometric mean titers against A/H3N2 antigen of the quadrivalent influenza **vaccine** in children post-allogeneic hematopoietic stem cell transplantation.
Kang KR, Kim YJ, Ahn MB, Kang HM, Kim SK, Lee JW, Chung NG, Cho B, Jeong DC, Kang JH. Bone Marrow Transplant. 2022 Oct;57(10):1620-1622. doi: 10.1038/s41409-022-01768-6. Epub 2022 Aug 1. PMID: 35915154 F

The elusive goal of COVID-19 **vaccine** immunity.
Abu-Raddad LJ, Chemaitelly H. Lancet Respir Med. 2022 Oct 7:S2213-2600(22)00394-0. doi: 10.1016/S2213-2600(22)00394-0. Online ahead of print. PMID: 36216010

Letter by Kounis et al Regarding Article, "Biopsy-Proven Giant Cell Myocarditis Following the COVID-19 **Vaccine**".
Kounis NG, Koniari I, Mplani V, Velissaris D, Plotas P. Circ Heart Fail. 2022 Oct 10:CIRCHEARTFAILURE122009826. doi: 10.1161/CIRCHEARTFAILURE.122.009826. Online ahead of print. PMID: 36214154

A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford-AstraZeneca COVID-19 **vaccine**.
Filippi F, Baraldi C, Zinzani PL, Casadei B, Pileri A. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):e747-e749. doi: 10.1111/jdv.18269. Epub 2022 Jun 7. PMID: 35617206

Flare-up of generalized pustular psoriasis following Pfizer-BioNTech BNT162b2 mRNA COVID-19 **vaccine**: Two cases without mutations of IL36RN and CARD14 genes.
Tachibana K, Kawakami Y, Tokuda M, Sato S, Sugihara S, Miyake T, Sugiura K, Morizane S. J Dermatol. 2022 Oct;49(10):e393-e394. doi: 10.1111/1346-8138.16442. Epub 2022 May 13. PMID: 35560571

Effectiveness of mRNA vaccines against SARS-CoV-2 infections during the periods of Delta and Omicron variant predominance in Japan: The VENUS Study.
Mimura W, Ishiguro C, Maeda M, Murata F, Fukuda H. Int J Infect Dis. 2022 Oct 8:S1201-9712(22)00539-2. doi: 10.1016/j.ijid.2022.10.001. Online ahead of print. PMID: 36220547

A Case of Sequential Development of Polymyalgia Rheumatica and Guillain-Barré Syndrome Following Administration of the Pfizer-BioNTech COVID-19 **Vaccine**.
Yamada S, Yamada K, Nishida H. Intern Med. 2022 Oct 1;61(19):2995. doi: 10.2169/internalmedicine.0319-22. Epub 2022 Jul 22. PMID: 35871588

Determinants of COVID-19 **vaccine** uptake among healthcare professionals and the general population: Correspondence.

Mungmunpuntipantip R, Wiwanitkit V. J Eval Clin Pract. 2022 Oct 7. doi: 10.1111/jep.13777. Online ahead of print. PMID: 36205634

Correction: Google Trends on Human Papillomavirus **Vaccine** Searches in the United States From 2010 to 2021: Infodemiology Study.
Bhagavathula AS, Massey PM. JMIR Public Health Surveill. 2022 Oct 4;8(10):e42812. doi: 10.2196/42812. PMID: 36194875 F

Genetic characterization of sheep pox virus strains from outbreaks in Central Russia in 2018 - 2019.
Krotova A, Shalina K, Mazloum A, Kwon D, Van Schalkwyk A, Byadovskaya O, Sprygin A. Transbound Emerg Dis. 2022 Oct 10. doi: 10.1111/tbed.14727. Online ahead of print. PMID: 36217254

Fulminant Myocarditis After SARS-CoV-2 mRNA **Vaccine** Successfully Managed With Biventricular Impella Support: Multimodality Imaging Follow-Up.
Ching S, Yue CS. Korean Circ J. 2022 Oct;52(10):797-798. doi: 10.4070/kcj.2022.0109. PMID: 36217602

Current challenges in the manufacture of clinical-grade autologous whole cell vaccines for hematological malignancies.
Bastin DJ, Quizi J, Kennedy MA, Kekre N, Auer RC. Cytotherapy. 2022 Oct;24(10):979-989. doi: 10.1016/j.jcyt.2022.03.010. Epub 2022 May 11. PMID: 35562303

Dynamic SARS-CoV-2 emergence algorithm for rationally-designed logical next-generation vaccines.
Maison DP, Ching LL, Cleveland SB, Tseng AC, Nakano E, Shikuma CM, Nerurkar VR. Commun Biol. 2022 Oct 10;5(1):1081. doi: 10.1038/s42003-022-04030-3. PMID: 36217024

The Burden of **Vaccine**-preventable Diseases in Patients With Inflammatory Bowel Disease.
Kröner PT, Picco MF, Cangemi JR, Hayney MS, Farraye FA, Caldera F. J Clin Gastroenterol. 2022 Oct 1;56(9):798-804. doi: 10.1097/MCG.0000000000001635. Epub 2022 Feb 14. PMID: 35152238

Vaccine Effectiveness, School Reopening, and Risk of Omicron Infection Among Adolescents Aged 12-17 Years.
Risk M, Miao H, Freed G, Shen C. J Adolesc Health. 2022 Oct 7:S1054-139X(22)00643-7. doi: 10.1016/j.jadohealth.2022.09.006. Online ahead of print. PMID: 36216679

Efficacy of COVID-19 vaccines.
Saadh MJ, Jaber SA. Microb Pathog. 2022 Oct;171:105729. doi: 10.1016/j.micpath.2022.105729. Epub 2022 Sep 2. PMID: 36058411

Risk of gout flares after COVID-19 vaccination: A case-crossover study.
Li H, Dalbeth N, Wallace ZS, Sparks JA, Li X, Zeng C, Wang Y, Xie D, Lei G, Wei J, Zhang Y. Semin Arthritis Rheum. 2022 Oct;56:152059. doi: 10.1016/j.semarthrit.2022.152059. Epub 2022 Jun 28. PMID: 35797765

COVID-19 outbreak in an elderly care home: Very low **vaccine** effectiveness and late impact of booster vaccination campaign.
van Ewijk CE, Hazelhorst EI, Hahné SJM, Knol MJ. Vaccine. 2022 Oct 4:S0264-410X(22)01213-0. doi: 10.1016/j.vaccine.2022.09.080. Online ahead of print. PMID: 36216647

A Case of Herpes Zoster Due to Varicella-Zoster Virus Vaccines in a 14-Month-old Girl.
Koide T, Nishigaki T. Pediatr Infect Dis J. 2022 Oct 1;41(10):860-861. doi: 10.1097/INF.0000000000003638. Epub 2022 Jun 6. PMID: 36197397

An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.
Isnardi CA, Schneeberger EE, Kreimer JL, Luna PC, Echeverría C, Roberts K, de la Vega MC, Virasoro BM, Landi M, Quintana R, Exeni MED, Kogan N, Petkovic I, Pereira D, De Los Ángeles Correa M, Zelaya MD, Tissera Y, Elkin MSG, Pisoni CN, Alonso C, Cogo AK, Cosatti MA, García L, Retamozo C, de Los Ángeles Severina M, Nieto RE, Rosemffet M, Mussano E, Bertoli A, Savio VG, Cosentino V, Pons-Estel GJ. Clin Rheumatol. 2022 Oct;41(10):3199-3209. doi: 10.1007/s10067-022-06253-5. Epub 2022 Jun 28. PMID: 35760939

COVID-19 immunization in people with cancer-Is it safe and efficient? What do we know?
Lazăr DE, Munteanu A. Tumori. 2022 Oct;108(5):420-430. doi: 10.1177/03008916221090544. Epub 2022 Apr 15. PMID: 35426773

Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020-March 2022.
Yamayoshi S, Iwatsuki-Horimoto K, Okuda M, Ujie M, Yasuhara A, Murakami J, Duong C, Hamabata T, Ito M, Chiba S, Kobayashi R, Takahashi S, Mitamura K, Hagihara M, Shibata A, Uwamino Y, Hasegawa N, Ebina T, Izumi A, Kato H, Nakajima H, Sugaya N, Seki Y, Iqbal A, Kamimaki I, Yamazaki M, Kawaoka Y, Furuse Y. Emerg Infect Dis. 2022 Oct 5;28(11). doi: 10.3201/eid2811.221127. Online ahead of print. PMID: 36198306

Small-sample continual learning classification method with **vaccine** to update memory cells based on the artificial immune system.
Zhang H, Jiang L, Jiao W, Liu S, Xiao H. Biosystems. 2022 Oct;220:104737. doi: 10.1016/j.biosystems.2022.104737. Epub 2022 Jul 30. PMID: 35917952

Improving preparedness for next pandemics: Max level of COVID-19 vaccinations without social impositions to design effective health policy and avoid flawed democracies.
Coccia M. Environ Res. 2022 Oct;213:113566. doi: 10.1016/j.envres.2022.113566. Epub 2022 May 31. PMID: 35660409

New-onset myasthenia gravis after mRNA SARS-CoV-2 vaccination: a case series.
Fanella G, Baiata C, Candeloro E, Toscano G, Colnaghi S, Mauri M, Cariddi LP, Rebecchi V, Solazzo F, Banfi P, Piatti M, Ferrarese C, Versino M. Neurol Sci. 2022 Oct;43(10):5799-5802. doi: 10.1007/s10072-022-06284-5. Epub 2022 Jul 23. PMID: 35870026

Reductions in perceived COVID-19 threat amid UK's mass public vaccination programme coincide with reductions in outgroup avoidance (but not prejudice).
Meleady R, Hodson G. Br J Soc Psychol. 2022 Oct;61(4):1286-1304. doi: 10.1111/bjso.12537. Epub 2022 Mar 31. PMID: 35357017

Using the Health Belief Model to improve influenza vaccination rates.

Gutierrez F, Wolfe J. JAAPA. 2022 Oct 1;35(10):46-47. doi: 10.1097/01.JAA.0000873832.52485.65. PMID: 36165548

CML-127 Results of a Vaccination Against COVID-19 by a Vector Based **Vaccine** Sputnik V in Patients With Chronic Myeloid Leukemia.
Chelysheva E, Petrova A, Gurianova M, Shukhov O, Bykova A, Nemchenko I, Tikhomirov D, Julhakyan H, Kokhno A, Turkina A. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S287-S288. doi: 10.1016/S2152-2650(22)01364-7. PMID: 36163909

Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA **vaccine** booster dose in patients on hemodialysis: the prospective SENCOVAC study.
Quiroga B, Soler MJ, Ortiz A, Jaravaca Mantecón CJ, Nava Pérez N, Serra Martín M, Sato Y, Marin Franco AJ, Pazmiño Zambrano DF, Lucena Valverde R, Ortega Diaz M, Calderón González C, Cazorla López JM, Pereira M, González Parra E, Sánchez Horrillo A, Sánchez González C, Toapanta N, Cigarrán Guldris S, Sánchez Hernández R, Pizarro Sánchez S, Muñiz Rincón M, Garcia-Fernández N, Blanco Castro N, Collantes Mateo R, Quiroz Morales MA, Escamilla-Cabrera B, Berdud Godoy I, Gil-Casares Casanova B, Leyva A, Rojas J, Gansevoort RT, de Sequera P; SENCOVAC collaborative network. Clin Kidney J. 2022 Jul 26;15(10):1856-1864. doi: 10.1093/ckj/sfac169. eCollection 2022 Oct. PMID: 36147708

Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: a multi-center prospective observational study.
Terada M, Kondo N, Wanifuchi-Endo Y, Fujita T, Asano T, Hisada T, Uemoto Y, Akiko Kato, Yamanaka N, Sugiura H, Mita K, Wada A, Takahashi E, Saito K, Yoshioka R, Toyama T. Breast Cancer Res Treat. 2022 Oct;195(3):311-323. doi: 10.1007/s10549-022-06693-2. Epub 2022 Aug 8. PMID: 35941421

Gam-COVID-Vac, EpiVacCorona, and CoviVac effectiveness against lung injury during Delta and Omicron variant surges in St. Petersburg, Russia: a test-negative case-control study.
Barchuk A, Bulina A, Cherkashin M, Berezina N, Rakova T, Kuplevatskaya D, Skougarevskiy D, Okhotin A. Respir Res. 2022 Oct 10;23(1):276. doi: 10.1186/s12931-022-02206-3. PMID: 36217139

Respiratory Virus Surveillance Among Children with Acute Respiratory Illnesses - New **Vaccine** Surveillance Network, United States, 2016-2021.
Perez A, Lively JY, Curns A, Weinberg GA, Halasa NB, Staat MA, Szilagyi PG, Stewart LS, McNeal MM, Clopper B, Zhou Y, Whitaker BL, LeMasters E, Harker E, Englund JA, Klein EJ, Selvarangan R, Harrison CJ, Boom JA, Sahni LC, Michaels MG, Williams JV, Langley GE, Gerber SI, Campbell A, Hall AJ, Rha B, McMorrow M; New Vaccine Surveillance Network Collaborators. MMWR Morb Mortal Wkly Rep. 2022 Oct 7;71(40):1253-1259. doi: 10.15585/mmwr.mm7140a1. PMID: 36201373

Cervical cancer in Morocco: A systematic review.
Arechkik A, Lahlou L, Obtel M, Kharbach A, Razine R. Rev Epidemiol Sante Publique. 2022 Oct;70(5):230-242. doi: 10.1016/j.respe.2022.05.008. Epub 2022 Aug 1. PMID: 35927117

Relative efficacy of varicella vaccines: network meta-analysis of randomized controlled trials.
Pawaskar M, Siddiqui MK, Takyar J, Sharma A, Fergie J. Curr Med Res Opin. 2022 Oct;38(10):1772-1782. doi: 10.1080/03007995.2022.2091334. Epub 2022 Jul 18. PMID: 35713564

Efficacy of recombinant subunit OMP and hly vaccines against Aeromonas hydrophila in Rohu (Labeo rohita).
Thirumalaikumar E, Sathishkumar R, Vimal S, Babu MM, Uma G, Lusiastuti AM, Citarasu T. J Fish Dis. 2022 Oct;45(10):1581-1592. doi: 10.1111/jfd.13682. Epub 2022 Jul 10. PMID: 35810483

Safety and efficacy of COVID-19 vaccines in children and adolescents: A systematic review of randomized controlled trials.
Tian F, Yang R, Chen Z. J Med Virol. 2022 Oct;94(10):4644-4653. doi: 10.1002/jmv.27940. Epub 2022 Jun 29. PMID: 35705969

The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern.
Graham C, Lechmere T, Rehman A, Seow J, Kurshan A, Huettner I, Maguire TJA, Tam J, Cox D, Ward C, Racz M, Waters A, Mant C, Malim MH, Fox J, Doores KJ. PLoS Pathog. 2022 Oct 3;18(10):e1010882. doi: 10.1371/journal.ppat.1010882. Online ahead of print. PMID: 36191037

Research Note: High genetic diversity of infectious bronchitis virus from Mexico.
Mendoza-González L, Marandino A, Panzera Y, Tomás G, Williman J, Techera C, Gayosso-Vázquez A, Ramírez-Andoney V, Alonso-Morales R, Realpe-Quintero M, Pérez R. Poult Sci. 2022 Oct;101(10):102076. doi: 10.1016/j.psj.2022.102076. Epub 2022 Jul 26. PMID: 36041394

Pfizer/BioNTech SARS-CoV-2 **vaccine** as a potential trigger for the development of narcolepsy: a case report.
Mahamid A, Bornstein RJ, Amir H. J Clin Sleep Med. 2022 Oct 1;18(10):2503-2506. doi: 10.5664/jcsm.10134. PMID: 35733336

Immunization for midlife women.
Brown V. Menopause. 2022 Oct 1;29(10):1204-1209. doi: 10.1097/GME.0000000000002024. Epub 2022 Aug 23. PMID: 35998660

Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and **vaccine**.
Shirzad M, Nourigorji M, Sajedi A, Ranjbar M, Rasti F, Sourani Z, Moradi M, Mostafa Mir S, Memar MY. Int Immunopharmacol. 2022 Oct;111:109161. doi: 10.1016/j.intimp.2022.109161. Epub 2022 Aug 18. PMID: 35998506

Immunising older Australians: Pre-COVID-19 associations of opportunistic immunisation in general practice registrar consultations.
Tranter I, Magin P, Tapley A, Holliday E, Davey AR, Fielding A, Spike N, FitzGerald K, Ball J, van Driel ML. Aust J Gen Pract. 2022 Oct;51(10):793-797. doi: 10.31128/AJGP-09-21-6165. PMID: 36184864

Safety assessment of compliant, highly invasive, lipid A-altered, O-antigen-defected Salmonella strains as prospective **vaccine** delivery systems.
Aganja RP, Sivasankar C, Hewawaduge C, Lee JH. Vet Res. 2022 Oct 1;53(1):76. doi: 10.1186/s13567-022-01096-z. PMID: 36183131

Detection of **vaccine**-derived poliovirus type 2 amid the burden of infectious diseases in the UK: A cause for alarm.

Kamran A, Salman M, Siddiqui R, Shabbir NZ, Rohail S, Sukaina M. Ann Med Surg (Lond). 2022 Oct;82:104773. doi: 10.1016/j.amsu.2022.104773. Epub 2022 Sep 22. PMID: 36164645

The role of bacterial ATP-binding cassette (ABC) transporters in pathogenesis and virulence: Therapeutic and **vaccine** potential.
Akhtar AA, Turner DP. Microb Pathog. 2022 Oct;171:105734. doi: 10.1016/j.micpath.2022.105734. Epub 2022 Aug 23. PMID: 36007845

FOXP4 inhibits squamous differentiation of atypical cells in cervical intraepithelial neoplasia via an ELF3-dependent pathway.
Matsumoto T, Iizuka T, Nakamura M, Suzuki T, Yamamoto M, Ono M, Kagami K, Kasama H, Wakae K, Muramatsu M, Horike SI, Kyo S, Yamamoto Y, Mizumoto Y, Daikoku T, Fujiwara H. Cancer Sci. 2022 Oct;113(10):3376-3389. doi: 10.1111/cas.15489. Epub 2022 Aug 1. PMID: 35838233

Neurology of Acute Viral Infections.
Krett JD, Beckham JD, Tyler KL, Piquet AL, Chauhan L, Wallace CJ, Pastula DM, Kapadia RK. Neurohospitalist. 2022 Oct;12(4):632-646. doi: 10.1177/19418744221104778. Epub 2022 May 27. PMID: 36147750

Septic arthritis of shoulder joint following a COVID-19 vaccination: A case report.
Klabklay P, Chuaychoosakoon C. Int J Surg Case Rep. 2022 Oct;99:107686. doi: 10.1016/j.ijscr.2022.107686. Epub 2022 Sep 20. PMID: 36160625

Cancer stem cell antigen nanodisc cocktail elicits anti-tumor immune responses in melanoma.
Aikins ME, Qin Y, Dobson H, Najafabadi AH, Lyu K, Xu Y, Xin Y, Schwendeman A, Wicha MS, Chang AE, Li Q, Moon JJ. J Control Release. 2022 Oct 4:S0168-3659(22)00664-2. doi: 10.1016/j.jconrel.2022.09.061. Online ahead of print. PMID: 36206945

Detection and genetic characterization of novel infectious bronchitis viruses from recent outbreaks in broiler and layer chicken flocks in southern China, 2021.
Yuan S, Cheng Q, Guo J, Li Z, Yang J, Wang C, Liang Z, Zhang X, Yu H, Li Y, Huang S, Wen F. Poult Sci. 2022 Oct;101(10):102082. doi: 10.1016/j.psj.2022.102082. Epub 2022 Jul 29. PMID: 36041395

Modelling herd immunity requirements in Queensland: impact of vaccination effectiveness, hesitancy and variants of SARS-CoV-2.
Sanz-Leon P, Hamilton LHW, Raison SJ, Pan AJX, Stevenson NJ, Stuart RM, Abeysuriya RG, Kerr CC, Lambert SB, Roberts JA. Philos Trans A Math Phys Eng Sci. 2022 Oct 3;380(2233):20210311. doi: 10.1098/rsta.2021.0311. Epub 2022 Aug 15. PMID: 35965469

From functional genomics of vero cells to CRISPR-based genomic deletion for improved viral production rates.
Sène MA, Xia Y, Kamen AA. Biotechnol Bioeng. 2022 Oct;119(10):2794-2805. doi: 10.1002/bit.28190. Epub 2022 Jul 30. PMID: 35869699

Intranasal administration of cold-adapted live-attenuated SARS-CoV-2 candidate **vaccine** confers protection against SARS-CoV-2.

Abdoli M, Shafaati M, Ghamsari LK, Abdoli A. Virus Res. 2022 Oct 2;319:198857. doi: 10.1016/j.virusres.2022.198857. Epub 2022 Jul 9. PMID: 35820511

Comparison of the immunogenicity of five COVID-19 vaccines in Sri Lanka.
Jeewandara C, Aberathna IS, Danasekara S, Gomes L, Fernando S, Guruge D, Ranasinghe T, Gunasekera B, Kamaladasa A, Kuruppu H, Somathilake G, Jayamali J, Jayathilaka D, Wijayatilake HDK, Pushpakumara PD, Harvie M, Nimasha T, de Silva SDG, Wijayamuni R, Schimanski L, Rijal P, Tan J, Townsend A, Ogg GS, Malavige GN. Immunology. 2022 Oct;167(2):263-274. doi: 10.1111/imm.13535. Epub 2022 Jul 9. PMID: 35751563

From vaccines to nanovaccines: A promising strategy to revolutionize rheumatoid arthritis treatment.
Zhang N, Li M, Hou Z, Ma L, Younas A, Wang Z, Jiang X, Gao J. J Control Release. 2022 Oct;350:107-121. doi: 10.1016/j.jconrel.2022.08.020. Epub 2022 Aug 17. PMID: 35977582

Multiple sclerosis relapse after COVID-19 vaccination: A case report-based systematic review.
Nabizadeh F, Ramezannezhad E, Kazemzadeh K, Khalili E, Ghaffary EM, Mirmosayyeb O. J Clin Neurosci. 2022 Oct;104:118-125. doi: 10.1016/j.jocn.2022.08.012. Epub 2022 Aug 19. PMID: 36029752

Cyanobacterial natural products as sources for antiviral drug discovery against COVID-19.
Jafari Porzani S, Konur O, Nowruzi B. J Biomol Struct Dyn. 2022 Oct;40(16):7629-7644. doi: 10.1080/07391102.2021.1899050. Epub 2021 Mar 22. PMID: 33749496

Adverse events after administration of the first and second doses of messenger RNA-based COVID-19 vaccines in Japanese subjects aged 12-18 years.
Ogawa T, Yamada T, Matsumoto Y, Minami K, Kawanishi F, Nakano T, Ukimura A. J Int Med Res. 2022 Oct;50(10):3000605221127518. doi: 10.1177/03000605221127518. PMID: 36217268

The effect of SARS-CoV-2 mRNA vaccination on AMH concentrations in infertile women.
Horowitz E, Mizrachi Y, Ganer Herman H, Oz Marcuschamer E, Shalev A, Farhi J, Barber E, Orna SH, Raziel A, Weissman A. Reprod Biomed Online. 2022 Oct;45(4):779-784. doi: 10.1016/j.rbmo.2022.06.015. Epub 2022 Jun 22. PMID: 35985956

Protective Duration of ChAdOx1 and BNT162b2 Vaccines Against SARS-CoV-2 Infection.
Alfaleh A, Alkattan A, Alzaher A, Radwan N, Mahmoud N, Alageel A, Alhabib D, Alsalameen E, Sagor K, Haji A, Alfaifi A, Alabdulkareem K, Ibrahim M. Clin Drug Investig. 2022 Oct;42(10):799-806. doi: 10.1007/s40261-022-01195-x. Epub 2022 Aug 30. PMID: 36040662

SARS-CoV-2 Secondary Attack Rates in Vaccinated and Unvaccinated Household Contacts during Replacement of Delta with Omicron Variant, Spain.
López-Muñoz I, Torrella A, Pérez-Quílez O, Castillo-Zuza A, Martró E, Bordoy AE, Saludes V, Blanco I, Soldevila L, Estrada O, Valerio L, Roure S, Vallès X. Emerg Infect Dis. 2022 Oct;28(10):1999-2008. doi: 10.3201/eid2810.220494. Epub 2022 Aug 29. PMID: 36037811

Parental COVID-19 vaccination hesitancy among parents of children aged 5-18 years in Thailand: a cross-sectional survey study.
Parinyarux P, Sunkonkit K, Yotsombut K. J Pharm Policy Pract. 2022 Oct 6;15(1):59. doi: 10.1186/s40545-022-00455-7. PMID: 36203192

Sequential Deletions of Interferon Inhibitors MGF110-9L and MGF505-7R Result in Sterile Immunity against the Eurasia Strain of Africa Swine Fever.
Ding M, Dang W, Liu H, Zhang K, Xu F, Tian H, Huang H, Shi Z, Sunkang Y, Qin X, Zhang Y, Zheng H. J Virol. 2022 Oct 5:e0119222. doi: 10.1128/jvi.01192-22. Online ahead of print. PMID: 36197109

CLL-050 Induction of Neutralizing Antibodies in Chronic Lymphocytic Leukemia Patients After SARS-CoV-2 mRNA Vaccination: A Monocentric Experience.
Mavilia F, Pratesi F, Baratè C, Benedetti E, Guerri V, Sammuri P, Migliorini P, Galimberti S. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S262-S263. doi: 10.1016/S2152-2650(22)01318-0. PMID: 36163863

Respiratory Syncytial Virus.
Khan L. Pediatr Ann. 2022 Oct;51(10):e376-e378. doi: 10.3928/19382359-20220807-01. Epub 2022 Oct 1. PMID: 36215084

Type 1 diabetes mellitus following SARS-CoV-2 mRNA vaccination.
Aydoğan Bİ, Ünlütürk U, Cesur M. Endocrine. 2022 Oct;78(1):42-46. doi: 10.1007/s12020-022-03130-8. Epub 2022 Jul 9. PMID: 35809159

The genetic characterization of hemagglutinin (HA), neuraminidase (NA) and polymerase acidic (PA) genes of H3N2 influenza viruses circulated in Guangdong Province of China during 2019-2020.
Liu Y, Jin W, Guan W, Zeng Z, Yang Z. Virus Genes. 2022 Oct;58(5):392-402. doi: 10.1007/s11262-022-01923-7. Epub 2022 Jul 28. PMID: 35900664

Physical activity and antibody persistence 6 months after the second dose of CoronaVac in immunocompromised patients.
Gualano B, Lemes ÍR, da Silva RP, Pinto AJ, Mazzolani BC, Smaira FI, Sieczkowska SM, Aikawa NE, Pasoto S, Medeiros-Ribeiro AC, Saad C, Yuk E, Silva C, Swinton P, Hallal PC, Roschel H, Bonfa E. Scand J Med Sci Sports. 2022 Oct;32(10):1510-1515. doi: 10.1111/sms.14213. Epub 2022 Jul 26. PMID: 35844042

Comparative effectiveness and durability of COVID-19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign.
Lytras T, Kontopidou F, Lambrou A, Tsiodras S. J Med Virol. 2022 Oct;94(10):5044-5050. doi: 10.1002/jmv.27934. Epub 2022 Jun 23. PMID: 35701379

Associations of Neuralgic Amyotrophy with COVID-19 Vaccination: Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database.
Kim JE, Park J, Min YG, Hong YH, Song TJ. Muscle Nerve. 2022 Oct 10. doi: 10.1002/mus.27734. Online ahead of print. PMID: 36214181

A point-of-care dot blot ELISA assay for detection of protective antibody against canine adenovirus, canine parvovirus, and canine distemper virus is diagnostically accurate.
Egerer A, Schaefer Z, Larson L. J Am Vet Med Assoc. 2022 Oct 4:1-6. doi: 10.2460/javma.22.05.0224. Online ahead of print. PMID: 36198054

Effect of heat-inactivated Mycobacterium avium subspecies paratuberculosis (MAP) **vaccine** on the lesions and immunopathology developed in target tissues of naturally MAP-infected goats.

Agulló-Ros I, Andrada M, Pérez-Sancho M, Roy Á, Bezos J, Bonnet T, Moreno I, Paz-Sánchez Y, Domínguez M, Gómez-Villamandos JC, Domínguez L, Risalde MA. Vet Microbiol. 2022 Oct;273:109543. doi: 10.1016/j.vetmic.2022.109543. Epub 2022 Aug 8. PMID: 36037619

γδ TCRs Function as Innate-like Receptors in the Bovine γδ T Cell Response against *Leptospira*.
Gillespie AE, Loonie K, Lefevre L, Hope JC, Baldwin CL, Connelley TK. J Immunol. 2022 Oct 7:ji2200319. doi: 10.4049/jimmunol.2200319. Online ahead of print. PMID: 36207133

Dermatopathology of COVID-19 infection and vaccination.
Fernández-Figueras MT. Pathologie (Heidelb). 2022 Oct 5:1-5. doi: 10.1007/s00292-022-01126-9. Online ahead of print. PMID: 36197514

A Randomized Trial of Behavioral Nudges Delivered Through Text Messages to Increase Influenza Vaccination Among Patients With an Upcoming Primary Care Visit.
Patel MS, Milkman KL, Gandhi L, Graci HN, Gromet D, Ho H, Kay JS, Lee TW, Rothschild J, Akinola M, Beshears J, Bogard JE, Buttenheim A, Chabris C, Chapman GB, Choi JJ, Dai H, Fox CR, Goren A, Hilchey MD, Hmurovic J, John LK, Karlan D, Kim M, Laibson D, Lamberton C, Madrian BC, Meyer MN, Modanu M, Nam J, Rogers T, Rondina R, Saccardo S, Shermohammed M, Soman D, Sparks J, Warren C, Weber M, Berman R, Evans CN, Lee SH, Snider CK, Tsukayama E, Van den Bulte C, Volpp KG, Duckworth AL. Am J Health Promot. 2022 Oct 4:8901171221131021. doi: 10.1177/08901171221131021. Online ahead of print. PMID: 36195982

A single intranasal administration of AdCOVID protects against SARS-CoV-2 infection in the upper and lower respiratory tracts.
Schultz MD, Suschak JJ, Botta D, Silva-Sanchez A, King RG, Detchemendy TW, Meshram CD, Foote JB, Zhou F, Tipper JL, Zhang J, Harrod KS, Leal SM Jr, Randall TD, Roberts MS, Georges B, Lund FE. Hum Vaccin Immunother. 2022 Oct 4:2127292. doi: 10.1080/21645515.2022.2127292. Online ahead of print. PMID: 36194255

The impact of HPV **vaccine** narratives on social media: Testing narrative engagement theory with a diverse sample of young adults.
Leader AE, Miller-Day M, Rey RT, Selvan P, Pezalla AE, Hecht ML. Prev Med Rep. 2022 Jul 22;29:101920. doi: 10.1016/j.pmedr.2022.101920. eCollection 2022 Oct. PMID: 36161120

Ensuring **vaccine** potency and availability: how evidence shaped Gavi's Immunization Supply Chain Strategy.
Prosser W, Sagar K, Seidel M, Alva S. BMC Health Serv Res. 2022 Oct 7;22(1):1237. doi: 10.1186/s12913-022-08616-9. PMID: 36207724

Infection Rate of SARS-CoV-2 in Asymptomatic Healthcare Workers, Sweden, June 2022.
Blom K, Havervall S, Marking U, Norin NG, Bacchus P, Groenheit R, Bråve A, Thålin C, Klingström J. Emerg Infect Dis. 2022 Oct;28(10):2119-2121. doi: 10.3201/eid2810.221093. Epub 2022 Aug 23. PMID: 35997692

Analysis of vaccination strategy against cystic echinococcosis developed in the Province of Río Negro, Argentina: 12 years of work.

Labanchi JL, Poggio TV, Gutiérrez A, Mujica G, Araya D, Grizmado C, Calabro A, Crowley P, Arezo M, Seleiman M, Herrero E, Sepulveda L, Talmon G, Diaz O, Larrieu E. Vet Parasitol. 2022 Oct;310:109790. doi: 10.1016/j.vetpar.2022.109790. Epub 2022 Aug 28. PMID: 36054969

The impact of COVID-19 vaccines on fertility-A systematic review and meta-analysis.
Zaçe D, La Gatta E, Petrella L, Di Pietro ML. Vaccine. 2022 Oct 6;40(42):6023-6034. doi: 10.1016/j.vaccine.2022.09.019. Epub 2022 Sep 12. PMID: 36137903

Long-term humoral immunity decline in hemodialysis patients following severe acute respiratory syndrome coronavirus 2 vaccination: A cohort study.
Goggins E, Sharma B, Ma JZ, Gautam J, Bowman B. Health Sci Rep. 2022 Oct 3;5(6):e854. doi: 10.1002/hsr2.854. eCollection 2022 Nov. PMID: 36210878

Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization.
Jagodinsky JC, Bates AM, Clark PA, Sriramaneni RN, Havighurst TC, Chakravarty I, Nystuen EJ, Kim K, Sondel PM, Jin WJ, Morris ZS. J Immunother Cancer. 2022 Oct;10(10):e005103. doi: 10.1136/jitc-2022-005103. PMID: 36192087

Heterologous adenovirus-vector/messenger RNA regimen is associated with improved severe acute respiratory syndrome coronavirus 2 humoral response in liver transplant recipients.
Mendizabal M, Ducasa N, Benencio P, Anders M, Cairo F, Barbero M, Etcheves P, Alter A, Scarton G, Abraldes JG, Biglione M, Mauro E. Hepatol Commun. 2022 Oct;6(10):2850-2859. doi: 10.1002/hep4.2034. Epub 2022 Jul 28. PMID: 35903818

Safety and Adverse Events Following COVID-19 Vaccination among People with Epilepsy: A Cross-Sectional Study.
Ong MJY, Khoo CS, Lee YX, Poongkuntran V, Tang CK, Choong YJ, Hod R, Tan HJ. Epilepsia Open. 2022 Oct 10. doi: 10.1002/epi4.12658. Online ahead of print. PMID: 36214033

Knowledge, attitudes, and behaviors toward COVID-19 vaccination in a sample of Italian healthcare workers.
Regazzi L, Marziali E, Lontano A, Villani L, Paladini A, Calabrò GE, Laurenti P, Ricciardi W, Cadeddu C. Hum Vaccin Immunother. 2022 Oct 5:2116206. doi: 10.1080/21645515.2022.2116206. Online ahead of print. PMID: 36197125

Neutralizing antibody responses in vaccinated and unvaccinated individuals infected with Omicron BA.1 variant.
Oh SJ, O SW, Choi YJ, Kim JM, Kim D, Kim IH, Park AK, Kim HM, Rhee JE, Jang YR, Yoo CK, Kim JY, Kim EJ. J Clin Virol. 2022 Oct;155:105253. doi: 10.1016/j.jcv.2022.105253. Epub 2022 Aug 3. PMID: 35988369

Timing of headache after COVID-19 vaccines and its association with cerebrovascular events: An analysis of 41,700 VAERS reports.
Garcia-Azorin D, Baykan B, Beghi E, Doheim MF, Fernandez-de-Las-Penas C, Gezegen H, Guekht A, Hoo FK, Santacatterina M, Sejvar J, Tamborska AA, Thakur KT, Westenberg E, Winkler AS, Frontera JA;

Contributors from the Global COVID-19 Neuro Research Coalition. Cephalalgia. 2022 Oct;42(11-12):1207-1217. doi: 10.1177/03331024221099231. Epub 2022 May 6. PMID: 35514199

Glycosylation of OVA antigen-loaded PLGA nanoparticles enhances DC-targeting for cancer vaccination.
Chou PY, Lin SY, Wu YN, Shen CY, Sheu MT, Ho HO. J Control Release. 2022 Oct 8:S0168-3659(22)00672-1. doi: 10.1016/j.jconrel.2022.10.002. Online ahead of print. PMID: 36220488

The Monkeypox Outbreak and Implications for Dental Practice.
Samaranayake L, Anil S. Int Dent J. 2022 Oct;72(5):589-596. doi: 10.1016/j.identj.2022.07.006. Epub 2022 Aug 5. PMID: 35934521

Immune responses to Sinopharm/BBIBP-CorV in individuals in Sri Lanka.
Jeewandara C, Aberathna IS, Pushpakumara PD, Kamaladasa A, Guruge D, Wijesinghe A, Gunasekera B, Tanussiya S, Kuruppu H, Ranasinghe T, Dayarathne S, Dissanayake O, Gamalath N, Ekanayake D, Jayamali J, Jayathilaka D, Dissanayake M, Madusanka D, Jayadas TT, Mudunkotuwa A, Somathilake G, Harvie M, Nimasha T, Danasekara S, Wijayamuni R, Schimanski L, Rijal P, Tan TK, Dong T, Townsend A, Ogg GS, Malavige GN. Immunology. 2022 Oct;167(2):275-285. doi: 10.1111/imm.13536. Epub 2022 Jul 12. PMID: 35758860

Optimization of the heterologous expression and purification of Plasmodium falciparum generative cell specific 1 in Escherichia coli.
Ayoub Meigouni M, Abouie Mehrizi A, Fazaeli A, Zakeri S, Djadid ND. Protein Expr Purif. 2022 Oct;198:106126. doi: 10.1016/j.pep.2022.106126. Epub 2022 May 31. PMID: 35661702

COVID-19 vaccinations and counselling: a mixed-methods survey of Australian general practice in July 2021.
O'Brien K, Barnes K, Hall Dykgraaf S, Douglas KA. Aust J Prim Health. 2022 Oct;28(5):399-407. doi: 10.1071/PY21301. PMID: 35710104

Evolving dynamics of Aedes-borne diseases in Africa: a cause for concern.
Sang R, Lutomiah J, Chepkorir E, Tchouassi DP. Curr Opin Insect Sci. 2022 Oct;53:100958. doi: 10.1016/j.cois.2022.100958. Epub 2022 Jul 22. PMID: 35878761

Shining a spotlight on the dangerous consequences of conspiracy theories.
Jolley D, Marques MD, Cookson D. Curr Opin Psychol. 2022 Oct;47:101363. doi: 10.1016/j.copsyc.2022.101363. Epub 2022 May 28. PMID: 35732091

"Common variable immunodeficiency: Challenges for diagnosis".
Wang LA, Abbott JK. J Immunol Methods. 2022 Oct;509:113342. doi: 10.1016/j.jim.2022.113342. Epub 2022 Aug 24. PMID: 36027932

COVID-19 vaccination may enhance hippocampal neurogenesis in adults.
Kumar A, Narayan RK, Prasoon P, Jha RK, Kumar S, Kumari C, Pandey SN, Faiq MA. Brain Behav Immun. 2022 Oct 3;107:87-89. doi: 10.1016/j.bbi.2022.09.020. Online ahead of print. PMID: 36202167

CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.

Chang A, Lai L, Akhtar A, Linderman S, Orellana-Noia V, Saini M, Valanparambil R, Blum K, Allen P, Lechowicz M, Romancik J, Ayers A, O'Leary C, Churnetski M, Kives M, Nooka A, Koff J, Dhodapkar M, Suthar M, Cohen J, Ahmed R. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S281-S282. doi: 10.1016/S2152-2650(22)01352-0. PMID: 36163898

Antibody levels in people with diabetes after one dose of the ChAdOx1 nCoV-19 (AZD1222) **vaccine**.
Rangsrisaeneepitak V, Porntharukchareon T, Dechates B, Sirisreetreerux S, Tawinprai K. Diabetol Int. 2022 May 5;13(4):637-643. doi: 10.1007/s13340-022-00582-1. eCollection 2022 Oct. PMID: 35528950

COVID-19 and Thrombosis: Clinical Aspects.
Urano T, Yasumoto A, Yokoyama K, Horiuchi H, Morishita E, Suzuki Y. Curr Drug Targets. 2022 Oct 5. doi: 10.2174/1389450123666221005092350. Online ahead of print. PMID: 36200150

Recommendations for Prevention and Control of Influenza in Children, 2022-2023.
COMMITTEE ON INFECTIOUS DISEASES. Pediatrics. 2022 Oct 1;150(4):e2022059274. doi: 10.1542/peds.2022-059274. PMID: 36065749

Effectiveness of COVID-19 Booster on the Risk of Hospitalization Among Medicare Beneficiaries.
Mehta HB, Li S, Goodwin JS. Mayo Clin Proc. 2022 Oct;97(10):1780-1793. doi: 10.1016/j.mayocp.2022.06.029. Epub 2022 Jul 12. PMID: 36202492

Astragalus polysaccharide alleviated the inhibition of CSFV C-strain replication caused by PRRSV via the TLRs/NF-κB/TNF-α pathways.
Chen D, Kang H, Tuo T, Wang L, Xia Y, Zhang Y, Zhou L, Ge X, Han J, Guo X, Yang H. Virus Res. 2022 Oct 2;319:198854. doi: 10.1016/j.virusres.2022.198854. Epub 2022 Jul 1. PMID: 35788015

Tick-borne encephalitis epidemic in Hungary 1951-2021: The story and lessons learned.
Egyed L, Nagy A, Lakos A, Zöldi V, Lang Z. Zoonoses Public Health. 2022 Oct 7. doi: 10.1111/zph.13003. Online ahead of print. PMID: 36205381

COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management.
Li P, Liu Y, Cheng Z, Yu X, Li Y. Biomed Pharmacother. 2022 Oct;154:113568. doi: 10.1016/j.biopha.2022.113568. Epub 2022 Aug 17. PMID: 36029543

Evaluation of a rapid semiquantitative lateral flow assay for the prediction of serum neutralizing activity against SARS-CoV-2 variants.
Hirabidian M, Bocket L, Demaret J, Vuotto F, Rabat A, Faure K, Labalette M, Hober D, Lefevre G, Alidjinou EK. J Clin Virol. 2022 Oct;155:105268. doi: 10.1016/j.jcv.2022.105268. Epub 2022 Aug 17. PMID: 35998394

Intravesical Ty21a Treatment of Non-muscle-invasive Bladder Cancer Shows a Good Safety Profile.
Lucca I, Derré L, Cesson V, Bohner P, Crettenand F, Rodrigues-Dias S, Dartiguenave F, Masnada A, Texeira-Pereira C, Benmerzoug S, Chevalier M, Domingos-Pereira S, Nguyen S, Polak L, Schneider A, Roth B, Jichlinski P, Nardelli-Haefliger D. Eur Urol Open Sci. 2022 Oct 3;45:55-58. doi: 10.1016/j.euros.2022.09.004. eCollection 2022 Nov. PMID: 36212980

Rotavirus immunisation status affects the efficacy of *Lacticaseibacillus rhamnosus* GG for the treatment of children with acute diarrhoea: a meta-analysis.
Lo Vecchio A, Nunziata F, Bruzzese D, Conelli ML, Guarino A. Benef Microbes. 2022 Oct 4;13(4):283-294. doi: 10.3920/BM2022.0024. Epub 2022 Aug 25. PMID: 36004717

SARS-CoV-2 Omicron BA.1 Challenge after Ancestral or Delta Infection in Mice.
Baz M, Deshpande N, Mackenzie-Kludas C, Mordant F, Anderson D, Subbarao K. Emerg Infect Dis. 2022 Oct 3;28(11). doi: 10.3201/eid2811.220718. Online ahead of print. PMID: 36191630

Silicon-bridged (1→1)-disaccharides: an umpoled glycomimetic scaffold.
Choutka J, Kratochvíl M, Císařová I, Pohl R, Kaminský J, Parkan K. Org Biomol Chem. 2022 Oct 5;20(38):7613-7621. doi: 10.1039/d2ob01161a. PMID: 35861668

Does the BNT162b2 **Vaccine** Trigger Antimelanoma Differentiation-Associated Gene 5 Antibody-Positive Interstitial Lung Disease?
Mutoh T, Takahashi M, Nagai T, Kudo M. J Rheumatol. 2022 Oct 1:jrheum.220730. doi: 10.3899/jrheum.220730. Online ahead of print. PMID: 36182114

Serum polyethylene glycol-specific IgE and IgG in patients with hypersensitivity to COVID-19 mRNA vaccines.
Mouri M, Imamura M, Suzuki S, Kawasaki T, Ishizaki Y, Sakurai K, Nagafuchi H, Matsumura N, Uchida M, Ando T, Yoshioka K, Ooka S, Sugihara T, Miyoshi H, Mori M, Okada T, Yamaguchi M, Kunishima H, Kato M, Kawahata K. Allergol Int. 2022 Oct;71(4):512-519. doi: 10.1016/j.alit.2022.05.007. Epub 2022 Jun 6. PMID: 35718709

Emergence of a multidrug-resistant and virulent Streptococcus pneumoniae lineage mediates serotype replacement after PCV13: an international whole-genome sequencing study.
Lo SW, Mellor K, Cohen R, Alonso AR, Belman S, Kumar N, Hawkins PA, Gladstone RA, von Gottberg A, Veeraraghavan B, Ravikumar KL, Kandasamy R, Pollard SAJ, Saha SK, Bigogo G, Antonio M, Kwambana-Adams B, Mirza S, Shakoor S, Nisar I, Cornick JE, Lehmann D, Ford RL, Sigauque B, Turner P, Moïsi J, Obaro SK, Dagan R, Diawara I, Skoczyńska A, Wang H, Carter PE, Klugman KP, Rodgers G, Breiman RF, McGee L, Bentley SD, Muñoz-Almagro C, Varon E; Global Pneumococcal Sequencing Consortium. Lancet Microbe. 2022 Oct;3(10):e735-e743. doi: 10.1016/S2666-5247(22)00158-6. Epub 2022 Aug 16. PMID: 35985351

COVID-19 Outcomes and Risk Factors Among People Living with HIV.
Spinelli MA, Jones BLH, Gandhi M. Curr HIV/AIDS Rep. 2022 Oct;19(5):425-432. doi: 10.1007/s11904-022-00618-w. Epub 2022 Aug 5. PMID: 35930187

Predictors of COVID-19 **vaccine** hesitancy in Germany: a cross-sectional, population-based study.
Umakanthan S, Lawrence S. Postgrad Med J. 2022 Oct;98(1164):756-764. doi: 10.1136/postgradmedj-2021-141365. Epub 2022 Feb 3. PMID: 35115377

Lower incidence of hospital-treated infections in infants under 3 months of age vaccinated with BCG.
Nieminen H, Lahdenkari M, Syrjänen RK, Nohynek H, Ruokokoski E, Palmu AA. Vaccine. 2022 Oct 6;40(42):6048-6054. doi: 10.1016/j.vaccine.2022.09.004. Epub 2022 Sep 9. PMID: 36096971

Outcomes of Cerebral Venous Thrombosis due to **Vaccine**-Induced Immune Thrombotic Thrombocytopenia After the Acute Phase.
van de Munckhof A, Lindgren E, Kleinig TJ, Field TS, Cordonnier C, Krzywicka K, Poli S, Sánchez van Kammen M, Borhani-Haghighi A, Lemmens R, Scutelnic A, Ciccone A, Gattringer T, Wittstock M, Dizonno V, Devroye A, Elkady A, Günther A, Cervera A, Mengel A, Chew BLA, Buck B, Zanferrari C, Garcia-Esperon C, Jacobi C, Soriano C, Michalski D, Zamani Z, Blacquiere D, Johansson E, Cuadrado-Godia E, Vuillier F, Bode FJ, Caparros F, Maier F, Tsivgoulis G, Katzberg HD, Duan J, Burrow J, Pelz J, Mbroh J, Oen J, Schouten J, Zimmermann J, Ng K, Garambois K, Petruzzellis M, Carvalho Dias M, Ghiasian M, Romoli M, Miranda M, Wronski M, Skjelland M, Almasi-Dooghaee M, Cuisenier P, Murphy S, Timsit S, Coutts SB, Schönenberger S, Nagel S, Hiltunen S, Chatterton S, Cox T, Bartsch T, Shaygannejad V, Mirzaasgari Z, Middeldorp S, Levi MM, Kremer Hovinga JA, Jood K, Tatlisumak T, Putaala J, Heldner MR, Arnold M, Aguiar de Sousa D, Ferro JM, Coutinho JM; Cerebral Venous Sinus Thrombosis With Thrombocytopenia Syndrome Study Group. Stroke. 2022 Oct;53(10):3206-3210. doi: 10.1161/STROKEAHA.122.039575. Epub 2022 Sep 9. PMID: 36082668

Prevalence and Risk Factors of Anal HPV Infection in MSM Living With HIV: Identifying the Target Groups to Prioritize for Immunization.
Bruzzesi E, Galli L, Poli A, Bossolasco S, Cernuschi M, Spagnuolo V, Tamburini AM, Canetti D, Messina E, Gianotti N, Raccagni AR, Castagna A, Nozza S. J Acquir Immune Defic Syndr. 2022 Oct 1;91(2):226-231. doi: 10.1097/QAI.0000000000003057. PMID: 35973060

Effect of pneumococcal conjugate vaccines and SARS-CoV-2 on antimicrobial resistance and the emergence of Streptococcus pneumoniae serotypes with reduced susceptibility in Spain, 2004-20: a national surveillance study.
Sempere J, Llamosí M, López Ruiz B, Del Río I, Pérez-García C, Lago D, Gimeno M, Coronel P, González-Camacho F, Domenech M, Yuste J. Lancet Microbe. 2022 Oct;3(10):e744-e752. doi: 10.1016/S2666-5247(22)00127-6. Epub 2022 Aug 3. PMID: 35932764

Vaccine-induced seroconversion in participants in the North Carolina COVID-19 community Research Partnership.
Friedman-Klabanoff DJ, Tjaden AH, Santacatterina M, Munawar I, Sanders JW, Herrington DM, Wierzba TF, Berry AA; COVID-19 Community Research Partnership. Vaccine. 2022 Oct 6;40(42):6133-6140. doi: 10.1016/j.vaccine.2022.09.021. Epub 2022 Sep 12. PMID: 36117003

The clinical impact of multiple prevention strategies for respiratory syncytial virus infections in infants and high-risk toddlers in the United States.
Ektare V, Lang J, Choi Y, Finelli L. Vaccine. 2022 Oct 6;40(42):6064-6073. doi: 10.1016/j.vaccine.2022.08.011. Epub 2022 Sep 9. PMID: 36096968

Highly stable gold nanoparticle-antigen conjugates with self-adjuvanting property for induction of robust antigen-specific immune responses.
Lin ZY, Chen YH, Wu YW, Chen MC. Colloids Surf B Biointerfaces. 2022 Oct 2;220:112897. doi: 10.1016/j.colsurfb.2022.112897. Online ahead of print. PMID: 36215893

Reporting of COVID-19 Reinfection and Potential Role of Immunosuppressant/Immunomodulating Agents: A Cross-Sectional Observational Analysis Based on a Spontaneous Reporting Database.

Beyzarov E, Chen Y, Caubel P. Clin Drug Investig. 2022 Oct;42(10):807-812. doi: 10.1007/s40261-022-01200-3. Epub 2022 Sep 14. PMID: 36100734

Comparisons of the risk of myopericarditis between COVID-19 patients and individuals receiving COVID-19 vaccines: a population-based study.
Chou OHI, Zhou J, Lee TTL, Kot T, Lee S, Wai AKC, Wong WT, Zhang Q, Cheng SH, Liu T, Vassiliou VS, Cheung BMY, Tse G. Clin Res Cardiol. 2022 Oct;111(10):1098-1103. doi: 10.1007/s00392-022-02007-0. Epub 2022 Mar 25. PMID: 35333945

[Polyethylengylcole - Friend or Foe?].
Bayerl C, Herbst M. Laryngorhinootologie. 2022 Oct;101(10):784-786. doi: 10.1055/a-1861-7047. Epub 2022 Sep 29. PMID: 36174565

Detection and isolation of QX-like infectious bronchitis virus in Japan.
Nakanishi M, Soma J, Takahashi S, Matsune K, Ono M, Oosumi T. J Vet Med Sci. 2022 Oct 6. doi: 10.1292/jvms.22-0325. Online ahead of print. PMID: 36198507

Viral Neoliberalism: The Road to Herd Immunity Still A Rocky One.
Holst J. Int J Health Serv. 2022 Oct 9:207314221131214. doi: 10.1177/00207314221131214. Online ahead of print. PMID: 36214180

Experiences of New Zealand public health messaging while in lockdown.
Officer TN, McKinlay E, Imlach F, Kennedy J, Churchward M, McBride-Henry K. Aust N Z J Public Health. 2022 Oct 3. doi: 10.1111/1753-6405.13297. Online ahead of print. PMID: 36190208

Shortening Duration of Swine Exhibitions to Reduce Risk for Zoonotic Transmission of Influenza A Virus.
McBride DS, Nolting JM, Nelson SW, Spurck MM, Bliss NT, Kenah E, Trock SC, Bowman AS. Emerg Infect Dis. 2022 Oct;28(10):2035-2042. doi: 10.3201/eid2810.220649. Epub 2022 Sep 9. PMID: 36084650

State-of-the-art on monkeypox virus: an emerging zoonotic disease.
Shafaati M, Zandi M. Infection. 2022 Oct 3. doi: 10.1007/s15010-022-01935-3. Online ahead of print. PMID: 36192607

Use of financial incentives to increase adult vaccination coverage: a narrative review of lessons learned from COVID-19 and other adult vaccination efforts.
Schwalbe N, Hanbali L, Nunes MC, Lehtimaki S. Vaccine X. 2022 Oct 6;12:100225. doi: 10.1016/j.jvacx.2022.100225. Online ahead of print. PMID: 36217357

Vaccination efforts for Buruli ulcer.
Chavda VP, Haritopoulou-Sinanidou M, Bezbaruah R, Apostolopoulos V. Expert Rev Vaccines. 2022 Oct;21(10):1419-1428. doi: 10.1080/14760584.2022.2113514. Epub 2022 Aug 24. PMID: 35962475

The role of microbiota in colorectal cancer.
Dokht Khosravi A, Seyed-Mohammadi S, Teimoori A, Asarehzadegan Dezfuli A. Folia Microbiol (Praha). 2022 Oct;67(5):683-691. doi: 10.1007/s12223-022-00978-1. Epub 2022 May 10. PMID: 35534716

COVID-19 Vaccination Coverage Among People Experiencing Homelessness in a Highly Vaccinated Midwest County-Dane County, Wisconsin, 2021.
Gibson C, Schumann C, Neuschel K, McBride JA. J Infect Dis. 2022 Oct 7;226(Supplement_3):S335-S339. doi: 10.1093/infdis/jiac303. PMID: 36208167

mRNA (BNT162b2) and Inactivated (CoronaVac) COVID-19 Vaccination and Risk of Adverse Events and Acute Diabetic Complications in Patients with Type 2 Diabetes Mellitus: A Population-Based Study.
Wan EYF, Chui CSL, Mok AHY, Xu W, Yan VKC, Lai FTT, Li X, Wong CKH, Chan EWY, Lui DTW, Tan KCB, Hung IFN, Lam CLK, Leung GM, Wong ICK. Drug Saf. 2022 Oct 2:1-14. doi: 10.1007/s40264-022-01228-6. Online ahead of print. PMID: 36184720

Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2.
Vogel E, Kocher K, Priller A, Cheng CC, Steininger P, Liao BH, Körber N, Willmann A, Irrgang P, Held J, Moosmann C, Schmidt V, Beileke S, Wytopil M, Heringer S, Bauer T, Brockhoff R, Jeske S, Mijocevic H, Christa C, Salmanton-García J, Tinnefeld K, Bogdan C, Yazici S, Knolle P, Cornely OA, Überla K, Protzer U, Schober K, Tenbusch M. EBioMedicine. 2022 Oct 4;85:104294. doi: 10.1016/j.ebiom.2022.104294. Online ahead of print. PMID: 36206622

Limited humoral and specific T-cell responses after SARS-CoV-2 vaccination in PLWH with poor immune reconstitution.
Benet S, Blanch-Lombarte O, Ainsua-Enrich E, Pedreño-Lopez N, Muñoz-Basagoiti J, Raïch-Regué D, Perez-Zsolt D, Peña R, Jiménez E, de la Concepción MLR, Ávila C, Cedeño S, Escribà T, Romero-Martín L, Alarcón-Soto Y, Rodriguez-Lozano GF, Miranda C, González S, Bailón L, Blanco J, Massanella M, Brander C, Clotet B, Paredes R, Esteve M, Izquierdo-Useros N, Carrillo J, Prado JG, Moltó J, Mothe B. J Infect Dis. 2022 Oct 6:jiac406. doi: 10.1093/infdis/jiac406. Online ahead of print. PMID: 36200261

Multiple COVID-19 **vaccine** doses in CLL and MBL improve immune responses with progressive and high seroconversion.
Shen Y, Freeman JA, Holland J, Naidu K, Solterbeck A, Van Bilsen N, Downe P, Kerridge I, Wallman LL, Akerman A, Aggarwal A, Milogiannakis V, Martins Costa Gomes G, Doyle CM, Sandgren KJ, Turville S, Cunningham AL, Mulligan SP. Blood. 2022 Oct 7:blood.2022017814. doi: 10.1182/blood.2022017814. Online ahead of print. PMID: 36206503

SARS-CoV-2 mRNA vaccination is not associated with the induction of anti-HLA or non-HLA antibodies.
Wijtvliet VPWM, Verheyden S, Depreter B, Heylen C, Coeman E, Abrams S, De Winter BY, Massart A, Hellemans R, Pipeleers L, Claas FHJ, Ariën KK, Wissing KM, Abramowicz D, Ledeganck KJ. Transpl Immunol. 2022 Oct;74:101670. doi: 10.1016/j.trim.2022.101670. Epub 2022 Jul 11. PMID: 35835296

Heterologous gam-COVID-vac (sputnik V)/mRNA-1273 (moderna) vaccination induces a stronger humoral response than homologous sputnik V in a real-world data analysis.
Pereson MJ, Amaya L, Neukam K, Baré P, Echegoyen N, Badano MN, Lucero A, Martelli A, Garcia GH, Videla C, Martínez AP, Di Lello FA. Clin Microbiol Infect. 2022 Oct;28(10):1382-1388. doi: 10.1016/j.cmi.2022.05.009. Epub 2022 May 17. PMID: 35595128

Rational attenuation of RNA viruses with zinc finger antiviral protein.
Gonçalves-Carneiro D, Mastrocola E, Lei X, DaSilva J, Chan YF, Bieniasz PD. Nat Microbiol. 2022 Oct;7(10):1558-1567. doi: 10.1038/s41564-022-01223-8. Epub 2022 Sep 8. PMID: 36075961

Spike-antibody responses to COVID-19 vaccination by demographic and clinical factors in a prospective community cohort study.
Shrotri M, Fragaszy E, Nguyen V, Navaratnam AMD, Geismar C, Beale S, Kovar J, Byrne TE, Fong WLE, Patel P, Aryee A, Braithwaite I, Johnson AM, Rodger A, Hayward AC, Aldridge RW. Nat Commun. 2022 Oct 2;13(1):5780. doi: 10.1038/s41467-022-33550-z. PMID: 36184633

Peptide mimotopes to emulate carbohydrates.
Matsubara T. Chem Soc Rev. 2022 Oct 3;51(19):8160-8173. doi: 10.1039/d2cs00470d. PMID: 36128765

Advanced cardiac imaging in the spectrum of COVID-19 related cardiovascular involvement.
Palmisano A, Gambardella M, D'Angelo T, Vignale D, Ascione R, Gatti M, Peretto G, Federico F, Shah A, Esposito A. Clin Imaging. 2022 Oct;90:78-89. doi: 10.1016/j.clinimag.2022.07.009. Epub 2022 Jul 29. PMID: 35930942

Immunization with messenger RNA vaccines against COVID-19 in adolescents with a history of multisystem inflammatory syndrome: a case series.
Curtti T, Agrimbau Vázquez J, Yori S, Kantarovsky A, Torolla J, Di Santo M, Hammermüller E, Urrutia L, Parra A. Arch Argent Pediatr. 2022 Oct 6:e202202757. doi: 10.5546/aap.2022-02757.eng. Online ahead of print. PMID: 36194695

Codon-optimization of the respiratory syncytial virus (RSV) G protein expressed in a vesicular stomatitis virus (VSV) vector improves immune responses in a cotton rat model.
Brakel KA, Ma Y, Binjawadagi R, Harder O, Watts M, Li J, Binjawadagi B, Niewiesk S. Virology. 2022 Oct;575:101-110. doi: 10.1016/j.virol.2022.08.017. Epub 2022 Sep 6. PMID: 36096069

Humoral cross-coronavirus responses against the S2 region in children with Kawasaki disease.
Monteiro A, Chang AJ, Welliver RR, Baron S, Hicar MD. Virology. 2022 Oct;575:83-90. doi: 10.1016/j.virol.2022.08.010. Epub 2022 Sep 2. PMID: 36088793

Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variant.
Seaman MS, Siedner MJ, Boucau J, Lavine CL, Ghantous F, Liew MY, Mathews JI, Singh A, Marino C, Regan J, Uddin R, Choudhary MC, Flynn JP, Chen G, Stuckwisch AM, Lipiner T, Kittilson A, Melberg M, Gilbert RF, Reynolds Z, Iyer SL, Chamberlin GC, Vyas TD, Vyas JM, Goldberg MB, Luban J, Li JZ, Barczak AK, Lemieux JE. JCI Insight. 2022 Oct 10;7(19):e159944. doi: 10.1172/jci.insight.159944. PMID: 36214224

DRPADC: A novel drug repositioning algorithm predicting adaptive drugs for COVID-19.
Xie G, Xu H, Li J, Gu G, Sun Y, Lin Z, Zhu Y, Wang W, Wang Y, Shao J. Comput Chem Eng. 2022 Oct;166:107947. doi: 10.1016/j.compchemeng.2022.107947. Epub 2022 Aug 4. PMID: 35942213

Historically black college and university (HBCU) COVID-19 return-to-campus policies and prevention measures-Fall 2021.

Gazmararian JA, Liu Z, McLeod E, Cavallo M, Jiwani S, Paniagua U, Guest JL, Thomas ES, Good MK. J Am Coll Health. 2022 Oct 6:1-8. doi: 10.1080/07448481.2022.2128685. Online ahead of print. PMID: 36200830

Antibiotic resistance in aquaculture and aquatic organisms: a review of current nanotechnology applications for sustainable management.
Okeke ES, Chukwudozie KI, Nyaruaba R, Ita RE, Oladipo A, Ejeromedoghene O, Atakpa EO, Agu CV, Okoye CO. Environ Sci Pollut Res Int. 2022 Oct;29(46):69241-69274. doi: 10.1007/s11356-022-22319-y. Epub 2022 Aug 15. PMID: 35969340

Pestilence and famine: Continuing down the vicious cycle with COVID-19.
Hyder S, Chhem RK, Claes F, Karlsson EA. PLoS Pathog. 2022 Oct 6;18(10):e1010810. doi: 10.1371/journal.ppat.1010810. eCollection 2022 Oct. PMID: 36201447

COVID-19 Vaccination in those with mental health difficulties: A guide to assist decision-making in England, Scotland, and Wales.
Ross C, Brown P, Brown C, Chopra A, Adshead G, Tracy D, Towers K, McKay C, Black I, Forsberg L. Med Sci Law. 2022 Oct;62(4):275-282. doi: 10.1177/00258024221086054. Epub 2022 Mar 11. PMID: 35274997

Monitoring bromide loss in bromoacetyl-derivatized polyribosylribitol polysaccharide in Haemophilus influenzae type b for PedvaxHIB® by capillary electrophoresis and NMR spectroscopy.
Rustandi RR, Hamm M, Onimus M, Yuan Y, Anderson CL, Zong C. Vaccine. 2022 Oct 6;40(42):6012-6016. doi: 10.1016/j.vaccine.2022.09.026. Epub 2022 Sep 17. PMID: 36123258

Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges.
Deen J, Holmgren J, Clemens JD. Lancet Infect Dis. 2022 Oct;22(10):e292-e298. doi: 10.1016/S1473-3099(22)00215-8. Epub 2022 May 6. PMID: 35533702

The Excluded Voices from Africa's Sahel: Alternative Meanings of Health in Narratives of Resistance to the Global Polio Eradication Initiative in Northern Nigeria.
Olufowote JO, Livingston DJ. Health Commun. 2022 Oct;37(11):1389-1400. doi: 10.1080/10410236.2021.1895416. Epub 2021 Mar 8. PMID: 33685303

A Qualitative Study of Home Health Aides' Perspectives towards COVID-19 Vaccination.
Russell D, Onorato N, Stern A, Vergez S, Oberlink M, Luebke M, Feldman PH, McDonald MV, Sterling MR. J Appl Gerontol. 2022 Oct 8:7334648221130677. doi: 10.1177/07334648221130677. Online ahead of print. PMID: 36210760

Ipsilateral Radial Neuropathy after COVID-19 mRNA Vaccination in an Immunocompetent Young Man.
Lee SM, Hong JY, Kim SY, Na SJ. Yonsei Med J. 2022 Oct;63(10):966-970. doi: 10.3349/ymj.2022.0038. PMID: 36168250

Prioritizing interventions for preventing COVID-19 outbreaks in military basic training.
España G, Perkins TA, Pollett SD, Smith ME, Moore SM, Kwon PO, Hall TL, Beagle MH Jr, Murray CK, Hakre S, Peel SA, Modjarrad K, Scott PT. PLoS Comput Biol. 2022 Oct 7;18(10):e1010489. doi: 10.1371/journal.pcbi.1010489. Online ahead of print. PMID: 36206315

The duration of protection against clinical malaria provided by the combination of seasonal RTS,S/AS01$_E$ vaccination and seasonal malaria chemoprevention versus either intervention given alone.
Cairns M, Barry A, Zongo I, Sagara I, Yerbanga SR, Diarra M, Zoungrana C, Issiaka D, Sienou AA, Tapily A, Sanogo K, Kaya M, Traore S, Diarra K, Yalcouye H, Sidibe Y, Haro A, Thera I, Snell P, Grant J, Tinto H, Milligan P, Chandramohan D, Greenwood B, Dicko A, Ouedraogo JB. BMC Med. 2022 Oct 7;20(1):352. doi: 10.1186/s12916-022-02536-5. PMID: 36203149

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Outbreak at a College With High Coronavirus Disease 2019 (COVID-19) Vaccination Coverage-Connecticut, August 2021-September 2021.
Bart SM, Curtiss CC, Earnest R, Lobe-Costonis R, Peterson H, McWilliams C, Billig K, Hadler JL, Grubaugh ND, Arcelus VJ, Sosa LE. Clin Infect Dis. 2022 Oct 3;75(Supplement_2):S243-S250. doi: 10.1093/cid/ciac422. PMID: 35675696

Hesitancy for receiving regular SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis from the UK-REACH study.
Veli N, Martin CA, Woolf K, Nazareth J, Pan D, Al-Oraibi A, Baggaley RF, Bryant L, Nellums LB, Gray LJ, Khunti K, Pareek M; UK-REACH Study Collaborative Group. BMC Med. 2022 Oct 10;20(1):386. doi: 10.1186/s12916-022-02588-7. PMID: 36210437

Influence of Digital Intervention Messaging on Influenza Vaccination Rates Among Adults With Cardiovascular Disease in the United States: Decentralized Randomized Controlled Trial.
Marshall NJ, Lee JL, Schroeder J, Lee WN, See J, Madjid M, Munagala MR, Piette JD, Tan L, Vardeny O, Greenberg M, Liska J, Mercer M, Samson S. J Med Internet Res. 2022 Oct 7;24(10):e38710. doi: 10.2196/38710. PMID: 36206046

Severity of influenza illness by seasonal influenza vaccination status among hospitalised patients in four South American countries, 2013-19: a surveillance-based cohort study.
Regan AK, Arriola CS, Couto P, Duca L, Loayza S, Nogareda F, de Almeida WAF, Antman J, Araya S, Avendaño Vigueras MA, Battaglia Paredes SC, Brstilo IF, Bustos P, Fandiño ME, Fasce R, Giovacchini CM, González Caro CI, von Horoch M, Del Valle Juarez M, Katz N, Olivares MF, da Silva DA, da Silva ET, Sotomayor V, Vergara N, Azziz-Baumgartner E, Ropero AM. Lancet Infect Dis. 2022 Oct 4:S1473-3099(22)00493-5. doi: 10.1016/S1473-3099(22)00493-5. Online ahead of print. PMID: 36206790

Transmission Dynamics and Effectiveness of Control Measures during COVID-19 Surge, Taiwan, April-August 2021.
Akhmetzhanov AR, Cheng HY, Linton NM, Ponce L, Jian SW, Lin HH. Emerg Infect Dis. 2022 Oct;28(10):2051-2059. doi: 10.3201/eid2810.220456. Epub 2022 Sep 14. PMID: 36104202

Chlamydia psittaci plasmid-encoded CPSIT_P7 induces macrophage polarization to enhance the antibacterial response through TLR4-mediated MAPK and NF-κB pathways.
He S, Wang C, Huang Y, Lu S, Li W, Ding N, Chen C, Wu Y. Biochim Biophys Acta Mol Cell Res. 2022 Oct;1869(10):119324. doi: 10.1016/j.bbamcr.2022.119324. Epub 2022 Jul 6. PMID: 35809864

Immunotherapy: an alternative promising therapeutic approach against cancers.
Gupta SL, Basu S, Soni V, Jaiswal RK. Mol Biol Rep. 2022 Oct;49(10):9903-9913. doi: 10.1007/s11033-022-07525-8. Epub 2022 Jun 27. PMID: 35759082

A review targeting the infection by CHIKV using computational and experimental approaches.
Kumar D, Kumari K, Chandra R, Jain P, Vodwal L, Gambhir G, Singh P. J Biomol Struct Dyn. 2022 Oct;40(17):8127-8141. doi: 10.1080/07391102.2021.1904004. Epub 2021 Mar 30. PMID: 33783313

The use of adenoviral vectors in gene therapy and **vaccine** approaches.
Araújo NM, Rubio IGS, Toneto NPA, Morale MG, Tamura RE. Genet Mol Biol. 2022 Oct 7;45(3 Suppl 1):e20220079. doi: 10.1590/1678-4685-GMB-2022-0079. eCollection 2022. PMID: 36206378 F

Zoster-associated Prothrombotic Plasma Exosomes and Increased Stroke Risk.
Bubak AN, Coughlan C, Posey J, Saviola AJ, Niemeyer CS, Lewis SWR, Lopez SB, Solano A, Tyring SK, Delaney C, Neeves KB, Mahalingam R, Hansen KC, Nagel MA. J Infect Dis. 2022 Oct 6:jiac405. doi: 10.1093/infdis/jiac405. Online ahead of print. PMID: 36200236

Pickering emulsion stabilized by Chinese Yam polysaccharides PLGA for enhanced humoral and cellular immune responses.
Zhang Y, Fan Z, Gu P, Mao N, Peng S, Song Z, Liu Z, Yang Y, Wang D. Colloids Surf B Biointerfaces. 2022 Oct;218:112746. doi: 10.1016/j.colsurfb.2022.112746. Epub 2022 Aug 2. PMID: 35961114

Australia's 'No Jab No Play' policies: history, design and rationales.
Attwell K, Drislane S. Aust N Z J Public Health. 2022 Oct;46(5):640-646. doi: 10.1111/1753-6405.13289. Epub 2022 Aug 18. PMID: 35980171

Vaccination with human alphapapillomavirus-derived L2 multimer protects against human betapapillomavirus challenge, including in epidermodysplasia verruciformis model mice.
Olczak P, Wong M, Tsai HL, Wang H, Kirnbauer R, Griffith AJ, Lambert PF, Roden R. Virology. 2022 Oct;575:63-73. doi: 10.1016/j.virol.2022.08.006. Epub 2022 Aug 23. PMID: 36070626

Exploring the dynamic variations of viral genomes via a novel genetic network.
Zhang Y, Wen J, Xi K, Pan Q. Mol Phylogenet Evol. 2022 Oct;175:107583. doi: 10.1016/j.ympev.2022.107583. Epub 2022 Jul 8. PMID: 35810971

Continued evolution of the Eurasian avian-like H1N1 swine influenza viruses in China.
Meng F, Chen Y, Song Z, Zhong Q, Zhang Y, Qiao C, Yan C, Kong H, Liu L, Li C, Yang H, Chen H. Sci China Life Sci. 2022 Oct 9. doi: 10.1007/s11427-022-2208-0. Online ahead of print. PMID: 36219302

Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination.
Delshad M, Sanaei MJ, Pourbagheri-Sigaroodi A, Bashash D. Int Immunopharmacol. 2022 Oct;111:109128. doi: 10.1016/j.intimp.2022.109128. Epub 2022 Aug 8. PMID: 35963158

Does an Intradermal Vaccination for Monkeypox Make Sense?
Mrsny RJ. AAPS J. 2022 Oct 4;24(6):104. doi: 10.1208/s12248-022-00754-6. PMID: 36195806

Airline stock markets reaction to the COVID-19 outbreak and vaccines: An event study.
Martins AM, Cró S. J Air Transp Manag. 2022 Oct;105:102281. doi: 10.1016/j.jairtraman.2022.102281. Epub 2022 Aug 22. PMID: 36034526

First report on the isolation of Chlamydia abortus from female dromedary camels with ovarian hydrobursitis.
Ali A, Derar DR, Mousa HA, Osman SA, Refaai W, Almundarij TI, Al-Dubaib MA, Allam SA. Theriogenology. 2022 Oct 1;191:102-108. doi: 10.1016/j.theriogenology.2022.07.009. Epub 2022 Jul 19. PMID: 35981409

A secreted MIF homologue from Trichinella spiralis binds to and interacts with host monocytes.
Huang S, Qiu Y, Ma Z, Su Z, Hong W, Zuo H, Wu X, Yang Y. Acta Trop. 2022 Oct;234:106615. doi: 10.1016/j.actatropica.2022.106615. Epub 2022 Jul 25. PMID: 35901919

Immune senescence in multiple myeloma-a role for mitochondrial dysfunction?
Seymour F, Carmichael J, Taylor C, Parrish C, Cook G. Leukemia. 2022 Oct;36(10):2368-2373. doi: 10.1038/s41375-022-01653-7. Epub 2022 Jul 25. PMID: 35879358

What to expect when AGEP is induced by terbinafine? Case report and critical review of the literature.
de Oliveira GV, Maia MLP, Leão FAA, Sad EF, Miotto IZ, Silva MR, Ramos-E-Silva M. Mycoses. 2022 Oct;65(10):918-925. doi: 10.1111/myc.13506. Epub 2022 Aug 25. PMID: 35876217

Microbial carbohydrate-binding toxins - From etiology to biotechnological application.
Danielewicz N, Rosato F, Dai W, Römer W, Turnbull WB, Mairhofer J. Biotechnol Adv. 2022 Oct;59:107951. doi: 10.1016/j.biotechadv.2022.107951. Epub 2022 Apr 6. PMID: 35398203

Neutralizing and interfering human antibodies define the structural and mechanistic basis for antigenic diversion.
Patel PN, Dickey TH, Hopp CS, Diouf A, Tang WK, Long CA, Miura K, Crompton PD, Tolia NH. Nat Commun. 2022 Oct 6;13(1):5888. doi: 10.1038/s41467-022-33336-3. PMID: 36202833

Association of culturally competent care with influenza vaccination coverage in the United States.
Paguio JA, Ojikutu BO, Alfonso PG, Yao JS, Amen TB, Dee EC, Escota GV. Vaccine. 2022 Oct 5:S0264-410X(22)01065-9. doi: 10.1016/j.vaccine.2022.08.066. Online ahead of print. PMID: 36208977

Genomic Epidemiology and Phylodynamic Analysis of Enterovirus A71 Reveal Its Transmission Dynamics in Asia.
Xiao J, Huang K, Lu H, Song Y, Han Z, Zhang M, Li J, Zhou X, Chen J, Yu Q, Yang M, Yan D, Ji T, Yang Q, Zhu S, Xu W, Zhang Y. Microbiol Spectr. 2022 Oct 6:e0195822. doi: 10.1128/spectrum.01958-22. Online ahead of print. PMID: 36200890

SARS-CoV-2 spike protein antibody titers 6 months after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in Japan.
Kanai D, Wakui H, Haze T, Azushima K, Kinguchi S, Tsukamoto S, Kanaoka T, Urate S, Toya Y, Hirawa N, Kato H, Watanabe F, Hanaoka K, Hanaoka M, Mitsuhashi H, Yamaguchi S, Ohnishi T, Tamura K. Clin Exp Nephrol. 2022 Oct;26(10):988-996. doi: 10.1007/s10157-022-02243-8. Epub 2022 Jun 25. PMID: 35751753

PCV13 Pediatric Routine Schedule Completion and Adherence Before and During the COVID-19 Pandemic in the United States.
Huang L, Nguyen JL, Alfred T, Perdrizet J, Cane A, Arguedas A. Infect Dis Ther. 2022 Oct 10. doi: 10.1007/s40121-022-00699-5. Online ahead of print. PMID: 36219342

A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network.
Neuhann JM, Stemler J, Carcas A, Frías-Iniesta J, Bethe U, Heringer S, Tischmann L, Zarrouk M, Cüppers A, König F, Posch M, Cornely OA. Trials. 2022 Oct 8;23(1):865. doi: 10.1186/s13063-022-06791-y. PMID: 36209129

COVID-19 vaccination and mask wearing behaviors in the United States, August 2020 - June 2021.
Floyd CJ, Joachim GE, Boulton ML, Zelner J, Wagner AL. Expert Rev Vaccines. 2022 Oct;21(10):1487-1493. doi: 10.1080/14760584.2022.2104251. Epub 2022 Jul 22. PMID: 35856246

Adverse Event Following Immunization (AEFI) in Children: An Analysis of Reporting in VigiAccess.
Pandey D, Mehta G, Sachdeva M, Tripathi R. Drug Res (Stuttg). 2022 Oct;72(8):435-440. doi: 10.1055/a-1852-5335. Epub 2022 Jun 20. PMID: 35724674

Trust in Doctors, Positive Attitudes, and Vaccination Behavior: The Role of Doctor-Patient Communication in H1N1 Vaccination.
Borah P, Hwang J. Health Commun. 2022 Oct;37(11):1423-1431. doi: 10.1080/10410236.2021.1895426. Epub 2021 Mar 9. PMID: 33685304

Novel chimeric proteins mimicking SARS-CoV-2 spike epitopes with broad inhibitory activity.
Cano-Muñoz M, Polo-Megías D, Cámara-Artigas A, Gavira JA, López-Rodríguez MJ, Laumond G, Schmidt S, Demiselle J, Bahram S, Moog C, Conejero-Lara F. Int J Biol Macromol. 2022 Oct 8:S0141-8130(22)02263-2. doi: 10.1016/j.ijbiomac.2022.10.031. Online ahead of print. PMID: 36220405

Monkeypox virus: The changing facets of a zoonotic pathogen.
Forni D, Cagliani R, Molteni C, Clerici M, Sironi M. Infect Genet Evol. 2022 Oct 4;105:105372. doi: 10.1016/j.meegid.2022.105372. Online ahead of print. PMID: 36202208

Recombinant vaccines in 2022: a perspective from the cell factory.
de Pinho Favaro MT, Atienza-Garriga J, Martínez-Torró C, Parladé E, Vázquez E, Corchero JL, Ferrer-Miralles N, Villaverde A. Microb Cell Fact. 2022 Oct 5;21(1):203. doi: 10.1186/s12934-022-01929-8. PMID: 36199085

Collection, compilation and analysis of bacterial vaccines.
Gupta S, Sharma N, Naorem LD, Jain S, Raghava GPS. Comput Biol Med. 2022 Oct;149:106030. doi: 10.1016/j.compbiomed.2022.106030. Epub 2022 Sep 2. PMID: 36084380

Dermatological adverse reactions after vaccination with BNT162b2 in a cohort of healthcare workers.
Ruiz-Villaverde R, Rivera-Izquierdo M, Gil-Villalba A, Pegalajar-García MD, Pérez-Rojas J, Soler-Iborte E, Valero-Ubierna MC. Int J Dermatol. 2022 Oct;61(10):1289-1293. doi: 10.1111/ijd.16336. Epub 2022 Jun 30. PMID: 35775137

Immunomodulatory effects of chitosan nanoparticles as **vaccine** delivery agent against lymphatic filariasis through mucosal immunization.
Balasubramaniyan M, Santhanam M, Vinayagam V, Perumal K. Int J Biol Macromol. 2022 Oct 8:S0141-8130(22)02257-7. doi: 10.1016/j.ijbiomac.2022.10.025. Online ahead of print. PMID: 36220408

Current therapeutic strategies and possible effective drug delivery strategies against COVID-19.
Dastidar DG, Ghosh D, Ghosh S, Chakrabarti G. Curr Drug Deliv. 2022 Oct 4. doi: 10.2174/1567201819666221004094509. Online ahead of print. PMID: 36200202

Enhancement of antiviral activity of egg yolk antibodies against Chinese sacbrood virus.
Feng S, Li A, Wang B, Hu L, Li S, Li Y, Yu Y, Zhang H, Yuan J. Virus Res. 2022 Oct 2;319:198878. doi: 10.1016/j.virusres.2022.198878. Epub 2022 Jul 23. PMID: 35882266

As the virus evolves, so too must we: a drug developer's perspective : We need a new paradigm in searching for next-generation countermeasures.
Fang FF. Virol J. 2022 Oct 10;19(1):159. doi: 10.1186/s12985-022-01887-y. PMID: 36217145

Elucidation of the role of nucleolin as a cell surface receptor for nucleic acid-based adjuvants.
Kitagawa S, Matsuda T, Washizaki A, Murakami H, Yamamoto T, Yoshioka Y. NPJ Vaccines. 2022 Oct 6;7(1):115. doi: 10.1038/s41541-022-00541-6. PMID: 36202858

Tumor immunotherapy boosted by R837 nanocrystals through combining chemotherapy and mild hyperthermia.
Meng Z, Fang X, Fu B, Qian C, Yang Z, Bai Y, Tao X, Huang H, Ma C, Miao W, Ren H, Wang A, Li X. J Control Release. 2022 Oct;350:841-856. doi: 10.1016/j.jconrel.2022.09.009. Epub 2022 Sep 14. PMID: 36096366

A comprehensive examination of association between belief in **vaccine** misinformation and vaccination intention in the COVID-19 context.
Kim K, Lee CJ, Ihm J, Kim Y. J Health Commun. 2022 Oct 7:1-15. doi: 10.1080/10810730.2022.2130479. Online ahead of print. PMID: 36205037

FHUSPA2/10 is a bactericidal monoclonal antibody targeting multiple repeated sequences of Moraxella catarrhalis UspA2.
Donnarumma D, Giusti F, Ysebaert C, Hermand P, Devos N, Ferlenghi I, Margarit I, Rossi Paccani S, Scarselli M, Norais N. Vaccine. 2022 Oct 3:S0264-410X(22)01156-2. doi: 10.1016/j.vaccine.2022.09.048. Online ahead of print. PMID: 36202640

Chemical complementarity between tumor resident, T-cell receptor CDR3s and MAGEA3/6 correlates with increased melanoma survival: Potential relevance to MAGE **vaccine** auto-reactivity.
Eakins RA, Chobrutskiy A, Teer JK, Patel DN, Hsiang M, Huda TI, Zaman S, Sexton WJ, Coppola D, Falasiri S, Blanck G, Chobrutskiy BI. Mol Immunol. 2022 Oct;150:58-66. doi: 10.1016/j.molimm.2022.08.001. Epub 2022 Aug 17. PMID: 35987136

Augmenting glycosylation-directed folding pathways enhances the fidelity of HIV Env immunogen production in plants.

Margolin E, Allen JD, Verbeek M, Chapman R, Meyers A, van Diepen M, Ximba P, Motlou T, Moore PL, Woodward J, Strasser R, Crispin M, Williamson AL, Rybicki EP. Biotechnol Bioeng. 2022 Oct;119(10):2919-2937. doi: 10.1002/bit.28169. Epub 2022 Jul 19. PMID: 35781691

Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 **vaccine** over six months in heart transplant recipients - implications for the omicron variant.
Peled Y, Afek A, Kreiss Y, Rahav G, Nemet I, Kliker L, Indenbaum V, Ram E, Lavee J, Segev A, Matezki S, Sternik L, Raanani E, Lustig Y, Patel JK, Mandelboim M. J Heart Lung Transplant. 2022 Oct;41(10):1417-1425. doi: 10.1016/j.healun.2022.05.014. Epub 2022 May 24. PMID: 35710484

Use of surveillance data to elucidate household clustering of SARS-CoV-2 in Fulton County, Georgia a major metropolitan area.
Liu CY, Smith S, Chamberlain AT, Gandhi NR, Khan F, Williams S, Shah S. Ann Epidemiol. 2022 Oct 6:S1047-2797(22)00245-9. doi: 10.1016/j.annepidem.2022.09.010. Online ahead of print. PMID: 36210009

Time of Day of BNT162b2 COVID-19 Immunization Affects Total SARS-CoV-2 Antibody Levels but Not Neutralizing Activity.
Filippatos F, Tatsi EB, Efthymiou V, Syriopoulou V, Michos A. J Biol Rhythms. 2022 Oct;37(5):562-566. doi: 10.1177/07487304221100951. Epub 2022 Jun 22. PMID: 35730571

Poliovirus nonpermissive CD155 knockout cells derived from RD cell line for handling poliovirus potentially infectious materials in virology laboratories.
Nandi SS, Sawant S, Gohil T, Lambe U, Sangal L, Patel D, Krishnasamy K, Ghoshal U, Harvey P, Deshpande J. J Med Virol. 2022 Oct;94(10):4901-4909. doi: 10.1002/jmv.27897. Epub 2022 Jun 8. PMID: 35642597

Does information by pharmacists convince the public to get vaccinated for pneumococcal disease and herpes zoster?
Bayraktar-Ekincioglu A, Kara E, Bahap M, Cankurtaran M, Demirkan K, Unal S. Ir J Med Sci. 2022 Oct;191(5):2193-2200. doi: 10.1007/s11845-021-02778-x. Epub 2021 Oct 28. PMID: 34708289

Epidemiological assessment of SARS-CoV-2 reinfection.
Almadhi M, Alsayyad AS, Conroy R, Atkin S, Awadhi AA, Al-Tawfiq JA, AlQahtani M. Int J Infect Dis. 2022 Oct;123:9-16. doi: 10.1016/j.ijid.2022.07.075. Epub 2022 Aug 2. PMID: 35931371

Mathematical modeling and AI based decision making for COVID-19 suspects backed by novel distance and similarity measures on plithogenic hypersoft sets.
Ahmad MR, Afzal U. Artif Intell Med. 2022 Oct;132:102390. doi: 10.1016/j.artmed.2022.102390. Epub 2022 Sep 2. PMID: 36207091

Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody.
Kumar S, Patel A, Lai L, Chakravarthy C, Valanparambil R, Reddy ES, Gottimukkala K, Davis-Gardner ME, Edara VV, Linderman S, Nayak K, Dixit K, Sharma P, Bajpai P, Singh V, Frank F, Cheedarla N, Verkerke HP, Neish AS, Roback JD, Mantus G, Goel PK, Rahi M, Davis CW, Wrammert J, Godbole S, Henry AR, Douek DC, Suthar MS, Ahmed R, Ortlund E, Sharma A, Murali-Krishna K, Chandele A. Sci Adv. 2022 Oct 7;8(40):eadd2032. doi: 10.1126/sciadv.add2032. Epub 2022 Oct 5. PMID: 36197988

An update on the considerations for patients with rheumatic disease being treated with rituximab during the COVID-19 pandemic and the potential drug treatment strategies.
Bennett B, Tahir H, Ganguly S, Moorthy A. Expert Opin Pharmacother. 2022 Oct 5:1-6. doi: 10.1080/14656566.2022.2131395. Online ahead of print. PMID: 36180063

Construction of an attenuated glutamyl endopeptidase deletion strain of Nocardia seriolae.
Wang W, Hou S, Chen J, Xia L, Lu Y. Fish Shellfish Immunol. 2022 Oct;129:161-169. doi: 10.1016/j.fsi.2022.08.044. Epub 2022 Aug 21. PMID: 36002085

Memory CD8⁺ T cell diversity and B cell responses correlate with protection against SARS-CoV-2 following mRNA vaccination.
Brasu N, Elia I, Russo V, Montacchiesi G, Stabile SA, De Intinis C, Fesi F, Gizzi K, Macagno M, Montone M, Mussolin B, Grifoni A, Faravelli S, Marchese S, Forneris F, De Francesco R, Sette A, Barnaba V, Sottile A, Sapino A, Pace L. Nat Immunol. 2022 Oct;23(10):1445-1456. doi: 10.1038/s41590-022-01313-z. Epub 2022 Sep 22. PMID: 36138186

COVID-19 positive donor for solid organ transplantation.
Peghin M, Grossi PA. J Hepatol. 2022 Oct;77(4):1198-1204. doi: 10.1016/j.jhep.2022.06.021. Epub 2022 Jul 4. PMID: 35798131

Engineering Self-Assembled Endolysin Nanoparticles against Antibiotic-Resistant Bacteria.
Dzuvor CKO, Shanbhag BK, Younas T, Shen HH, Haritos VS, He L. ACS Appl Bio Mater. 2022 Oct 4. doi: 10.1021/acsabm.2c00741. Online ahead of print. PMID: 36194892

Unusual total anti-SARS-CoV-2 antibody kinetics observed during longitudinal monitoring after BNT162b2 vaccination.
Lapić I, Rogić D, Šegulja D, Kozmar A, Kmet M, Đerek L, Zadro R. Scand J Clin Lab Invest. 2022 Oct;82(6):486-491. doi: 10.1080/00365513.2022.2123388. Epub 2022 Sep 21. PMID: 36129409

Determinants of voluntary compliance: COVID-19 mitigation.
Li MH, Haynes K, Kulkarni R, Siddique AB. Soc Sci Med. 2022 Oct;310:115308. doi: 10.1016/j.socscimed.2022.115308. Epub 2022 Aug 25. PMID: 36041237

The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies.
Wang Y, Xiao S, Xia Y, Wang H. Clin Rev Allergy Immunol. 2022 Oct;63(2):152-165. doi: 10.1007/s12016-021-08898-7. Epub 2021 Sep 20. PMID: 34542806

COVID19-inhibitory activity of withanolides involves targeting of the host cell surface receptor ACE2: insights from computational and biochemical assays.
Kalra RS, Kumar V, Dhanjal JK, Garg S, Li X, Kaul SC, Sundar D, Wadhwa R. J Biomol Struct Dyn. 2022 Oct;40(17):7885-7898. doi: 10.1080/07391102.2021.1902858. Epub 2021 Apr 2. PMID: 33797339

Recent developments in the probiotics as live biotherapeutic products (LBPs) as modulators of gut brain axis related neurological conditions.
Ağagündüz D, Gençer Bingöl F, Çelik E, Cemali Ö, Özenir Ç, Özoğul F, Capasso R. J Transl Med. 2022 Oct 8;20(1):460. doi: 10.1186/s12967-022-03609-y. PMID: 36209124

Antibody response after two doses of homologous or heterologous SARS-CoV-2 vaccines in healthcare workers at health promotion centers: A prospective observational study.
Nah EH, Cho S, Park H, Kim S, Noh D, Kwon E, Cho HI. J Med Virol. 2022 Oct;94(10):4719-4726. doi: 10.1002/jmv.27911. Epub 2022 Jun 14. PMID: 35655438

Association Between Vaccination Status and Mortality Among Intubated Patients With COVID-19-Related Acute Respiratory Distress Syndrome.
Grapsa E, Adamos G, Andrianopoulos I, Tsolaki V, Giannakoulis VG, Karavidas N, Giannopoulou V, Sarri K, Mizi E, Gavrielatou E, Papathanakos G, Mantzarlis KD, Mastora Z, Magira E, Koulouras V, Kotanidou A, Siempos II. JAMA Netw Open. 2022 Oct 3;5(10):e2235219. doi: 10.1001/jamanetworkopen.2022.35219. PMID: 36205996

Infection with adenovirus, rotavirus, and coinfection among hospitalized children with gastroenteritis in an Egyptian university hospital.
Montasser KA, Youssef MI, Ghandour AA, Kamal M. J Med Virol. 2022 Oct;94(10):4950-4958. doi: 10.1002/jmv.27935. Epub 2022 Jun 22. PMID: 35705322

SARS-CoV-2 vaccination associated venous sinus thrombosis in three patients.
Finsterer J. J Appl Biomed. 2022 Oct;20(3):83-86. doi: 10.32725/jab.2022.011. Epub 2022 Jul 26. PMID: 36218128

Trends and focuses of hantavirus researches: a global bibliometric analysis and visualization from 1980 to 2020.
Wei X, Li X, Song S, Wen X, Jin T, Zhao C, Wu X, Liu K, Shao Z. Arch Public Health. 2022 Oct 1;80(1):218. doi: 10.1186/s13690-022-00973-5. PMID: 36182906

Change of HPV vaccination rates in Japan: the effect of individual notifications implemented by local governments.
Yagi A, Ueda Y, Nakagawa S, Ikeda S, Kakuda M, Hiramatsu K, Miyoshi A, Kobayashi E, Kimura T, Hirai K, Nakayama T, Miyagi E, Sekine M, Enomoto T, Kimura T. Int J Clin Oncol. 2022 Oct;27(10):1651-1659. doi: 10.1007/s10147-022-02213-w. Epub 2022 Jul 25. PMID: 35879494

SARS-CoV-2 humoral responses following booster BNT162b2 vaccination in patients with B-cell malignancies.
Terpos E, Fotiou D, Karalis V, Ntanasis-Stathopoulos I, Sklirou AD, Gavriatopoulou M, Malandrakis P, Iconomidou VA, Kastritis E, Trougakos IP, Dimopoulos MA. Am J Hematol. 2022 Oct;97(10):1300-1308. doi: 10.1002/ajh.26669. Epub 2022 Aug 2. PMID: 35871310

Interleukin-6 affects the severity of olfactory disorder: a cross-sectional survey of 148 patients who recovered from Omicron infection using the Sniffin' Sticks test in Tianjin, China.
Liang Y, Mao X, Kuang M, Zhi J, Zhang Z, Bo M, Zhang G, Lin P, Wang W, Shen Z. Int J Infect Dis. 2022 Oct;123:17-24. doi: 10.1016/j.ijid.2022.07.074. Epub 2022 Aug 2. PMID: 35931372

A UPLC-MS/MS Method for Plasma Biological Monitoring of Nirmatrelvir and Ritonavir in the Context of SARS-CoV-2 Infection and Application to a Case.

Guyon J, Novion M, Fulda V, Ducint D, Molimard M, Couzi L, Kaminski H, Salvo F, Bouchet S. J Am Soc Mass Spectrom. 2022 Oct 5;33(10):1975-1981. doi: 10.1021/jasms.2c00204. Epub 2022 Sep 9. PMID: 36084269

Will COVID-19 be the end for the public transit? Investigating the impacts of public health crisis on transit mode choice.
Mashrur SM, Wang K, Habib KN. Transp Res Part A Policy Pract. 2022 Oct;164:352-378. doi: 10.1016/j.tra.2022.08.020. Epub 2022 Aug 31. PMID: 36060447

Acute Hepatitis of Unknown Etiology Among Young Children: Research Agenda by the ESPGHAN Hepatology Committee.
Indolfi G, Czubkowski P, Fitzpatrick E, Gonzales E, Gupte G, Mancell S, Mozer-Glassberg Y, Nicastro E, Norman J, Stephenne X, Zellos A, Samyn M. J Pediatr Gastroenterol Nutr. 2022 Oct 1;75(4):543-548. doi: 10.1097/MPG.0000000000003567. Epub 2022 Sep 20. PMID: 35848740

Cytotoxic lesions of the corpus callosum after COVID-19 vaccination.
Ohara H, Shimizu H, Kasamatsu T, Kajita A, Uno K, Lai KW, Vellingiri B, Sugie K, Kinoshita M. Neuroradiology. 2022 Oct;64(10):2085-2089. doi: 10.1007/s00234-022-03010-y. Epub 2022 Jul 9. PMID: 35809100

Thrombosis, cancer, and COVID-19.
Brito-Dellan N, Tsoukalas N, Font C. Support Care Cancer. 2022 Oct;30(10):8491-8500. doi: 10.1007/s00520-022-07098-z. Epub 2022 May 14. PMID: 35567609

Humoral and cellular immune response over 9 months of mRNA-1273, BNT162b2 and ChAdOx1 vaccination in a University Hospital in Spain.
Fernández-Ciriza L, González Á, Del Pozo JL, Fernández-Montero A, Carmona-Torre F, Carlos S, Sarasa MDM, Reina G. Sci Rep. 2022 Oct 7;12(1):15606. doi: 10.1038/s41598-022-19537-2. PMID: 36207324

Designing appropriate, acceptable and feasible community-engagement approaches to improve routine immunisation outcomes in low- and middle-income countries: A synthesis of 3ie-supported formative evaluations.
Tripathi S, Jain M, Bagai A, Rao KV. PLoS One. 2022 Oct 7;17(10):e0275278. doi: 10.1371/journal.pone.0275278. eCollection 2022. PMID: 36206206

The engineered probiotics for the treatment of chronic diseases: A systematic review.
Barati M, Jabbari M, Abdi Ghavidel A, Nikmehr P, Arzhang P, Aynehchi A, Babashahi M, Mosharkesh E, Roshanravan N, Shabani M, Davoodi SH. J Food Biochem. 2022 Oct;46(10):e14343. doi: 10.1111/jfbc.14343. Epub 2022 Jul 26. PMID: 35880960

Optimized infection control practices augment the robust protective effect of vaccination for ESRD patients during a hemodialysis facility SARS-CoV-2 outbreak.
Meller ME, Pfaff BL, Borgert AJ, Richmond CS, Athas DM, Kenny PA, Sabin AP. Am J Infect Control. 2022 Oct;50(10):1118-1124. doi: 10.1016/j.ajic.2022.06.025. Epub 2022 Jul 19. PMID: 35868457

In silico inquest reveals the efficacy of Cannabis in the treatment of post-Covid-19 related neurodegeneration.

Sarkar I, Sen G, Bhattacharya M, Bhattacharyya S, Sen A. J Biomol Struct Dyn. 2022 Oct;40(17):8030-8039. doi: 10.1080/07391102.2021.1905556. Epub 2021 Apr 2. PMID: 33810774

Repurposing of anticancer phytochemicals for identifying potential fusion inhibitor for SARS-CoV-2 using molecular docking and molecular dynamics (MD) simulations.
Patel CN, Goswami D, Sivakumar PK, Pandya HA. J Biomol Struct Dyn. 2022 Oct;40(17):7744-7761. doi: 10.1080/07391102.2021.1902393. Epub 2021 Mar 22. PMID: 33749528

Actinobacillus suis isolated from diseased pigs are phylogenetically related but harbour different number of toxin gene copies in their genomes.
Kulathunga DGRS, Fakher AA, Costa MO. Vet Rec Open. 2022 Oct 3;9(1):e45. doi: 10.1002/vro2.45. eCollection 2022 Dec. PMID: 36213600

Promising natural products against SARS-CoV-2: Structure, function, and clinical trials.
Zhao Y, Deng S, Bai Y, Guo J, Kai G, Huang X, Jia X. Phytother Res. 2022 Oct;36(10):3833-3858. doi: 10.1002/ptr.7580. Epub 2022 Aug 5. PMID: 35932157

Estimation of yellow fever incidence in Togo between 2010 and 2020.
Zida-Compaore WIC, Gbeasor-Komlanvi FA, Tchankoni MK, Halatoko WA, Sadio AJ, Konu YR, Gnatou GY, Koba AK, Agbonon A, Ekouevi DK. Travel Med Infect Dis. 2022 Oct 5;50:102470. doi: 10.1016/j.tmaid.2022.102470. Online ahead of print. PMID: 36208863

The titers, duration, and residual clinical protection of passively transferred nasal and serum antibodies are similar among beef calves that nursed colostrum from vaccinated or unvaccinated dams and were challenged experimentally with bovine respiratory syncytial virus at three months of age.
Martínez DA, Chamorro MF, Passler T, Huber L, Walz PH, Thoresen M, Raithel G, Silvis S, Stockler R, Woolums AR. Am J Vet Res. 2022 Oct 4:1-9. doi: 10.2460/ajvr.22.07.0118. Online ahead of print. PMID: 36173761

Structural Reshaping of the Zinc-Finger Domain of the SARS-CoV-2 nsp13 Protein Using Bismuth(III) Ions: A Multilevel Computational Study.
Tolbatov I, Storchi L, Marrone A. Inorg Chem. 2022 Oct 3;61(39):15664-15677. doi: 10.1021/acs.inorgchem.2c02685. Epub 2022 Sep 20. PMID: 36125417

Respiratory syncytial virus, recurrent wheeze and asthma: A narrative review of pathophysiology, prevention and future directions.
Binns E, Tuckerman J, Licciardi PV, Wurzel D. J Paediatr Child Health. 2022 Oct;58(10):1741-1746. doi: 10.1111/jpc.16197. Epub 2022 Sep 8. PMID: 36073299

Guillain-Barré syndrome in an era of global infections and 21st century vaccination.
Lunn MP. Curr Opin Neurol. 2022 Oct 1;35(5):571-578. doi: 10.1097/WCO.0000000000001086. Epub 2022 Jul 18. PMID: 36069416

Pregnant and Postpartum Patients' Views of COVID-19 Vaccination.
Huang L, Riggan KA, Ashby GB, Rivera-Chiauzzi EY, Allyse MA. J Community Health. 2022 Oct;47(5):871-878. doi: 10.1007/s10900-022-01118-z. Epub 2022 Jul 16. PMID: 35841461

An in-silico investigation of potential natural polyphenols for the targeting of COVID main protease inhibitor.
Aljarba NH, Hasnain MS, Bin-Meferij MM, Alkahtani S. J King Saud Univ Sci. 2022 Oct;34(7):102214. doi: 10.1016/j.jksus.2022.102214. Epub 2022 Jul 2. PMID: 35811756

Intranasal and Intramuscular Immunization with Outer Membrane Vesicles from Serogroup C Meningococci Induced Functional Antibodies and Immunologic Memory.
Izeli Portilho A, Araujo Correa V, Dos Santos Cirqueira C, De Gaspari E. Immunol Invest. 2022 Oct;51(7):2066-2085. doi: 10.1080/08820139.2022.2107931. Epub 2022 Aug 11. PMID: 35950702

Investigation of monotherapy and combined anticoronaviral therapies against feline coronavirus serotype II in vitro.
Cook SE, Vogel H, Castillo D, Olsen M, Pedersen N, Murphy BG. J Feline Med Surg. 2022 Oct;24(10):943-953. doi: 10.1177/1098612X211048647. Epub 2021 Oct 22. PMID: 34676775

Dynamics of Neutralizing Antibodies and Binding Antibodies to Domains of SARS-CoV-2 Spike Protein in COVID-19 Survivors.
Phakaratsakul S, Manopwisedjaroen S, Boonarkart C, Kupatawintu P, Chaiwanichsiri D, Roytrakul T, Auewarakul P, Thitithanyanont A. Viral Immunol. 2022 Oct 3. doi: 10.1089/vim.2022.0059. Online ahead of print. PMID: 36190505

Managing organic dairy herd health: Current roles and possible future roles for veterinarians with organic dairy clientele.
Brock CC, Pempek JA, Jackson-Smith D, Habing GG, da Costa L, Weaver K. J Dairy Sci. 2022 Oct;105(10):8328-8341. doi: 10.3168/jds.2021-21720. Epub 2022 Aug 12. PMID: 35965116

Adolescent microglia stimulation produces long-lasting protection against chronic stress-induced behavioral abnormalities in adult male mice.
Wang Y, Hu Z, Liu H, Gu Y, Ye M, Lu Q, Lu X, Huang C. Brain Behav Immun. 2022 Oct;105:44-66. doi: 10.1016/j.bbi.2022.06.015. Epub 2022 Jul 1. PMID: 35781008

Potential mechanisms involved on how systemic IgG antibodies specific to vascular endothelial growth factor (VEGF) and induced by active immunotherapy decrease platelet derived free-VEGF.
Sánchez Ramírez J, Morera Díaz Y, Bequet-Romero M, Ayala Ávila M. Platelets. 2022 Oct 3;33(7):964-968. doi: 10.1080/09537104.2022.2042235. Epub 2022 Apr 3. PMID: 35373709

Development of optimized protocol for culturing African swine fever virus field isolates in MA104 cells.
Kwon HI, Do DT, Van Vo H, Lee SC, Kim MH, Nguyen DTT, Tran TM, Le QTV, Ngo TTN, Nguyen NM, Lee JY, Nguyen TT. Can J Vet Res. 2022 Oct;86(4):261-268. PMID: 36211218

MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
Jarius S, Bieber N, Haas J, Wildemann B. J Neurol. 2022 Oct;269(10):5198-5212. doi: 10.1007/s00415-022-11194-9. Epub 2022 Jun 23. PMID: 35737110

SARS-CoV-2 reinfections with BA.1 (Omicron) variant among fully vaccinated individuals in northeastern Brazil.

Freire-Neto FP, Teixeira DG, da Cunha DCS, Morais IC, Tavares CPM, Gurgel GP, Medeiros SDN, Santos DCD, Sales AO, Jeronimo SMB. PLoS Negl Trop Dis. 2022 Oct 3;16(10):e0010337. doi: 10.1371/journal.pntd.0010337. Online ahead of print. PMID: 36191040

The relationship between COVID-19 and fibromyalgia syndrome: prevalence, pandemic effects, symptom mechanisms, and COVID-19 vaccines.
Kocyigit BF, Akyol A. Clin Rheumatol. 2022 Oct;41(10):3245-3252. doi: 10.1007/s10067-022-06279-9. Epub 2022 Jul 8. PMID: 35804273

Immunogenicity against hepatitis C virus with mesenchymal stem cells of inbreed BALB/c mice sub cloned with HCVcp protein gene.
Masoudi MR, Rafati A. Transpl Immunol. 2022 Oct;74:101651. doi: 10.1016/j.trim.2022.101651. Epub 2022 Jun 25. PMID: 35764239

COVID-19 mRNA vaccines have no effect on endometrial receptivity after euploid embryo transfer.
Brandão P, Pellicer A, Meseguer M, Remohí J, Garrido N, García-Velasco JA. Reprod Biomed Online. 2022 Oct;45(4):688-695. doi: 10.1016/j.rbmo.2022.05.017. Epub 2022 May 29. PMID: 35803877

HPV Vaccination Initiation and Completion Among Pediatric, Adolescent, and Young Adult Cancer Survivors and a Comparison Population Sample Receiving Primary Care.
Kaddas HK, Ramsay JM, Ou JY, Fair D, Kepka D, Kirchhoff AC. J Pediatr Hematol Oncol. 2022 Oct 3. doi: 10.1097/MPH.0000000000002484. Online ahead of print. PMID: 36219685

Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination.
Habermann E, Gieselmann L, Tober-Lau P, Klotsche J, Albach FN, Ten Hagen A, Zernicke J, Ahmadov E, Arumahandi de Silva AN, Frommert LM, Kurth F, Sander LE, Burmester GR, Klein F, Biesen R. RMD Open. 2022 Oct;8(2):e002639. doi: 10.1136/rmdopen-2022-002639. PMID: 36216410

Comparison of vaccination efficacy using live or ultraviolet-inactivated influenza viruses introduced by different routes in a mouse model.
Baek K, Maharjan S, Akauliya M, Thapa B, Kim D, Kim J, Kim M, Kang M, Kim S, Bae JY, Lee KW, Park MS, Lee Y, Kwon HJ. PLoS One. 2022 Oct 10;17(10):e0275722. doi: 10.1371/journal.pone.0275722. eCollection 2022. PMID: 36215268

The risk and consequences of breakthrough SARS-CoV-2 infection in solid organ transplant recipients relative to non-immunosuppressed controls.
Vinson AJ, Anzalone AJ, Sun J, Dai R, Agarwal G, Lee SB, French E, Olex A, Ison MG, Mannon RB; N3C consortium. Am J Transplant. 2022 Oct;22(10):2418-2432. doi: 10.1111/ajt.17117. Epub 2022 Jun 20. PMID: 35674237

Medicinal plant compounds as promising inhibitors of coronavirus (COVID-19) main protease: an *in silico* study.
Jamali N, Soureshjani EH, Mobini GR, Samare-Najaf M, Clark CCT, Saffari-Chaleshtori J. J Biomol Struct Dyn. 2022 Oct;40(17):8073-8084. doi: 10.1080/07391102.2021.1906749. Epub 2021 May 10. PMID: 33970805

IL-1β induced by PRRSV co-infection inhibited CSFV C-strain proliferation via the TLR4/NF-κB/MAPK pathways and the NLRP3 inflammasome.
Chen D, Xu S, Jiang R, Guo Y, Yang X, Zhang Y, Zhou L, Ge X, Han J, Guo X, Yang H. Vet Microbiol. 2022 Oct;273:109513. doi: 10.1016/j.vetmic.2022.109513. Epub 2022 Jul 15. PMID: 35952491

Landscape of B Cell Receptor Repertoires in COVID-19 Patients Revealed Through CDR3 Sequencing of Immunoglobulin Heavy and Light Chains.
Gao H, Yu L, Yan F, Zheng Y, Huang H, Zhuang X, Zeng Y. Immunol Invest. 2022 Oct;51(7):1994-2008. doi: 10.1080/08820139.2022.2092407. Epub 2022 Jul 7. PMID: 35797435

Generation of a DNA-launched classical swine fever virus infectious clone packaged in bacterial artificial chromosome.
Fan D, Hu C, Yang X, Yang X, Chen Y, Lin J. Virus Res. 2022 Oct 6:198961. doi: 10.1016/j.virusres.2022.198961. Online ahead of print. PMID: 36209918

A generally minimalist strategy of constructing biomineralized high-efficiency personalized nanovaccine combined with immune checkpoint blockade for cancer immunotherapy.
Zhang S, Feng Y, Meng M, Li Z, Li H, Lin L, Xu C, Chen J, Hao K, Tang Z, Tian H, Chen X. Biomaterials. 2022 Oct;289:121794. doi: 10.1016/j.biomaterials.2022.121794. Epub 2022 Sep 7. PMID: 36113330

Higher vaccination rates predict reduction in SARS-CoV-2 transmission across the United States.
Au J. Infection. 2022 Oct;50(5):1255-1266. doi: 10.1007/s15010-022-01802-1. Epub 2022 Mar 22. PMID: 35314944

Identification of essential oil phytocompounds as natural inhibitors of Odorant-binding protein to prevent malaria through *in silico* approach.
Pundir H, Pant M, Joshi T, Bhat S, Pathak R, Bajpai AB, Chandra S, Tamta S. J Biomol Struct Dyn. 2022 Oct 10:1-11. doi: 10.1080/07391102.2022.2132419. Online ahead of print. PMID: 36214706

Development of facial palsy following COVID-19 vaccination: A systematic review.
Khurshid M, Ansari I, Ahmad H, Ghaffar H, Khurshid A, Shahid A, Essar MY, Ullah I, Cheema HA. Ann Med Surg (Lond). 2022 Oct;82:104758. doi: 10.1016/j.amsu.2022.104758. Epub 2022 Sep 30. PMID: 36212732

Equity considerations in COVID-19 vaccination studies of individuals with autoimmune inflammatory rheumatic diseases.
Wang H, Dewidar O, Whittle SL, Ghogomu E, Hazlewood G, Leder K, Mbuagbaw L, Pardo Pardo J, Robinson PC, Buchbinder R, Welch V. Arthritis Care Res (Hoboken). 2022 Oct 4. doi: 10.1002/acr.25034. Online ahead of print. PMID: 36194078

Prognostic value of lncRNA HOXA-AS3 in cervical cancer by targeting miR-29a-3p and its regulatory effect on tumor progression.
Xu H, Tang Y, He C, Tian Y, Ni R. J Obstet Gynaecol Res. 2022 Oct;48(10):2594-2602. doi: 10.1111/jog.15360. Epub 2022 Jul 11. PMID: 35817473

Inactivated Covid-19 **vaccine** did not undermine live birth and neonatal outcomes of women with frozen-thawed embryo transfer.

Cao M, Wu Y, Lin Y, Xu Z, Liang Z, Huang Q, Li S, B H, An C, Luo Y, Liu H, Liu J. Hum Reprod. 2022 Oct 6:deac220. doi: 10.1093/humrep/deac220. Online ahead of print. PMID: 36200874

COVID-19 Symptoms and Duration of Rapid Antigen Test Positivity at a Community Testing and Surveillance Site During Pre-Delta, Delta, and Omicron BA.1 Periods.
Marquez C, Kerkhoff AD, Schrom J, Rojas S, Black D, Mitchell A, Wang CY, Pilarowski G, Ribeiro S, Jones D, Payan J, Manganelli S, Rojas S, Lemus J, Jain V, Chamie G, Tulier-Laiwa V, Petersen M, DeRisi J, Havlir DV. JAMA Netw Open. 2022 Oct 3;5(10):e2235844. doi: 10.1001/jamanetworkopen.2022.35844. PMID: 36215069

Evaluating the Cost-Effectiveness of Hepatitis B Vaccination Strategies in High-impact Settings for Adults.
Hall EW, Gounder P, Angles J, Nelson NP, Rosenberg ES, Weng MK. J Viral Hepat. 2022 Oct 6. doi: 10.1111/jvh.13759. Online ahead of print. PMID: 36200313

Art v 1 IgE epitopes of patients and humanized mice are conformational.
Zabel M, Weber M, Kratzer B, Köhler C, Jahn-Schmid B, Gadermaier G, Gattinger P, Bidovec-Stojkovič U, Korošec P, Smole U, Wurzinger G, Chen KW, Panaitescu CB, Klimek L, Pablos I, Niespodziana K, Neunkirchner A, Keller W, Valenta R, Pickl WF. J Allergy Clin Immunol. 2022 Oct;150(4):920-930. doi: 10.1016/j.jaci.2022.04.031. Epub 2022 Jun 21. PMID: 35738928

Dissecting Naturally Arising Amino Acid Substitutions at Position L452 of SARS-CoV-2 Spike.
Tan TS, Toyoda M, Ode H, Barabona G, Hamana H, Kitamatsu M, Kishi H, Motozono C, Iwatani Y, Ueno T. J Virol. 2022 Oct 10:e0116222. doi: 10.1128/jvi.01162-22. Online ahead of print. PMID: 36214577

Adjuvant effect of IRES-based single-stranded RNA on melanoma immunotherapy.
Kwak HW, Hong SH, Park HJ, Park HJ, Bang YJ, Kim JY, Lee YS, Bae SH, Yoon H, Nam JH. BMC Cancer. 2022 Oct 5;22(1):1041. doi: 10.1186/s12885-022-10140-2. PMID: 36199130

Active vaccination campaign to increase seasonal influenza vaccination coverage: a monocenter experience in a cohort of Italian patients with systemic autoimmune diseases.
Chevallard M, Adinolfi A, Belloli L, Casu C, Di Cicco M, Destefani C, Di Rosa B, Gentile MG, Filippini DA, Luisi A, Muscarà M, Schito E, Ughi N, Verduci E, Vincenti EM, Zoppini L, Epis OM. Clin Rheumatol. 2022 Oct 7:1-6. doi: 10.1007/s10067-022-06380-z. Online ahead of print. PMID: 36205812

Risk of reinfection and disease after SARS-CoV-2 primary infection: Meta-analysis.
Flacco ME, Acuti Martellucci C, Baccolini V, De Vito C, Renzi E, Villari P, Manzoli L. Eur J Clin Invest. 2022 Oct;52(10):e13845. doi: 10.1111/eci.13845. Epub 2022 Aug 8. PMID: 35904405

Peimine inhibits variants of SARS-CoV-2 cell entry via blocking the interaction between viral spike protein and ACE2.
Wang WJ, Chen Y, Su WC, Liu YY, Shen WJ, Chang WC, Huang ST, Lin CW, Wang YC, Yang CS, Hou MH, Chou YC, Wu YC, Wang SC, Hung MC. J Food Biochem. 2022 Oct;46(10):e14354. doi: 10.1111/jfbc.14354. Epub 2022 Jul 27. PMID: 35894128

Analysis of hesitancy and motivational factors for COVID-19 vaccination among patients presenting to eye care hospitals - A multicenter questionnaire-based survey.

Kaur K, Annamalai O, Gurnani B, Rekha S, Jayashree B, Venugopal A, Narendran K, Ravilla ST, Aswin PR, Venkatesh R. Indian J Ophthalmol. 2022 Oct;70(10):3650-3657. doi: 10.4103/ijo.IJO_618_22. PMID: 36190066

"How we can improve Covid-19 safety in schools using digital tools for contact tracing: A qualitative study exploring views and experiences among school staff".
Chantziara S, Brigden Lc A, Mccallum CH, Craddock IJ. JMIR Form Res. 2022 Oct 3. doi: 10.2196/36412. Online ahead of print. PMID: 36191172

A Cross-Sectional Study on Factors Affecting the Decision to Conduct Dermatologic Surgery Procedures During the COVID-19 Pandemic.
Wanitphakdeedecha R, Jantarakolica T, Sudhipongpracha T, Wongdama S, Gervasio MKR, Gulfan MCB, Yogya Y, Dim-Jamora KCC. Dermatol Ther (Heidelb). 2022 Oct;12(10):2355-2369. doi: 10.1007/s13555-022-00803-0. Epub 2022 Sep 16. PMID: 36112298

COVID-19 Among Non-Hispanic American Indian and Alaska Native People Residing in Urban Areas Before and After **Vaccine** Rollout-Selected States and Counties, United States, January 2020-October 2021.
Pete D, Erickson SL, Jim MA, Hatcher SM, Echo-Hawk A, Dominguez AE. Am J Public Health. 2022 Oct;112(10):1489-1497. doi: 10.2105/AJPH.2022.306966. PMID: 36103693

Enhancing half-life and cytotoxicity of porcine respiratory and reproductive syndrome virus soluble receptors by taming their Fc domains.
Liu X, Zhou X, Noor AU, Zhang X, Song C, Sun H. Vet Microbiol. 2022 Oct;273:109526. doi: 10.1016/j.vetmic.2022.109526. Epub 2022 Aug 5. PMID: 35988378

Covid-19 and SARS-CoV-2 infection in periodontology: A narrative review.
Drozdzik A. J Periodontal Res. 2022 Oct;57(5):933-941. doi: 10.1111/jre.13034. Epub 2022 Jul 15. PMID: 35839286

Radiation recall dermatitis induced by COVID-19 vaccination in breast cancer patients treated with postoperative radiation therapy.
Vinante L, Caroli A, Revelant A, Bertini F, Giroldi A, Marson M, Franchin G, Muraro E, Brisotto G, Steffan A, Baboci L. Breast. 2022 Oct;65:49-54. doi: 10.1016/j.breast.2022.06.008. Epub 2022 Jul 2. PMID: 35816893

External validation of the COVID-19 4C mortality score in an urban United States cohort.
Riley JM, Moeller PJ, Crawford AG, Schaefer JW, Cheney-Peters DR, Venkataraman CM, Li CJ, Smaltz CM, Bradley CG, Lee CY, Fitzpatrick DM, Ney DB, Zaret DS, Chalikonda DM, Mairose JD, Chauhan K, Szot MV, Jones RB, Bashir-Hamidu R, Mitsuhashi S, Kubey AA. Am J Med Sci. 2022 Oct;364(4):409-413. doi: 10.1016/j.amjms.2022.04.030. Epub 2022 Apr 30. PMID: 35500663

Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?
Dhawan M, Saied AA, Mitra S, Alhumaydhi FA, Emran TB, Wilairatana P. Biomed Pharmacother. 2022 Oct;154:113522. doi: 10.1016/j.biopha.2022.113522. Epub 2022 Aug 15. PMID: 36030585

Horizontal transmission might be a common route of hepatitis B virus exposure in highly endemic areas.
Zheng XQ, Li X, Liu J, Shi L, Wang HZ, Tian KG, Pan XB. J Med Virol. 2022 Oct;94(10):4983-4992. doi: 10.1002/jmv.27905. Epub 2022 Jun 10. PMID: 35652312

Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Guérin treatment.
Miyake M, Kikuchi E, Shinozaki K, Piao Y, Hayashi N, Koto R, Jinushi M, Kobayashi T. Int J Urol. 2022 Oct;29(10):1120-1129. doi: 10.1111/iju.14933. Epub 2022 May 21. PMID: 35598101

A single administration of hIL-7-hyFc induces long-lasting T-cell expansion with maintained functions and TCR diversity.
Kim S, Lee SW, Koh JY, Choi D, Heo M, Chung JY, Lee BH, Yang SH, Sung YC, Lee H, Shin EC, Park SH. Blood Adv. 2022 Oct 7:bloodadvances.2021006591. doi: 10.1182/bloodadvances.2021006591. Online ahead of print. PMID: 36206199

Stimulation of naïve B cells with a fusion protein consisting of FlaA and Bet v 1 induces regulatory B cells ex vivo.
Goretzki A, Lin YJ, Meier C, Dorn B, Wolfheimer S, Jamin A, Schott M, Wangorsch A, Vieths S, Jakob T, Scheurer S, Schülke S. Allergy. 2022 Oct 4. doi: 10.1111/all.15542. Online ahead of print. PMID: 36196479

Feasibility of measles and rubella vaccination programmes for disease elimination: a modelling study.
Winter AK, Lambert B, Klein D, Klepac P, Papadopoulos T, Truelove S, Burgess C, Santos H, Knapp JK, Reef SE, Kayembe LK, Shendale S, Kretsinger K, Lessler J, Vynnycky E, McCarthy K, Ferrari M, Jit M. Lancet Glob Health. 2022 Oct;10(10):e1412-e1422. doi: 10.1016/S2214-109X(22)00335-7. PMID: 36113527

COVID-19-related health outcomes in people with primary immunodeficiency: A systematic review.
Drzymalla E, Green RF, Knuth M, Khoury MJ, Dotson WD, Gundlapalli A. Clin Immunol. 2022 Oct;243:109097. doi: 10.1016/j.clim.2022.109097. Epub 2022 Aug 13. PMID: 35973637

Serological response to SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease treated with disease modifying anti-rheumatic drugs: A cohort study and a meta-analysis.
Auroux M, Laurent B, Coste B, Massy E, Mercier A, Durieu I, Confavreux CB, Lega JC, Mainbourg S, Coury F. Joint Bone Spine. 2022 Oct;89(5):105380. doi: 10.1016/j.jbspin.2022.105380. Epub 2022 Apr 28. PMID: 35490940

COVID-19 incidence, severity, medication use, and vaccination among dentists: survey during the second wave in Brazil.
Moraes RR, Correa MB, Martins-Filho PR, Lima GS, Demarco FF. J Appl Oral Sci. 2022 Oct 3;30:e20220016. doi: 10.1590/1678-7757-2022-0016. eCollection 2022. PMID: 36197403

Relapses of idiopathic inflammatory myopathies after vaccination against COVID-19: a real-life multicenter Italian study.
Conticini E, d'Alessandro M, Grazzini S, Fornaro M, Sabella D, Lopalco G, Giardina F, Colafrancesco S, Rizzo C, Guggino G, Priori R, Conti F, Iannone F, Bargagli E, Cantarini L, Frediani B. Intern Emerg Med. 2022 Oct;17(7):1921-1928. doi: 10.1007/s11739-022-03028-3. Epub 2022 Jun 26. PMID: 35754076

Investigating Impacts of CoronaVac Vaccination in Males on *In Vitro* Fertilization: A Propensity Score Matched Cohort Study.
Wang M, Yang Q, Zhu L, Jin L. World J Mens Health. 2022 Oct;40(4):570-579. doi: 10.5534/wjmh.220017. Epub 2022 May 31. PMID: 36047069

Recent advances in natural products as potential inhibitors of dengue virus with a special emphasis on NS2b/NS3 protease.
Saqallah FG, Abbas MA, Wahab HA. Phytochemistry. 2022 Oct;202:113362. doi: 10.1016/j.phytochem.2022.113362. Epub 2022 Aug 7. PMID: 35948138

Effect of ontological insecurity on vaccination behavior against COVID-19: a hospital-based cross-sectional study.
Zhang MX, Lv XY, Shi GF, Luo C, Wu XY, Wang WZ, Cheng FM, Chen HX, Tung TH. Public Health. 2022 Oct;211:157-163. doi: 10.1016/j.puhe.2022.07.008. Epub 2022 Jul 18. PMID: 36122529

Transfusion-transmitted arboviruses: Update and systematic review.
Giménez-Richarte Á, Ortiz de Salazar MI, Giménez-Richarte MP, Collado M, Fernández PL, Clavijo C, Navarro L, Arbona C, Marco P, Ramos-Rincon JM. PLoS Negl Trop Dis. 2022 Oct 6;16(10):e0010843. doi: 10.1371/journal.pntd.0010843. Online ahead of print. PMID: 36201547

Live attenuated VZV vaccination induces antitumor immunity in ATLL patients.
Jo T, Kubota-Koketsu R, Kaneko Y, Sakai T, Noguchi K, Irie S, Matsuo M, Taguchi J, Abe K, Shigematsu K. Cancer Immunol Immunother. 2022 Oct 1. doi: 10.1007/s00262-022-03301-6. Online ahead of print. PMID: 36181532

Management of Cerebral Venous Thrombosis Due to Adenoviral COVID-19 Vaccination.
Scutelnic A, Krzywicka K, Mbroh J, van de Munckhof A, van Kammen MS, de Sousa DA, Lindgren E, Jood K, Günther A, Hiltunen S, Putaala J, Tiede A, Maier F, Kern R, Bartsch T, Althaus K, Ciccone A, Wiedmann M, Skjelland M, Medina A, Cuadrado-Godia E, Cox T, Aujayeb A, Raposo N, Garambois K, Payen JF, Vuillier F, Franchineau G, Timsit S, Bougon D, Dubois MC, Tawa A, Tracol C, De Maistre E, Bonneville F, Vayne C, Mengel A, Michalski D, Pelz J, Wittstock M, Bode F, Zimmermann J, Schouten J, Buture A, Murphy S, Palma V, Negro A, Gutschalk A, Nagel S, Schoenenberger S, Frisullo G, Zanferrari C, Grillo F, Giammello F, Martin MM, Cervera A, Burrow J, Esperon CG, Chew BLA, Kleinig TJ, Soriano C, Zimatore DS, Petruzzellis M, Elkady A, Miranda MS, Fernandes J, Vogel ÅH, Johansson E, Philip AP, Coutts SB, Bal S, Buck B, Legault C, Blacquiere D, Katzberg HD, Field TS, Dizonno V, Gattringer T, Jacobi C, Devroye A, Lemmens R, Kristoffersen ES, di Poggio MB, Ghiasian M, Karapanayiotides T, Chatterton S, Wronski M, Ng K, Kahnis R, Geeraerts T, Reiner P, Cordonnier C, Middeldorp S, Levi M, van Gorp ECM, van de Beek D, Brodard J, Kremer Hovinga JA, Kruip MJHA, Tatlisumak T, Ferro JM, Coutinho JM, Arnold M, Poli S, Heldner MR. Ann Neurol. 2022 Oct;92(4):562-573. doi: 10.1002/ana.26431. Epub 2022 Jul 4. PMID: 35689346

Comparison of Persistent Symptoms Following SARS-CoV-2 Infection by Antibody Status in Nonhospitalized Children and Adolescents.
Messiah SE, Hao T, DeSantis SM, Swartz MD, Talebi Y, Kohl HW 3rd, Zhang S, Valerio-Shewmaker M, Yaseen A, Kelder SH, Ross J, Gonzalez MO, Wu L, Padilla LN, Lopez KR, Lakey D, Shuford JA, Pont SJ,

Boerwinkle E. Pediatr Infect Dis J. 2022 Oct 1;41(10):e409-e417. doi: 10.1097/INF.0000000000003653. Epub 2022 Aug 1. PMID: 35939608

Clinical Efficacy of SARS-CoV-2 Vaccination in Hemodialysis Patients.
Torres R, Toro L, Sanhueza ME, Lorca E, Ortiz M, Pefaur J, Clavero R, Machuca E, Gonzalez F, Herrera P, Mocarquer A, Frias A, Roessler E, Muñoz C, Nuñez M, Aravena C, Quintana E, Lemus J, Lillo M, Reynolds E, Morales A, Pais E, Fiabane A, Parra-Lucares A, Garrido C, Mendez-Valdes G, Villa E, Mansilla R, Sotomayor G, Gonzalez M, Miranda C, Briones E, Gomez E, Mezzano S, Bernales W, Rocca X, Espinoza O, Zuñiga E, Aragon H, Badilla M, Valenzuela M, Escobar L, Zamora D, Flores I, Tapia B, Borquez T, Herrera P. Kidney Int Rep. 2022 Oct;7(10):2176-2185. doi: 10.1016/j.ekir.2022.07.007. Epub 2022 Jul 16. PMID: 35874643

Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022.
Chen X, Yan X, Sun K, Zheng N, Sun R, Zhou J, Deng X, Zhuang T, Cai J, Zhang J, Ajelli M, Yu H. Emerg Microbes Infect. 2022 Oct 7:1-10. doi: 10.1080/22221751.2022.2128435. Online ahead of print. PMID: 36205530

Genome-Wide Analysis Reveals that PhoP Regulates Pathogenicity in Riemerella anatipestifer.
Zhang Y, Wang Y, Zhang Y, Jia X, Li C, Zhou Z, Hu S, Li Z. Microbiol Spectr. 2022 Oct 5:e0188322. doi: 10.1128/spectrum.01883-22. Online ahead of print. PMID: 36197298

Diagnostic performance of the SARS-CoV-2 S1RBD IgG ELISA (ImmunoDiagnostics) for the quantitative detection of SARS-CoV-2 antibodies on dried blood spots.
Meyers E, Coen A, De Sutter A, Padalko E, Callens S, Vandekerckhove L, Witkowski W, Heytens S, Cools P. J Clin Virol. 2022 Oct;155:105270. doi: 10.1016/j.jcv.2022.105270. Epub 2022 Aug 19. PMID: 36027822

The effect of COVID-19 mRNA vaccines against postvaccination laboratory-confirmed SARS-CoV-2 infection, symptomatic COVID-19 infection, hospitalization, and mortality rate: a systematic review and meta-analysis.
Baradaran HR, Dehghanbanadaki H, Moradpour F, Eshrati B, Moradi G, Azami M, Haji Ghadery A, Mehrabi Nejad MM, Moradi Y. Expert Rev Vaccines. 2022 Oct;21(10):1455-1464. doi: 10.1080/14760584.2022.2102001. Epub 2022 Jul 22. PMID: 35830883

Impaired serological response to COVID-19 vaccination following anticancer therapy: A systematic review and meta-analysis.
Tang K, Wei Z, Wu X. J Med Virol. 2022 Oct;94(10):4860-4868. doi: 10.1002/jmv.27956. Epub 2022 Jul 6. PMID: 35750492

Impact of in vitro fertilization-embryo transfer on mother-to-infant transmission in women with chronic HBV infection.
Yi W, Li M, Sun F, Lu H, Zeng Z, Bi X, Yang L, Lin Y, Cao X, Hu Y, Zhou M, Zhang L, Lu Y, Wan G, Xie Y. Liver Int. 2022 Oct;42(10):2167-2174. doi: 10.1111/liv.15349. Epub 2022 Jul 1. PMID: 35758891

An *in-silico* approach to identify the potential hot spots in SARS-CoV-2 spike RBD to block the interaction with ACE2 receptor.

Stalin A, Lin D, Senthamarai Kannan B, Feng Y, Wang Y, Zhao W, Ignacimuthu S, Wei DQ, Chen Y. J Biomol Struct Dyn. 2022 Oct;40(16):7408-7423. doi: 10.1080/07391102.2021.1897682. Epub 2021 Mar 9. PMID: 33685364

Increasing access and uptake of SARS-CoV-2 at-home tests using a community-engaged approach.
D'Agostino EM, Corbie G, Kibbe WA, Hornik CP, Richmond A, Dunston A, Damman A, Wruck L, Alvarado M, Cohen-Wolkowiez M. Prev Med Rep. 2022 Oct;29:101967. doi: 10.1016/j.pmedr.2022.101967. Epub 2022 Aug 30. PMID: 36061814

Risks of infection, hospital and ICU admission, and death from COVID-19 in people with asthma: systematic review and meta-analyses.
Otunla A, Rees K, Dennison P, Hobbs R, Suklan J, Schofield E, Gunnell J, Mighiu A, Hartmann-Boyce J. BMJ Evid Based Med. 2022 Oct;27(5):263-273. doi: 10.1136/bmjebm-2021-111788. Epub 2021 Dec 21. PMID: 34933924

Control of Simian Immunodeficiency Virus Infection in Prophylactically Vaccinated, Antiretroviral Treatment-Naive Macaques Is Required for the Most Efficacious CD8 T Cell Response during Treatment with the Interleukin-15 Superagonist N-803.
Ellis-Connell AL, Balgeman AJ, Harwood OE, Moriarty RV, Safrit JT, Weiler AM, Friedrich TC, O'Connor SL. J Virol. 2022 Oct 3:e0118522. doi: 10.1128/jvi.01185-22. Online ahead of print. PMID: 36190241

Diabetes Affects Antibody Response to SARS-CoV-2 Vaccination in Older Residents of Long-Term Care Facilities: Data From the GeroCovid Vax Study.
Virgilio E, Trevisan C, Abbatecola A, Malara A, Palmieri A, Fedele G, Stefanelli P, Leone P, Schiavoni I, Maggi S, Volpato S, Antonelli Incalzi R, Onder G; GeroCovid Vax Working Group; GeroCovid Vax Working Group. Diabetes Care. 2022 Oct 6:dc221255. doi: 10.2337/dc22-1255. Online ahead of print. PMID: 36201657

Comparison between enzyme-linked immunospot assay and intracellular cytokine flow cytometry assays for the evaluation of T cell response to SARS-CoV-2 after symptomatic COVID-19.
Villemonteix J, Cohen L, Guihot A, Guérin V, Moulin C, Caseris M, Carol A, Bonacorsi S, Carcelain G. Immun Inflamm Dis. 2022 Oct;10(10):e617. doi: 10.1002/iid3.617. PMID: 36169252

Thyroid dysfunction following vaccination with COVID-19 vaccines: a basic review of the preliminary evidence.
Jafarzadeh A, Nemati M, Jafarzadeh S, Nozari P, Mortazavi SMJ. J Endocrinol Invest. 2022 Oct;45(10):1835-1863. doi: 10.1007/s40618-022-01786-7. Epub 2022 Mar 26. PMID: 35347651

HPV vaccination coverage for pediatric, adolescent and young adult patients receiving care in a childhood cancer survivor program.
Thomaier L, Aase DA, Vogel RI, Parsons HM, Sadak KT, Teoh D. Prev Med Rep. 2022 Sep 7;29:101972. doi: 10.1016/j.pmedr.2022.101972. eCollection 2022 Oct. PMID: 36161114

Recall responses in the lung environment are impacted by age in a pilot study of Mycobacterium bovis-BCG vaccinated rhesus macaques.
Scordo JM, Piergallini TJ, Olmo-Fontánez AM, Thomas A, Raué HP, Slifka M, Turner J. Exp Gerontol. 2022 Oct 1;167:111904. doi: 10.1016/j.exger.2022.111904. Epub 2022 Jul 30. PMID: 35918043

Multiplex Detection of Antibody Landscapes to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/Influenza/Common Human Coronaviruses Following Vaccination or Infection With SARS-CoV-2 and Influenza.
Li ZN, Liu F, Jefferson S, Horner L, Carney P, Johnson MDL, King JP, Martin ET, Zimmerman RK, Wernli K, Gaglani M, Thompson M, Flannery B, Stevens J, Tumpey T, Levine MZ. Clin Infect Dis. 2022 Oct 3;75(Supplement_2):S271-S284. doi: 10.1093/cid/ciac472. PMID: 35684961

Active Safety Surveillance of Four Types of COVID-19 Vaccines: A National Study from Jordan.
Abdel-Qader DH, Abdel-Qader H, Silverthorne J, Kongkaew C, Al Meslamani AZ, Hayajneh W, Ata OMA, Shnaigat W, AbuRuz S, Al Nsour M, Alhariri A, Shnewer K, Da'ssan M, Obeidat NM, Nusair KE, Jalamdeh MS, Hawari F, Khader K, Hakim T, Hammad FA, Al Qudah M, Asad M. Clin Drug Investig. 2022 Oct;42(10):813-827. doi: 10.1007/s40261-022-01191-1. Epub 2022 Aug 23. PMID: 35999428

COVID-19 vaccination and carditis in children and adolescents: a systematic review and meta-analysis.
Chou OHI, Mui J, Chung CT, Radford D, Ranjithkumar S, Evbayekha E, Nam R, Pay L, Satti DI, Garcia-Zamora S, Bazoukis G, Çinier G, Lee S, Vassiliou VS, Liu T, Tse G, Wong ICK; Cardiovascular Analytics Group, the International Health Informatics Study Network, Chou OHI, Liu T, Tse G. Clin Res Cardiol. 2022 Oct;111(10):1161-1173. doi: 10.1007/s00392-022-02070-7. Epub 2022 Jul 30. PMID: 35906423

Regional differences in human papillomavirus type 52 prevalence among Japanese women with cervical intraepithelial neoplasia†.
Kukimoto I, Onuki M, Yamamoto K, Yahata H, Aoki Y, Yokota H, Konnai K, Nio A, Takehara K, Kamiura S, Tsuda N, Takei Y, Shimada M, Nakai H, Yoshida H, Motohara T, Yamazaki H, Nakamura K, Okunomiya A, Tasaka N, Ishikawa M, Hirashima Y, Shimoji Y, Mori M, Iwata T, Takahashi F, Yoshikawa H, Yaegashi N, Matsumoto K; MINT Study Group. Jpn J Clin Oncol. 2022 Oct 6;52(10):1242-1247. doi: 10.1093/jjco/hyac127. PMID: 35938523

SARS-CoV-2 spike IgG titres up to 137 days following Comirnaty mRNA COVID-19 vaccination, Israel, February to May 2021.
Patalon T, Ben Moshe S, Peretz A, Neuberger A, Schreiber L, Lazar R, Supino-Rosin L, Perez G, Mizrahi-Reuveni M, Gazit S. Euro Surveill. 2022 Oct;27(40). doi: 10.2807/1560-7917.ES.2022.27.40.2100703. PMID: 36205168 F

The influence of SARS-CoV-2 vaccination on post-operative outcomes in microsurgery patients.
Taghioff SM, Slavin BR, Narasimman M, Samaha G, Samaha M, Holton T, Singh D. Microsurgery. 2022 Oct;42(7):685-695. doi: 10.1002/micr.30940. Epub 2022 Jul 15. PMID: 35838137

CML-384 Immunological Response to SARS-CoV-2 After Infection and/or Vaccination Among Chronic Myeloid Leukemia Patients - A Prospective Study.
Galvis MM, Bradshaw D, Farmaha J, Jones K, Singh H, Vashisht A, Sahajpal N, Kolhe R, Cortes J. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S294-S295. doi: 10.1016/S2152-2650(22)01378-7. PMID: 36163923

T-cells in human trigeminal ganglia express canonical tissue-resident memory T-cell markers.
Unger PA, Oja AE, Khemai-Mehraban T, Ouwendijk WJD, Hombrink P, Verjans GMGM. J Neuroinflammation. 2022 Oct 6;19(1):249. doi: 10.1186/s12974-022-02611-x. PMID: 36203181

Unsymmetrical aromatic disulfides as SARS-CoV-2 Mpro inhibitors: Molecular docking, molecular dynamics, and ADME scoring investigations.
Chtita S, Belaidi S, Qais FA, Ouassaf M, AlMogren MM, Al-Zahrani AA, Bakhouch M, Belhassan A, Zaki H, Bouachrine M, Lakhlifi T. J King Saud Univ Sci. 2022 Oct;34(7):102226. doi: 10.1016/j.jksus.2022.102226. Epub 2022 Jul 20. PMID: 35875823

[Clinical characteristics of convalescent children infected with SARS-CoV-2 Omicron variant in Tianjin].
Sun Y, Wang B, Zhang GF, Zhang X, Wang CJ, Wang DY, Li YX, Zhang J. Zhonghua Er Ke Za Zhi. 2022 Oct 2;60(10):1054-1058. doi: 10.3760/cma.j.cn112140-20220711-00631. PMID: 36207853

Pregnancy outcomes after SARS-CoV-2 infection in periods dominated by delta and omicron variants in Scotland: a population-based cohort study.
Stock SJ, Moore E, Calvert C, Carruthers J, Denny C, Donaghy J, Hillman S, Hopcroft LEM, Hopkins L, Goulding A, Lindsay L, McLaughlin T, Taylor B, Auyeung B, Katikireddi SV, McCowan C, Ritchie LD, Rudan I, Simpson CR, Robertson C, Sheikh A, Wood R. Lancet Respir Med. 2022 Oct 7:S2213-2600(22)00360-5. doi: 10.1016/S2213-2600(22)00360-5. Online ahead of print. PMID: 36216011

Patentes registradas en Patentscope

Estrategia de búqueda: *Vaccine in the title or abstract AND 20221001:20221011 as the publication date 46 records*

1.WO/2022/205572BLETILLAE RHIZOMA POLYSACCHARIDE, PREPARATION METHOD THEREFOR AND USE THEREOF, AND IMMUNOLOGICAL ADJUVANT AND NANO VACCINE CONTAINING SAME
WO - 06.10.2022
Clasificación Internacional A61K 31/715 Nº de solicitud PCT/CN2021/093326 Solicitante KUNMING INSTITUTE OF BOTANY, CHINESE ACADEMY OF SCIENCES Inventor/a HU, Jiangmiao
A Bletillae rhizoma polysaccharide, a preparation method therefor and the use thereof, and an immunological adjuvant and a nano vaccine containing same. The Bletillae rhizoma polysaccharide has an immunoregulatory effect. After the Bletillae rhizoma polysaccharide and a protein vaccine are mixed, a self-assembly phenomenon can occur to generate a nano vaccine, and the self-assembled nano vaccine is a relatively uniform circular particle.

2.WO/2022/211482VIRUS VACCINE BASED ON VIRUS SURFACE ENGINEERING PROVIDING INCREASED IMMUNITY
WO - 06.10.2022
Clasificación Internacional C07K 14/00 Nº de solicitud PCT/KR2022/004491 Solicitante THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC) Inventor/a SHIN, Hyun-Jin
The present invention relates to a virus vaccine based on virus surface engineering, wherein the virus vaccine provides increased immunity. A linker peptide according to one aspect of the present invention has the characteristic of being attachable to a virus, and thus can improve the immunogenicity of a vaccine by being used as a linker capable of effectively binding, to the virus surface, an immune-enhancing substance that activates the immune system. When the linker peptide is combined with virus surface engineering technology, the immune-enhancing substance can be attached to the virus surface, and thus the linker peptide may be effectively used as a vaccine platform providing increased immunity.

3.WO/2022/210465NANOGEL-COATED VACCINE
WO - 06.10.2022

Clasificación Internacional A61K 39/00 Nº de solicitud PCT/JP2022/014798 Solicitante THE UNIVERSITY OF TOKYO Inventor/a KIYONO Hiroshi
The purpose of the present invention is to provide a composite of a nanogel with an antigen not contained in nanogel, and a vaccine formulation that contains this composite. Specifically, the present invention provides a nanogel/vaccine antigen composite, wherein the vaccine antigen is coated by nanogel.

4.WO/2022/206222NOVEL CORONAVIRUS S-RBD TRIMERIC PROTEIN VACCINE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
WO - 06.10.2022
Clasificación Internacional C07K 14/165 Nº de solicitud PCT/CN2022/077527 Solicitante NATIONAL VACCINE AND SERUM INSTITUTE(NVSI) Inventor/a LI, Qiming
Disclosed is a novel coronavirus S-RBD trimeric protein. The trimeric protein is composed of amino acid fragments of positions 319-537 in an RBD region of a novel coronavirus S protein in a trimeric form. A vaccine prepared by the present invention uses the S-RBD trimeric protein as an antigen; once an adjuvant is added, the body can be immunized and high-titer protective neutralizing antibodies against the novel coronavirus can be produced. The vaccine can be used for the treatment and/or prevention of novel coronavirus (SARS-CoV-2) infections and/or novel coronavirus diseases.

5.WO/2022/212704METHODS FOR CHARACTERIZING THE IMMUNE RESPONSE OF A SUBJECT TO A DENGUE VIRUS COMPOSITION
WO - 06.10.2022
Clasificación Internacional G01N 33/543 Nº de solicitud PCT/US2022/022822 Solicitante TAKEDA VACCINES, INC. Inventor/a TSUJI, Isamu
The present invention relates to a method for characterizing the immune response of a subject to a tetravalent dengue virus composition by performing the method for determining affinity, binding kinetics and/or concentration of an antibody or of an antibody mixture and at least one other method. In a further embodiment, the present invention relates to a method for characterizing the immune response of a subject to a virus-containing vaccine composition by performing a combination of assays. In a further embodiment, the present invention relates to a method for predicting protective efficacy of a dengue vaccine candidate. In another embodiment the present invention relates to a method for preparing a vaccine formulation.

6.WO/2022/208040VACCINE ADJUVANT
WO - 06.10.2022
Clasificación Internacional A61K 31/454 Nº de solicitud PCT/GB2021/050811 Solicitante CELLERON THERAPEUTICS LIMITED Inventor/a LA THANGUE, Nicholas
The present invention relates to the therapeutic use of the HDAC inhibitor compound, N–(2-aminophenyl)-4-(1-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin-4-yl)benzamide, or a pharmaceutically acceptable salt or solvate thereof, as a vaccine adjuvant. The present invention also relates to the combination of N–(2-aminophenyl)-4-(1-[(1,3-dimethyl-1H- pyrazol-4-yl)methyl]piperidin-4-yl)benzamide and a vaccine and the therapeutic uses thereof

7.WO/2022/212342PRODUCTION OF VACCINIA CAPPING ENZYME
WO - 06.10.2022
Clasificación Internacional C12N 15/67 Nº de solicitud PCT/US2022/022303 Solicitante GINKGO BIOWORKS, INC. Inventor/a BOBER, Josef
Aspects of the disclosure relate to production of vaccinia capping enzyme (VCE) in host cells. For example, host cells may comprise: a promoter; a ribosome binding site (RBS); a nucleic acid encoding a vaccinia capping enzyme (VCE) or VCE subunit; and a terminator.

8.WO/2022/206954NEW-TYPE CORONAVIRUS VACCINE COMPOSITION AND USE THEREOF

WO - 06.10.2022
Clasificación Internacional C07K 14/00 Nº de solicitud PCT/CN2022/084807 Solicitante WU, Suh-Chin Inventor/a WU, Suh-Chin
Provided are a new-type coronavirus vaccine composition and the use thereof. The new-type coronavirus vaccine composition comprises an N-glycosylation-shielded new-type coronavirus spike protein mutant in an N-terminal domain or a receptor-binding domain, and can effectively induce an individual to generate an immune response towards different new-type coronavirus variants.

9.WO/2022/210764INFLUENZA VACCINE FOR TRANSNASAL ADMINISTRATION
WO - 06.10.2022
Clasificación Internacional A61K 39/145 Nº de solicitud PCT/JP2022/015639 Solicitante DENKA COMPANY LIMITED Inventor/a MITSUMATA, Ryotaro
Provided is an influenza vaccine for transnasal administration which is efficiently taken up though the nasal mucosa. This influenza vaccine composition for transnasal administration contains an influenza antigen to which TGDK is linked via a chemical bond.

10.WO/2022/207016COMPOSICIONES VACUNALES DEPLETANTES DE FACTORES DE CRECIMIENTO HEMATOPOYÉTICOS PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS
WO - 06.10.2022
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/CU2022/050002 Solicitante CENTRO DE INMUNOLOGIA MOLECULAR Inventor/a LAGE DÁVILA, Agustín Bienvenido
La presente invención se relaciona con la rama de la Biotecnología y la Medicina. Específicamente describe composiciones vacunales terapéuticas capaces de producir una reacción autoinmune contra factores de crecimiento hematopoyéticos como el G-SCF y/o GM-CSF unidas por conjugación química o fusión a otras moléculas o partes de ella. Dichas composiciones vacunales son útiles en el tratamiento de enfermedades inflamatorias, en especial donde ocurra una elevación patológica de neutrófilos circulantes.

11.20220313813ROTAVIRUS MRNA VACCINE
US - 06.10.2022
Clasificación Internacional A61K 39/15 Nº de solicitud 17620047 Solicitante CureVac AG Inventor/a Susanne RAUCH
The invention is directed to a coding RNA for a Rotavirus vaccine. The coding RNA comprises at least one coding region encoding at least one antigenic peptide or protein of a Rotavirus, in particular VPS* of a Rotavirus, or immunogenic fragment or immunogenic variant thereof. The present invention is also directed to compositions and vaccines comprising said coding RNA in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP). Further, the invention concerns a kit, particularly a kit of parts comprising the coding RNA, or the composition, or the vaccine. The invention is also directed to a kit or kit of parts, medical treatments, and the first and second medical uses.

12.WO/2022/210763INFLUENZA VACCINE
WO - 06.10.2022
Clasificación Internacional A61K 39/145 Nº de solicitud PCT/JP2022/015638 Solicitante DENKA COMPANY LIMITED Inventor/a MITSUMATA, Ryotaro
The present invention provides an influenza vaccine that has high immunogenicity in children and elderly people and that is highly effective in comparison with conventional split vaccines. Provided is an influenza vaccine composition to be administered to children and/or elderly people, said composition containing, as viral antigens, inactivated whole virions that have been subjected to an inactivation process with β-propiolactone.

13.20220313810SINGLE SHOT CHIKUNGUNYA VIRUS VACCINE
US - 06.10.2022
Clasificación Internacional A61K 39/12 Nº de solicitud 17632946 Solicitante Valneva SE Inventor/a Nina Wressnigg
The present invention relates to a single-shot live attenuated vaccine against Chikungunya virus which is well-tolerated and induces long-lasting protective immunity in adult human subjects.

14.WO/2022/212511CLADE C HIV-1 ENVELOPE (ENV) TRIMER IMMUNOGENS, COMPOSITIONS INCLUDING THE CLADE C HIV-1 ENVELOPE (ENV) TRIMER IMMUNOGENS, AND USES THEREOF
WO - 06.10.2022
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/US2022/022557 Solicitante NOVA SOUTHEASTERN UNIVERSITY Inventor/a CAYABYAB, Mark J.
The invention encompasses a non-naturally occurring clade C human immunodeficiency virus type-1 (HIV-1) 1086.C envelope (ENV) SOSIP trimer protein. This trimer protein contains broadly neutralizing epitopes and epitopes that induce anti-V1/V2 antibodies and thus is an immunogen for creation of HIV-1 vaccines. The invention also includes prophylactic or therapeutic vaccine compositions/kits and methods for using the trimer protein as a component of a vaccine against HIV-1 infection.

15.WO/2022/207645SARS-COV-2 SUBUNIT VACCINE
WO - 06.10.2022
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/EP2022/058280 Solicitante VIRAVAXX AG Inventor/a GATTINGER, Pia
An immunogenic subunit vaccine antigen which comprises at least two receptor-binding domains (RBDs) of the spike (S) protein of SARS-CoV-2 which are fused to a heterologous immunogenic carrier protein, wherein each of said at least two RBDs has a folded structure in an accessible conformation to bind the human angiotensin-converting enzyme 2 (ACE2) receptor protein.

16.20220315949SINGLE PLASMID VECTOR SYSTEM FOR PACKAGING RECOMBINANT HUMAN ADENOVIRUS TYPE 4 AND APPLICATION THEREOF
US - 06.10.2022
Clasificación Internacional C12N 15/86 Nº de solicitud 17629592 Solicitante ACADEMY OF MILITARY MEDICAL SCIENCE, PLA Inventor/a Wei Chen
A single plasmid vector system for packaging recombinant human adenovirus type 4. The vector system contains an E3 region-deleted human adenovirus type 4 (HAdV-4 or Ad4) genome, a vector sequence for amplifying plasmids in bacteria, a pBR322 replication origin, a kanamycin resistance gene, and a replication control sequence; and an exogenous gene embedding site is located behind a packaging signal of the human adenovirus type 4 and in front of an E1 region. The present invention further provides a method for packaging the recombinant human adenovirus type 4 by the single plasmid vector system and an application in vaccine and drug preparation. The vector system can be used for rapidly and efficiently preparing a human adenovirus type 4 vector recombinant virus for stably expressing an exogenous gene, and has a good application prospect in the fields of preparation of a diagnostic kit, a vaccine, a gene therapy kit and/or a tumor therapy drug, etc.

17.WO/2022/212289MUTANT HERPESVIRUS AND VACCINE COMPOSITIONS
WO - 06.10.2022
Clasificación Internacional A61K 35/763 Nº de solicitud PCT/US2022/022211 Solicitante RATIONAL VACCINES, INC. Inventor/a FERNANDEZ, Agustin
Compositions and methods related to a mutant herpesvirus and a mutant ICPO protein. Vaccine compositions comprising the mutant herpesvirus and/or mutant ICPO protein. Methods of treatment using the mutant herpesvirus and/or mutant ICPO protein.

18.WO/2022/204773CHIMERIC NUCLEOTIDE SEQUENCE, VECTOR FOR EXPRESSION IN MAMMALS, RNA VACCINE, CHIMERIC FUSION PROTEIN, USE IN THE PRODUCTION OF A VACCINE AGAINST CORONAVIRUS
WO - 06.10.2022
Clasificación Internacional C07K 19/00 Nº de solicitud PCT/BR2022/050112 Solicitante IMUNOTERA SOLUÇÕES TERAPÊUTICAS LTDA. Inventor/a ALVES, Rúbens Prince Dos Santos
The present invention pertains to the technical field of biotechnology. More specifically, a chimeric nucleotide sequence is described that corresponds to an encoded fusion protein comprising a polyepitope resulting from selecting and juxtaposing multiple epitopes from a coronavirus protein to induce an immune response in mammals. In one embodiment, said fusion protein comprises: a) a first peptide consisting of epitopes found in the amino acid sequence of replicase polyprotein 1ab (PR1ab); b) a first spacer; c) a modified form of herpes simplex virus type 1 (HSV-1) glycoprotein D (gD). In one embodiment, the replicase polyprotein is defined by SEQ ID NO: 96 flanked by a gD fragment comprising the amino acid sequence defined by SEQ ID NO: 98 in the N-terminal portion and another gD fragment comprising the amino acid sequence defined by SEQ ID NO: 100 in the C-terminal region. Use of the fusion protein has surprising results in inducing cellular and humoral immune responses against coronavirus, SARS-CoV-2, and related viruses.

19.20220315953MDBK IRF3/IRF7 KNOCK OUT MUTANT CELL AND ITS USE FOR VACCINE PRODUCTION
US - 06.10.2022
Clasificación Internacional C12N 15/90 Nº de solicitud 17615961 Solicitante Intervet Inc. Inventor/a Alexander Martijin Langereis
The present invention pertains to a Madin-Darby bovine kidney (MDBK) cell, wherein the interferon regulatory factors (IRF) IRF3 and/or IRF7 encoding genes are functionally inactivated. The invention also pertains to a cell culture comprising the MDBK cell, use of the MDBK cell culture, a method for the production of a virus using the cell and a vaccine prepared by using the cell.

20.WO/2022/207793VACCINE COMPOSITIONS FOR TRYPANOSOMATIDS
WO - 06.10.2022
Clasificación Internacional A61K 39/005 Nº de solicitud PCT/EP2022/058575 Solicitante VIB VZW Inventor/a STIJLEMANS, Benoit
The present invention provides vaccines and compositions, methods and uses of immunogenic vaccine compositions for eliciting an immune response to members of trypanosomatids such as Trypanosoma brucei, T. cruzi and Leishmania species.

21.20220313809CLOSTRIDIOIDES DIFFICILE TCDB VARIANTS, VACCINES AND METHODS OF USE
US - 06.10.2022
Clasificación Internacional A61K 39/08 Nº de solicitud 17608843 Solicitante The Board of Regents of the University of Oklahoma Inventor/a Jimmy D. Ballard
An immunogenic composition comprising a deletion mutant of a *Clostridioides difficile* TcdB toxin (such as TcdB2 or TcdB1) that lacks residues at least from amino acid residue 1769 to amino acid residue 1787 of a wild-type TcdB amino acid sequence or of a protein having high identity thereto, a vaccine comprising the immunogenic composition, a method of stimulating an immune response, a nucleic acid which encodes the amino acid sequence of the deletion mutant, a vector encoding the nucleic acid, and a host cell comprising the vector.

22.4065608REKOMBINANTE POLYPEPTIDE ZUR PROGRAMMIERUNG VON EXTRAZELLULÄREN VESIKELN
EP - 05.10.2022

Clasificación Internacional C07K 19/00 Nº de solicitud 20893234 Solicitante UNIV MCMASTER Inventor/a ILKOW CAROLINA SOLANGE
Herein is provided a recombinant tumor-selective viral particle comprising a nucleic acid encoding a recombinant polypeptide for directing an extracellular vesicle (EV) to at least one target cell, said recombinant polypeptide comprising: at least one targeting moiety for directing said EV to said at least one target molecule expressed by said at least one target cell; at least one EV-anchoring polypeptide; and at least one intravesicular polypeptide. The viral particle may be from an oncolytic viruses. Recombinant polypeptides for programming EVs to target particular molecules are also provided. Also described are therapeutic EVs for delivering payload polypeptides (and/or cargo molecules) to target cells, e.g., in vaccine or cell-free "CAR-T"-like applications, along with EVs for recruiting immune cells to target cells in EV-mediated BiTE -like applications. Oncolytic viruses may also be engineered to infect tumor cells and shed programmed EVs, yielding additional therapeutic effects.

23.4066824KOMBINATIONSTHERAPIE FÜR EINE COVID-19-IMPFUNG
EP - 05.10.2022
Clasificación Internacional A61K 31/085 Nº de solicitud 21166461 Solicitante DOMPE FARM SPA Inventor/a ALLEGRETTI MARCELLO
A combination of an estrogen receptor agonist and/or a vitamin D receptor agonist and a COVID-19 vaccine.

24.WO/2022/207860COMBINATION THERAPY FOR COVID-19 VACCINATION
WO - 06.10.2022
Clasificación Internacional A61K 31/085 Nº de solicitud PCT/EP2022/058688 Solicitante DOMPE' FARMACEUTICI SPA Inventor/a ALLEGRETTI, Marcello
The present invention relates to the combination of a Selective Estrogen Receptor Modulator (SERM) and a COVID-19 vaccine.

25.20220313814Protease Cleavage Site Peptides as an HIV Vaccine
US - 06.10.2022
Clasificación Internacional A61K 39/21 Nº de solicitud 17830652 Solicitante Her Majesty the Queen in Right of Canada as Represented by the Minister of Health Inventor/a Ma Luo
Instead of generating immune responses to several HIV proteins and risk over activating more CD4+ T cells (easy targets for HIV-1 infection) as current candidate vaccines try to do, a lower magnitude, narrowly focused, well maintained virus specific CD8+ T cell response to multiple subtypes should destroy and eliminate a few founder viruses without inducing inflammatory responses that may activate more CD4+ T cells and provide more targets for HIV-1 virus infection. Specifically, described herein is a method that focuses the immune response to the 12 protease cleavage sites.

26.4066852PHARMAZEUTISCHE ZUSAMMENSETZUNG
EP - 05.10.2022
Clasificación Internacional A61K 39/00 Nº de solicitud 20892141 Solicitante CYTLIMIC INC Inventor/a DOI SHUN
The present invention provides a novel technology useful for a cancer vaccine therapy, that is, a pharmaceutical composition wherein a Toll-like receptor agonist, LAG-3 protein, a variant thereof or a derivative thereof, at least one immunogenic agent, and an immune checkpoint inhibitor are administered in combination.

27.WO/2022/212659MULTI-GENIC MRNA VACCINE COMPOSITIONS AND METHODS OF USE
WO - 06.10.2022
Clasificación Internacional A61K 31/7105 Nº de solicitud PCT/US2022/022764 Solicitante THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor/a EBERWINE, James

The present invention relates to multi-genic mRNA immunogenic compositions and methods for inducing an immune response against one or more pathogenic microorganism in a subject. In some embodiments, the present invention provides a composition comprising at least one mRNA molecule encoding a plurality of pathogen antigens.

28.20220313802COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF PRION DISEASE
US - 06.10.2022
Clasificación Internacional A61K 39/00 Nº de solicitud 17610388 Solicitante NEW YORK UNIVERSITY Inventor/a Fernando GONI
The present disclosure is directed to a multi-species prion protein or peptide thereof, and vaccine compositions comprising the same that are useful for the vaccination and treatment of mammalian subjects at risk of having or having prion disease. Also disclosed herein are isolated proteins and peptides, polymers, vaccines, animal bait or feed, antibodies, and methods of inhibiting the onset of or treating a prion disease.

29.20220313803NOVEL NEOANTIGENS AND CANCER IMMUNOTHERAPY USING SAME
US - 06.10.2022
Clasificación Internacional A61K 39/00 Nº de solicitud 17420963 Solicitante BRIGHTPATH BIOTHERAPEUTICS CO., LTD. Inventor/a Tetsuro SASADA
Problem to be solved: An object of the present invention is to obtain medicinal effect that could not be obtained by conventional peptide vaccines that activate and proliferate a CD8-positive CTL by administering a Class II epitope as a peptide vaccine. Solution: The inventors of the present invention have found, as a result of diligent examination on the aforementioned problems, that these problems can be solved by acquiring a peptide having a partial amino acid sequence containing a mutated amino acid of a neoantigen expressed in cancer cells and being an epitope presented by a Class II molecule.

30.20220313807NOVEL PEPTIDES & COMBINATION OF PEPTIDES AS TARGETS OR ACTIVE INGREDIENTS FOR USE IN IMMUNOTHERAPY AGAINST AML & OTHER CANCERS
US - 06.10.2022
Clasificación Internacional A61K 39/00 Nº de solicitud 17838017 Solicitante Immatics Biotechnologies GmbH Inventor/a Andrea MAHR
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

31.20220315634TGF-BETA VACCINE
US - 06.10.2022
Clasificación Internacional C07K 14/495 Nº de solicitud 17616382 Solicitante IO BIOTECH APS Inventor/a Mads Hald ANDERSEN
The present invention relates to novel polypeptides derived from TGFb1. The invention also concerns uses of the polypeptides, polynucleotides encoding the peptides and uses thereof, and compositions comprising the polypeptides and uses thereof.

32.WO/2022/212667STAPHYLOCOCCUS AUREUS VACCINE COMPOSITIONS
WO - 06.10.2022

Clasificación Internacional A61P 31/04 Nº de solicitud PCT/US2022/022773 Solicitante JANSSEN PHARMACEUTICALS, INC. Inventor/a MORROW, Brian
The present disclosure relates to immunogenic compositions for inducing an immune response in a subject for the treatment and/or prevention of a Staphylococcus aureus infection. The immunogenic compositions disclosed herein comprise a S. aureus protein A (SpA) polypeptide and a S. aureus Leukocidin A (LukA) and/or Leukocidin B (LukB) variant polypeptide. The present disclosure further relates to methods of generating an immune response against S. aureus in a subject that involve administering the disclosed immunogenic compositions.

33.4066854IMMUNOGENES FUSIONSPROTEIN
EP - 05.10.2022
Clasificación Internacional A61K 39/09 Nº de solicitud 21165674 Solicitante MINERVAX Inventor/a PEDERSEN FISCHER PER BO
The present invention relates to an immunogenic fusion protein capable of eliciting protective immunity against group B Streptococcus, the immunogenic fusion protein comprising or consisting of an amino acid sequence consisting of: i. a first amino acid sequence part consisting of 170 to 178 amino acids, preferably 174 to 175 amino acids, and having at least 90% sequence identity with the amino acid sequence shown in SEQ ID NO 7; ii. a second amino acid sequence part consisting of 165 to 174 amino acids, preferably 169 to 170 amino acids, and having at least 90% sequence identity with the amino acid sequence shown in SEQ ID NO 14; and optionally: iii. a linker amino acid sequence part consisting of 1 to 20 amino acids and separating the first amino acid sequence part from the second amino acid part. The immunogenic fusion protein preferably consists of 335 to 372 amino acids, preferably 343 to 353 amino acids, more preferably 343 to 347 amino acids. The invention further pertains to nucleic acid molecule encoding the immunogenic fusion protein; a vector; a host cell; a vaccine; and a method of vaccination against group B Streptococcus infection or treating a group B Streptococcus infection.

34.WO/2022/207657IMMUNOGENIC FUSION PROTEIN
WO - 06.10.2022
Clasificación Internacional A61K 39/09 Nº de solicitud PCT/EP2022/058309 Solicitante MINERVAX APS Inventor/a PEDERSEN FISCHER, Per Bo
The present invention relates to an immunogenic fusion protein comprising or consisting of an amino acid sequence consisting of: i. a first amino acid sequence part consisting of 170 to 178 amino acids, preferably 174 to 175 amino acids, and having at least 90% sequence identity with the amino acid sequence shown in SEQ ID NO: 7; ii. a second amino acid sequence part consisting of 165 to 174 amino acids, preferably 169 to 170 amino acids, and having at least 90% sequence identity with the amino acid sequence shown in SEQ ID NO: 14; and optionally: iii. a linker amino acid sequence part consisting of 1 to 20 amino acids and separating the first amino acid sequence part from the second amino acid part. The immunogenic fusion protein preferably consists of 335 to 372 amino acids, preferably 343 to 353 amino acids, more preferably 343 to 347 amino acids. The invention further pertains to nucleic acid molecule encoding the immunogenic fusion protein; a vector; a host cell; a vaccine; and a method of vaccination against group B Streptococcus infection or treating a group B Streptococcus infection. It is suggested that Fig. 3 be published with the abstract.

35.WO/2022/212564TARGETING MULTIPLE T CELL TYPES USING SPHERICAL NUCLEIC ACID VACCINE ARCHITECTURE
WO - 06.10.2022
Clasificación Internacional A61K 47/64 Nº de solicitud PCT/US2022/022626 Solicitante NORTHWESTERN UNIVERSITY Inventor/a MIRKIN, Chad, A.

The disclosure is generally related to spherical nucleic acids (SNAs), nanostructures with a core surrounded by a radial presentation of oligonucleotides, that can target multiple classes of immune cells. Methods of making and using the nanoparticles are also provided herein. In some aspects, the disclosure provides a spherical nucleic acid (SNA) comprising: (a) a nanoparticle core; (b) a shell of oligonucleotides attached to the external surface of the nanoparticle core, the shell of oligonucleotides comprising one or more immunostimulatory oligonucleotides; and (c) a first antigen that is a major histocompatibility complex type I (MHC-I) antigen, and a second antigen that is a major histocompatibility complex type II (MHC-I I) antigen.

36.20220313816COMPOSITIONS AND METHODS FOR ANTIBODY-AS-ADJUVANT VACCINES AND THERAPEUTICS
US - 06.10.2022
Clasificación Internacional A61K 39/39 Nº de solicitud 17657696 Solicitante Human Vaccines Project Inventor/a Tobias KOLLMANN The invention provides antibody as adjuvant compositions and methods of using the same. Antibodies as adjuvant compositions can include antibodies that specifically bind to an antigen for use in a vaccine or can be non-specific toward the antigen.

37.WO/2022/212499HIGHLY ATTENUATED REPLICATION-COMPETENT RECOMBINANT POXVIRUSES AS A VACCINE PLATFORM AND METHODS OF USE
WO - 06.10.2022
Clasificación Internacional C12N 15/86 Nº de solicitud PCT/US2022/022541 Solicitante ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY Inventor/a JACOBS, Bertram Recombinant poxvirus expressing severe acute respiratory syndrome coronavirus 2 structural proteins and virus-like particles are described, along with methods of making and using the same.

38.4065162VERFAHREN ZUM REINIGEN VON POLYSACCHARIDEN
EP - 05.10.2022
Clasificación Internacional A61K 39/09 Nº de solicitud 20824874 Solicitante LONZA AG Inventor/a ZURBRIGGEN ANDREAS
The present disclosure provides a method of purifying polysaccharides from a cell lysate, comprising partially purifying the cell lysate comprising an impurity and a polysaccharide to obtain a clarified crude lysate; mixing the clarified crude lysate with a neutralization solution comprising a salt to form a neutralized lysate; mixing the neutralized lysate with a precipitation solution comprising cetyltrimethylammonium bromide to form a first supernatant and a first precipitate; and separating the first precipitate from the first supernatant, wherein the polysaccharide is located in the first supernatant. The present disclosure further provides a method of making a polysaccharide vaccine. Also provided are vaccines, delivery systems, compositions and polysaccharides made by the methods described herein.

39.WO/2022/208158VACUNAS EFECTIVAS PARA LA PREVENCIÓN DEL BOTULISMO
WO - 06.10.2022
Clasificación Internacional C07K 14/33 Nº de solicitud PCT/IB2021/062507 Solicitante CENTRO DE INVESTIGACIÓN Y DE ESTUDIOS AVANZADOS DEL INSTITUTO POLITÉCNICO NACIONAL Inventor/a RUÍZ MEDRANO, Roberto
La presente invención describe composiciones vacunales para la prevención del botulismo en animales, principalmente en animales de interés comercial como el ganado, que comprenden proteínas recombinantes basadas en determinantes antigénicos seleccionados de las toxinas C y D de Clostridium, las cuales poseen una gran capacidad antigénica y generan alta inmunidad y gran producción de anticuerpos en los animales vacunados.

40.WO/2022/208488BLOW-FILL-SEAL (BFS) ASSISTED VIAL DISPENSING SYSTEMS AND METHODS

WO - 06.10.2022
Clasificación Internacional A61M 5/28 Nº de solicitud PCT/IB2022/053130 Solicitante KOSKA FAMILY LIMITED Inventor/a KOSKA, Marc
Systems and methods for dispensing Blow-Fill-Seal (BFS) vials such as pre-filled vials containing a vaccine or other medicament via utilization of an assistive dispensing device to selectively compress the fluid reservoir of the BFS vial is shown and described. The assistive dispensing device includes one or more protrusions to aid in applying compressive force to assist in dispensing the liquid from the vial, and may also include a first dosage setting member and a second dosage setting member, that engage each other to limit movement of the one or more protrusions when the proper compression force has been reached.

41.4067480NEUE VERO-ZELLLINIE, DIE IN SERUMFREIEM MEDIUM SUSPENDIERBAR IST, HERSTELLUNGSVERFAHREN DAFÜR UND VERFAHREN ZUR HERSTELLUNG VON VIREN FÜR IMPFSTOFFE UNTER VERWENDUNG EINER NEUEN ZELLLINIE
EP - 05.10.2022
Clasificación Internacional C12N 5/071 Nº de solicitud 20893843 Solicitante SK BIOSCIENCE CO LTD Inventor/a KWAK JUN-SEOK
The present disclosure relates to sVERO 7C2, which is a Vero cell line derived from Vero cells (African Green Monkey Kidney Cell Line) distributed from the WHO and capable of suspension culture without serum components. Further, the present disclosure relates to a culture method for growing the Vero cells and a method for producing a vaccine virus using the Vero cells.

42.20220312748HUMANIZED TRANSGENIC MOUSE MODEL
US - 06.10.2022
Clasificación Internacional A01K 67/027 Nº de solicitud 17244302 Solicitante The United States of America as Represented by the Secretary of the Navy Inventor/a Sofia A. Casares
This invention relates to a transgenic animal model for testing immunogenicity and protective efficacy of human vaccines and the method for generating such a multi-transgenic animal. This invention also relates to methods for screening compositions for human vaccine development. More specifically, the present invention relates to a mouse model capable of expressing human leukocyte antigens DR4 and A2, and/or human costimulatory molecules (CD80) which upon infusion of human HLA-matched hematopoietic stem cells develop a functional human immune system able to respond to vaccination with human vaccines. The invention also relates to method of producing human antibodies specific for a desired antigen using the transgenic mouse.

43.4065163DREIFACHIMPFSTOFF GEGEN DAS AVIBACTERIUM PARAGALLINARUM UND VOGELMENINGOENZEPHALOMYELITIS UND DAS GEFLÜGELPOCKENVIRUS
EP - 05.10.2022
Clasificación Internacional A61K 39/12 Nº de solicitud 20811329 Solicitante BOEHRINGER INGELHEIM VETMEDICA GMBH Inventor/a MALO VERGARA ARISTOTELES
The present invention relates i.a. to an immunogenic composition comprising: a) one or more antigens of avibacterium paragallinarum and one or more antigens of avian encephalomyelitis virus and one or more antigens of fowl pox virus; and b) a pharmaceutically acceptable carrier. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by avibacterium paragallinarum, avian encephalomyelitis virus and fowl pox virus in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

44.WO/2022/211373RECOMBINANT CHIMERIC ADENOVIRAL VECTOR SUBSTITUTED BY KNOB GENE OF CHIMPANZEE ADENOVIRUS SEROTYPE 6, AND APPLICATION THEREOF
WO - 06.10.2022
Clasificación Internacional C12N 15/86 Nº de solicitud PCT/KR2022/004159 Solicitante GENEMATRIX INC. Inventor/a KIM, Soo-Ok
The present invention relates to: a chimeric adenoviral vector having a knob domain of an end of a fiber protein of human adenovirus 5 substituted by a knob gene of chimpanzee adenovirus serotype 6; and/or, additionally, a chimeric adenoviral vector having a hexon protein of human adenovirus 5 substituted by hypervariable regions 1-7 of human adenovirus serotype 28. The present invention may provide an optimal adenoviral vector for the development of therapeutic agents or vaccines for various diseases, and also, when a host cell for production is infected with the chimeric adenoviral vector prepared by the present invention, a more excellent cell infection ability is exhibited compared to a recombinant HAdV-5 vector-based vaccine, and thus the present invention may contribute to improving productivity.

45.20220313805NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS
US - 06.10.2022
Clasificación Internacional A61K 39/00 Nº de solicitud 17687297 Solicitante Immatics Biotechnologies GmbH Inventor/a Andrea MAHR
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

46.WO/2022/208318SYSTEMS AND METHODS FOR BLOW-FILL-SEAL (BFS) ASSISTED DISPENSING AND DISABLEMENT
WO - 06.10.2022
Clasificación Internacional A61M 5/28 Nº de solicitud PCT/IB2022/052849 Solicitante KOSKA FAMILY LIMITED Inventor/a KOSKA, Marc
Systems and methods for dispensing and disabling Blow-Fill-Seal (BFS) vials such as pre-filled vials containing a vaccine or other medicament via utilization of an assistive dispensing device to selectively compress the fluid reservoir of the BFS vial. The assistive dispensing device can aid in applying compressive force to assist in dispensing the liquid from the vial, and may also be utilized to lock in a mated position so that the BFS vial may not be reused and/or is otherwise readily identifiable as having already been administered.

***NOTA ACLARATORIA**: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.*

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Ma. Victoria Guzmán Sánchez mguzman@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.cu
Irina Crespo Molina icrespo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu
Rolando Ochoa Azze ochoa@finlay.edu.cu

FINLAY EDICIONES

